16. Literaturverzeichnis – Diffuses großzelligen B-Zell-Lymphom (DLBCL)

1. Guyatt, GH, Oxman, AD, Vist, GE, Kunz, R, Falck-Ytter, Y, Alonso-Coello, P, et.al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations., 2008. 336 (7650)(7650): p. 924-6., https://pubmed.ncbi.nlm.nih.gov/18436948/

2. Balshem, H, Helfand, M, Schünemann, HJ, Oxman, AD, Kunz, R, Brozek, J, et.al. GRADE guidelines: 3. Rating the quality of evidence., 2011. 64 (4)(4): p. 401-6., https://pubmed.ncbi.nlm.nih.gov/21208779/

3. Guyatt, GH, Oxman, AD, Vist, G, Kunz, R, Brozek, J, Alonso-Coello, P, et.al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)., 2011. 64 (4)(4): p. 407-15., https://pubmed.ncbi.nlm.nih.gov/21247734/

4. Guyatt, GH, Oxman, AD, Kunz, R, Woodcock, J, Brozek, J, Helfand, M, et.al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency., 2011. 64 (12)(12): p. 1294-302., https://pubmed.ncbi.nlm.nih.gov/21803546/

5. Guyatt, GH, Oxman, AD, Kunz, R, Brozek, J, Alonso-Coello, P, Rind, D, et.al. GRADE guidelines 6. Rating the quality of evidence--imprecision., 2011. 64 (12)(12): p. 1283-93., https://pubmed.ncbi.nlm.nih.gov/21839614/

6. Guyatt, GH, Oxman, AD, Kunz, R, Woodcock, J, Brozek, J, Helfand, M, et.al. GRADE guidelines: 8. Rating the quality of evidence--indirectness., 2011. 64 (12)(12): p. 1303-10., https://pubmed.ncbi.nlm.nih.gov/21802903/

7. Guyatt, GH, Oxman, AD, Montori, V, Vist, G, Kunz, R, Brozek, J, et.al. GRADE guidelines: 5. Rating the quality of evidence--publication bias., 2011. 64 (12)(12): p. 1277-82., https://pubmed.ncbi.nlm.nih.gov/21802904/

8. Guyatt, GH, Oxman, AD, Sultan, S, Glasziou, P, Akl, EA, Alonso-Coello, P, et.al. GRADE guidelines: 9. Rating up the quality of evidence., 2011. 64 (12)(12): p. 1311-6., https://pubmed.ncbi.nlm.nih.gov/21802902/

9. Armitage, JO, A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project., Blood, 1997. 89 (11)(11): p. 3909-18., https://pubmed.ncbi.nlm.nih.gov/9166827 /

10. Anderson, JR, Armitage, JO, Weisenburger, DD, Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's lymphoma classification project.Annals of Oncology, Ann Oncol, 1998. 9(7): p. 717-20., https://pubmed.ncbi.nlm.nih.gov/9739436/

11. Shapiro, RS, Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists.American Journal of Hematology, Am J Hematol, 2011. 86(1): p. 48-55., https://pubmed.ncbi.nlm.nih.gov/21120868/

12. Knight, JS, Tsodikov, A, Cibrik, DM, Ross, CW, Kaminski, MS, Blayney, DW, Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.Journal of Clinical Oncology, J Clin Oncol, 2009. 27(20): p. 3354-62., https://pubmed.ncbi.nlm.nih.gov/19451438/

13. Beral, V, Peterman, T, Berkelman, R, Jaffe, H, AIDS-associated non-Hodgkin lymphoma.The Lancet, Lancet, 1991. 337(8745): p. 805-9., https://pubmed.ncbi.nlm.nih.gov/1672911/

14. Gibson, SE, Hsi, ED, Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype.Human Pathology, Hum Pathol, 2009. 40(5): p. 653-61., https://pubmed.ncbi.nlm.nih.gov/19144386/

15. Dojcinov, SD, Venkataraman, G, Pittaluga, S, Wlodarska, I, Schrager, JA, Raffeld, M, et.al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.Blood, Blood, 2011. 117(18): p. 4726-35., https://pubmed.ncbi.nlm.nih.gov/21385849, /

16. Hashimoto, A, Chiba, N, Tsuno, H, Komiya, A, Furukawa, H, Matsui, T, et.al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population.The Journal of Rheumatology, J Rheumatol, 2015. 42(4): p. 564-71., https://pubmed.ncbi.nlm.nih.gov/25593236/

17. Swerdlow SH, Campo E, Harris NL, et al., World Health Organization classification of tumours - WHO classification of tumours of haematopoietic and lymphoid tissuesInternational Agency for Research on Cancer, 2017. Revised 4th edition:

18. Armitage, JO, Gascoyne, RD, Lunning, MA, Cavalli, F, Non-Hodgkin lymphoma.The Lancet, Lancet, 2017. 390(10091): p. 298-310., https://pubmed.ncbi.nlm.nih.gov/28153383/

19. Shi, Y, Han, Y, Yang, J, Liu, P, He, X, Zhang, C, et.al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China.Chinese Journal of Cancer Research, Chin J Cancer Res, 2019. 31(1): p. 152-61., https://pubmed.ncbi.nlm.nih.gov/30996573/

20. Johl, A, Lengfelder, E, Hiddemann, W, Klapper, W, Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel.Annals of Hematology, Ann Hematol, 2016. 95(8): p. 1281-6., https://pubmed.ncbi.nlm.nih.gov/27236576 /

21. Pappa, VI, Hussain, HK, Reznek, RH, Whelan, J, Norton, AJ, Wilson, AM, et.al. Role of image-guided core-needle biopsy in the management of patients with lymphoma.Journal of Clinical Oncology, J Clin Oncol, 1996. 14(9): p. 2427-30., https://pubmed.ncbi.nlm.nih.gov/8823320 /

22. de Kerviler, E, Guermazi, A, Zagdanski, AM, Meignin, V, Gossot, D, Oksenhendler, E, et.al. Image-guided core-needle biopsy in patients with suspected or recurrent lymphomas.Cancer, Cancer, 2000. 89(3): p. 647-52., https://pubmed.ncbi.nlm.nih.gov/10931465 /

23. Frederiksen, JK, Sharma, M, Casulo, C, Burack, WR, Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma.Archives of Pathology & Laboratory Medicine, Arch Pathol Lab Med, 2015. 139(2): p. 245-51., https://pubmed.ncbi.nlm.nih.gov/25611108 /

24. Loubeyre, P, McKee, TA, Copercini, M, Rosset, A, Dietrich, PY, Diagnostic precision of image-guided multisampling core needle biopsy of suspected lymphomas in a primary care hospital.British Journal of Cancer, Br J Cancer, 2009. 100(11): p. 1771-6., https://pubmed.ncbi.nlm.nih.gov/19401685 /

25. Skelton, E, Jewison, A, Okpaluba, C, Sallomi, J, Lowe, J, Ramesar, K, et.al. Image-guided core needle biopsy in the diagnosis of malignant lymphoma.European Journal of Surgical Oncology, Eur J Surg Oncol, 2015. 41(7): p. 852-8., https://pubmed.ncbi.nlm.nih.gov/25980745 /

26. Pugliese, N, Di Perna, M, Cozzolino, I, Ciancia, G, Pettinato, G, Zeppa, P, et.al. Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma.Annals of Hematology, Ann Hematol, 2017. 96(4): p. 627-37., https://pubmed.ncbi.nlm.nih.gov/28130574 /

27. Alaggio, R, Amador, C, Anagnostopoulos, I, Attygalle, AD, Araujo, IBO, Berti, E, et.al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms., Leukemia, 2022. 36 (7)(7): p. 1720-1748., https://pubmed.ncbi.nlm.nih.gov/35732829/

28. Staiger, AM, Ziepert, M, Horn, H, Scott, DW, Barth, TFE, Bernd, HW, et.al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(22): p. 2515-26., https://pubmed.ncbi.nlm.nih.gov/28525305 /

29. Masqué-Soler, N, Szczepanowski, M, Kohler, CW, Spang, R, Klapper, W, Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens.Blood, Blood, 2013. 122(11): p. 1985-6., https://pubmed.ncbi.nlm.nih.gov/24030260 /

30. Scott, DW, Wright, GW, Williams, PM, Lih, CJ, Walsh, W, Jaffe, ES, et.al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.Blood, Blood, 2014. 123(8): p. 1214-7., https://pubmed.ncbi.nlm.nih.gov/24398326 /

31. Hans, CP, Weisenburger, DD, Greiner, TC, Gascoyne, RD, Delabie, J, Ott, G, et.al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Blood, Blood, 2004. 103(1): p. 275-82., https://pubmed.ncbi.nlm.nih.gov/14504078 /

32. Staiger, AM, Altenbuchinger, M, Ziepert, M, Kohler, C, Horn, H, Huttner, M, et.al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.Leukemia, Leukemia, 2020. 34(2): p. 543-52., https://pubmed.ncbi.nlm.nih.gov/31530861 /

33. Horn, H, Ziepert, M, Wartenberg, M, Staiger, AM, Barth, TF, Bernd, HW, et.al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.Leukemia, Leukemia, 2015. 29(7): p. 1564-70., https://pubmed.ncbi.nlm.nih.gov/25687653 /

34. Horn, H, Ziepert, M, Becher, C, Barth, TF, Bernd, HW, Feller, AC, et.al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.Blood, Blood, 2013. 121(12): p. 2253-63., https://pubmed.ncbi.nlm.nih.gov/23335369 /

35. Chapuy, B, Stewart, C, Dunford, AJ, Kim, J, Kamburov, A, Redd, RA, et.al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nature Medicine, Nat Med, 2018. 24(5): p. 679-90., https://pubmed.ncbi.nlm.nih.gov/29713087 /

36. Schmitz, R, Wright, GW, Huang, DW, Johnson, CA, Phelan, JD, Wang, JQ, et.al. Genetics and pathogenesis of diffuse large B-cell lymphoma.The New England Journal of Medicine, N Engl J Med, 2018. 378(15): p. 1396-407., https://pubmed.ncbi.nlm.nih.gov/29641966 /

37. Chapuy, B, Roemer, MG, Stewart, C, Tan, Y, Abo, RP, Zhang, L, et.al. Targetable genetic features of primary testicular and primary central nervous system lymphomas.Blood, Blood, 2016. 127(7): p. 869-81., https://pubmed.ncbi.nlm.nih.gov/26702065 /

38. Carbone, PP, Kaplan, HS, Musshoff, K, Smithers, DW, Tubiana, M, Report of the committee on Hodgkin's disease staging classification.Cancer Research, Cancer Res, 1971. 31(11): p. 1860-1., https://pubmed.ncbi.nlm.nih.gov/5121694 /

39. Fallah, M, Kharazmi, E, Pukkala, E, Tretli, S, Olsen, JH, Tryggvadottir, L, et.al. Familial risk of non-Hodgkin lymphoma by sex, relationship, age at diagnosis and histology: a joint study from five Nordic countries.Leukemia, Leukemia, 2016. 30(2): p. 373-8., https://pubmed.ncbi.nlm.nih.gov/26442613 /

40. Smith, A, Howell, D, Patmore, R, Jack, A, Roman, E, Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.British Journal of Cancer, Br J Cancer, 2011. 105(11): p. 1684-92., https://pubmed.ncbi.nlm.nih.gov/22045184 /

41. Morton, LM, Wang, SS, Devesa, SS, Hartge, P, Weisenburger, DD, Linet, MS, Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.Blood, Blood, 2006. 107(1): p. 265-76., https://pubmed.ncbi.nlm.nih.gov/16150940 /

42. Di, M, Huntington, SF, Olszewski, AJ, Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients.The Oncologist, Oncologist, 2021. 26(2): p. 120-32., https://pubmed.ncbi.nlm.nih.gov/33230948 /

43. Balducci, L, Extermann, M, Management of cancer in the older person: a practical approach.The Oncologist, Oncologist, 2000. 5(3): p. 224-37., https://pubmed.ncbi.nlm.nih.gov/10884501 /

44. Merli, F, Luminari, S, Tucci, A, Arcari, A, Rigacci, L, Hawkes, E, et.al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: The prospective elderly project of the Fondazione Italiana Linfomi.Journal of Clinical Oncology, J Clin Oncol, 2021. 39(11): p. 1214-22., https://pubmed.ncbi.nlm.nih.gov/33577377 /

45. Sakurai, M, Karigane, D, Kasahara, H, Tanigawa, T, Ishida, A, Murakami, H, et.al. Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma.Annals of Hematology, Ann Hematol, 2019. 98(3): p. 669-78., https://pubmed.ncbi.nlm.nih.gov/30443764 /

46. Oiwa, K, Fujita, K, Lee, S, Morishita, T, Tsukasaki, H, Negoro, E, et.al. Utility of the geriatric 8 for the prediction of therapy-related toxicity in older adults with diffuse large B-cell lymphoma.The Oncologist, Oncologist, 2021. 26(3): p. 215-23., https://pubmed.ncbi.nlm.nih.gov/33320984 /

47. Gómez León, N, Vega, G, Rodríguez-Vigil Junco, B, Suevos Ballesteros, C, Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus Medicina Clinica, Med Clin (Barc), 2018. 151(7): p. 255-64., https://pubmed.ncbi.nlm.nih.gov/29705152 /

48. Sabaté-Llobera, A, Cortés-Romera, M, Mercadal, S, Hernández-Gañán, J, Pomares, H, González-Barca, E, et.al. Low-dose PET/CT and full-dose contrast-enhanced CT at the initial staging of localized diffuse large B-cell lymphomas.Clinical Medicine Insights. Blood Disorders., Clin Med Insights Blood Disord, 2016. 9: p. 29-32., https://pubmed.ncbi.nlm.nih.gov/27559300 /

49. Metser, U, Prica, A, Hodgson, DC, Mozuraitis, M, Eberg, M, Mak, V, et.al. Effect of PET/CT on the management and outcomes of participants with Hodgkin and aggressive non-Hodgkin lymphoma: A multicenter registry.Radiology, Radiology, 2019. 290(2): p. 488-95., https://pubmed.ncbi.nlm.nih.gov/30511907 /

50. Elstrom, R, Guan, L, Baker, G, Nakhoda, K, Vergilio, JA, Zhuang, H, et.al. Utility of FDG-PET scanning in lymphoma by WHO classification.Blood, Blood, 2003. 101(10): p. 3875-6., https://pubmed.ncbi.nlm.nih.gov/12531812 /

51. Weiler-Sagie, M, Bushelev, O, Epelbaum, R, Dann, EJ, Haim, N, Avivi, I, et.al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.Journal of Nuclear Medicine, J Nucl Med, 2010. 51(1): p. 25-30., https://pubmed.ncbi.nlm.nih.gov/20009002 /

52. Schöder, H, Noy, A, Gönen, M, Weng, L, Green, D, Erdi, YE, et.al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2005. 23(21): p. 4643-51., https://pubmed.ncbi.nlm.nih.gov/15837966 /

53. Hüttmann, A, Rekowski, J, Müller, SP, Hertenstein, B, Franzius, C, Mesters, R, et.al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.Annals of Hematology, Ann Hematol, 2019. 98(4): p. 897-907., https://pubmed.ncbi.nlm.nih.gov/30610279 /

54. Cheson, BD, Pfistner, B, Juweid, ME, Gascoyne, RD, Specht, L, Horning, SJ, et.al. Revised response criteria for malignant lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2007. 25(5): p. 579-86., https://pubmed.ncbi.nlm.nih.gov/17242396 /

55. Cheson, BD, Fisher, RI, Barrington, SF, Cavalli, F, Schwartz, LH, Zucca, E, et.al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.Journal of Clinical Oncology, J Clin Oncol, 2014. 32(27): p. 3059-68., https://pubmed.ncbi.nlm.nih.gov/25113753 /

56. Poeschel, V, Held, G, Ziepert, M, Witzens-Harig, M, Holte, H, Thurner, L, et.al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.The Lancet, Lancet, 2019. 394(10216): p. 2271-81., https://pubmed.ncbi.nlm.nih.gov/31868632 /

57. Persky, DO, Li, H, Stephens, DM, Park, SI, Bartlett, NL, Swinnen, LJ, et.al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: Results of intergroup National Clinical Trials Network Study s1001.Journal of Clinical Oncology, J Clin Oncol, 2020. 38(26): p. 3003-11., https://pubmed.ncbi.nlm.nih.gov/32658627 /

58. Schaefer, NG, Hany, TF, Taverna, C, Seifert, B, Stumpe, KD, von Schulthess, GK, et.al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?Radiology, Radiology, 2004. 232(3): p. 823-9., https://pubmed.ncbi.nlm.nih.gov/15273335 /

59. Pelosi, E, Pregno, P, Penna, D, Deandreis, D, Chiappella, A, Limerutti, G, et.al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.La Radiologia Medica, Radiol Med, 2008. 113(4): p. 578-90., https://pubmed.ncbi.nlm.nih.gov/18414808 /

60. Hernandez-Maraver, D, Hernandez-Navarro, F, Gomez-Leon, N, Coya, J, Rodriguez-Vigil, B, Madero, R, et.al. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.British Journal of Haematology, Br J Haematol, 2006. 135(3): p. 293-302., https://pubmed.ncbi.nlm.nih.gov/17032175 /

61. Alnouby, A, Ibraheem Nasr, IM, Ali, I, Rezk, M, F-18 FDG PET-CT versus contrast enhanced CT in detection of extra nodal involvement in patients with lymphoma.Indian Journal of Nuclear Medicine, Indian J Nucl Med, 2018. 33(3): p. 183-9., https://pubmed.ncbi.nlm.nih.gov/29962712 /

62. Raanani, P, Shasha, Y, Perry, C, Metser, U, Naparstek, E, Apter, S, et.al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?Annals of Oncology, Ann Oncol, 2006. 17(1): p. 117-22., https://pubmed.ncbi.nlm.nih.gov/16192294 /

63. Ömür, Ö, Baran, Y, Oral, A, Ceylan, Y, Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphomaDiagnostic and Interventional Radiology, Diagn Interv Radiol, 2014. 20(2): p. 185-92., https://pubmed.ncbi.nlm.nih.gov/24412817 /

64. Elstrom, RL, Leonard, JP, Coleman, M, Brown, RK, Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.Annals of Oncology, Ann Oncol, 2008. 19(10): p. 1770-3., https://pubmed.ncbi.nlm.nih.gov/18550578 /

65. Schaefer, NG, Strobel, K, Taverna, C, Hany, TF, Bone involvement in patients with lymphoma: the role of FDG-PET/CT.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2007. 34(1): p. 60-7., https://pubmed.ncbi.nlm.nih.gov/17021808 /

66. Rodríguez-Vigil, B, Gómez-León, N, Pinilla, I, Hernández-Maraver, D, Coya, J, Martín-Curto, L, et.al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.Journal of Nuclear Medicine, J Nucl Med, 2006. 47(10): p. 1643-8., https://pubmed.ncbi.nlm.nih.gov/17015900 /

67. Rodríguez-Vigil Junco, B, Gómez León, N, Pinilla Fernández, I, del Campo, L, Hernández Maraver, D, Coya, J, Non-Hodgkin's lymphoma staging: a prospective study of the value of positron emission tomography/computed tomography (PET/CT) versus PET and CT.Medicina Clinica, Med Clin (Barc), 2011. 137(9): p. 383-9., https://pubmed.ncbi.nlm.nih.gov/21703647 /

68. Brix, G, Lechel, U, Glatting, G, Ziegler, SI, Münzing, W, Müller, SP, et.al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.Journal of Nuclear Medicine, J Nucl Med, 2005. 46(4): p. 608-13., https://pubmed.ncbi.nlm.nih.gov/15809483 /

69. Bebbington, NA, Jørgensen, T, Dupont, E, Micheelsen, MA, Validation of CARE kV automated tube voltage selection for PET-CT: PET quantification and CT radiation dose reduction in phantoms.European Journal of Nuclear Medicine and Molecular Imaging Physics, EJNMMI Phys, 2021. 8(1): p. 29., https://pubmed.ncbi.nlm.nih.gov/33743091 /

70. Wang, D, Huo, Y, Chen, S, Wang, H, Ding, Y, Zhu, X, et.al. Whole-body MRI versus 18 F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysisOncoTargets and Therapy, Onco Targets Ther, 2018. 11: p. 3597-608., https://pubmed.ncbi.nlm.nih.gov/29950864/

71. Kwee, TC, Kwee, RM, Nievelstein, RA, Imaging in staging of malignant lymphoma: a systematic review.Blood, Blood, 2008. 111(2): p. 504-16., https://pubmed.ncbi.nlm.nih.gov/17916746 /

72. Chen-Liang, TH, Martín-Santos, T, Jerez, A, Rodríguez-García, G, Senent, L, Martínez-Millán, C, et.al. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.Cancer Medicine, Cancer Med, 2017. 6(11): p. 2507-14., https://pubmed.ncbi.nlm.nih.gov/28960797 /

73. Liang, JH, Sun, J, Wang, L, Fan, L, Chen, YY, Qu, XY, et.al. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.Oncotarget, Oncotarget, 2016. 7(14): p. 19072-80., https://pubmed.ncbi.nlm.nih.gov/26919239 /

74. Adams, HJ, Kwee, TC, de Keizer, B, Fijnheer, R, de Klerk, JM, Nievelstein, RA, FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2014. 41(3): p. 565-74., https://pubmed.ncbi.nlm.nih.gov/24281821 /

75. Cerci, JJ, Györke, T, Fanti, S, Paez, D, Meneghetti, JC, Redondo, F, et.al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.Journal of Nuclear Medicine, J Nucl Med, 2014. 55(10): p. 1591-7., https://pubmed.ncbi.nlm.nih.gov/25214642 /

76. Alzahrani, M, El-Galaly, TC, Hutchings, M, Hansen, JW, Loft, A, Johnsen, HE, et.al. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.Annals of Oncology, Ann Oncol, 2016. 27(6): p. 1095-9., https://pubmed.ncbi.nlm.nih.gov/27002106 /

77. Kaddu-Mulindwa, D, Altmann, B, Held, G, Angel, S, Stilgenbauer, S, Thurner, L, et.al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2021. 48(11): p. 3550-9., https://pubmed.ncbi.nlm.nih.gov/33928400 /

78. Chen-Liang, TH, Martin-Santos, T, Jerez, A, Senent, L, Orero, MT, Remigia, MJ, et.al. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients.American Journal of Hematology, Am J Hematol, 2015. 90(8): p. 686-90., https://pubmed.ncbi.nlm.nih.gov/25925613 /

79. Lidén, Y, Landgren, O, Arnér, S, Sjölund, KF, Johansson, E, Procedure-related pain among adult patients with hematologic malignancies.Acta Anaesthesiologica Scandinavica, Acta Anaesthesiol Scand, 2009. 53(3): p. 354-63., https://pubmed.ncbi.nlm.nih.gov/19243321 /

80. Bain, BJ, Bone marrow biopsy morbidity and mortality.British Journal of Haematology, Br J Haematol, 2003. 121(6): p. 949-51., https://pubmed.ncbi.nlm.nih.gov/12786808 /

81. Liang, JH, Sun, J, Wang, L, Fan, L, Chen, YY, Qu, XY, et.al. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.Oncotarget, Oncotarget, 2016. 7(14): p. 19072-80., https://pubmed.ncbi.nlm.nih.gov/26919239 /

82. Ngeow, JYY, Quek, RHH, Ng, DCE, Hee, SW, Tao, M, Lim, LC, et.al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.Annals of Oncology, Ann Oncol, 2009. 20(9): p. 1543-7., https://pubmed.ncbi.nlm.nih.gov/19474116 /

83. Hong, J, Lee, Y, Park, Y, Kim, SG, Hwang, KH, Park, SH, et.al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.Annals of Hematology, Ann Hematol, 2012. 91(5): p. 687-95., https://pubmed.ncbi.nlm.nih.gov/22008868 /

84. Berthet, L, Cochet, A, Kanoun, S, Berriolo-Riedinger, A, Humbert, O, Toubeau, M, et.al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.Journal of Nuclear Medicine, J Nucl Med, 2013. 54(8): p. 1244-50., https://pubmed.ncbi.nlm.nih.gov/23674577 /

85. Khan, AB, Barrington, SF, Mikhaeel, NG, Hunt, AA, Cameron, L, Morris, T, et.al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.Blood, Blood, 2013. 122(1): p. 61-7., https://pubmed.ncbi.nlm.nih.gov/23660958/

86. Cortés-Romera, M, Sabaté-Llobera, A, Mercadal-Vilchez, S, Climent-Esteller, F, Serrano-Maestro, A, Gámez-Cenzano, C, et.al. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy.Clinical Nuclear Medicine, Clin Nucl Med, 2014. 39(1): p. e46-52., https://pubmed.ncbi.nlm.nih.gov/23640215 /

87. El-Galaly, TC, Villa, D, Alzahrani, M, Hansen, JW, Sehn, LH, Wilson, D, et.al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.American Journal of Hematology, Am J Hematol, 2015. 90(11): p. 1041-6., https://pubmed.ncbi.nlm.nih.gov/26260224 /

88. El Karak, F, Bou-Orm, IR, Ghosn, M, Kattan, J, Farhat, F, Ibrahim, T, et.al. PET/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma.PLOS One, PLoS One, 2017. 12(1): p. e0170299., https://pubmed.ncbi.nlm.nih.gov/28099514 /

89. Kandeel, AA, Hussein, M, Zidan, L, Younis, J, Edesa, W, Alsayed, Y, Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.Nuclear Medicine Communications, Nucl Med Commun, 2020. 41(3): p. 269-79., https://pubmed.ncbi.nlm.nih.gov/31895758 /

90. Muslimani, AA, Farag, HL, Francis, S, Spiro, TP, Chaudhry, AA, Chan, VC, et.al. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.American Journal of Clinical Oncology, Am J Clin Oncol, 2008. 31(5): p. 409-12., https://pubmed.ncbi.nlm.nih.gov/18838874 /

91. Campbell, J, Seymour, JF, Matthews, J, Wolf, M, Stone, J, Juneja, S, The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.European Journal of Haematology, Eur J Haematol, 2006. 76(6): p. 473-80., https://pubmed.ncbi.nlm.nih.gov/16529599 /

92. Ebie, N, Loew, JM, Gregory, SA, Bilateral trephine bone marrow biopsy for staging non-Hodgkin's lymphoma--a second look.Hematologic Pathology, Hematol Pathol, 1989. 3(1): p. 29-33., https://pubmed.ncbi.nlm.nih.gov/2745358 /

93. Juneja, SK, Wolf, MM, Cooper, IA, Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma.Journal of Clinical Pathology, J Clin Pathol, 1990. 43(8): p. 630-2., https://pubmed.ncbi.nlm.nih.gov/2401730 /

94. Wang, J, Weiss, LM, Chang, KL, Slovak, ML, Gaal, K, Forman, SJ, et.al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy.Cancer, Cancer, 2002. 94(5): p. 1522-31., https://pubmed.ncbi.nlm.nih.gov/11920510 /

95. Conlan, MG, Bast, M, Armitage, JO, Weisenburger, DD, Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.Journal of Clinical Oncology, J Clin Oncol, 1990. 8(7): p. 1163-72., https://pubmed.ncbi.nlm.nih.gov/1694234 /

96. Chung, R, Lai, R, Wei, P, Lee, J, Hanson, J, Belch, AR, et.al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.Blood, Blood, 2007. 110(4): p. 1278-82., https://pubmed.ncbi.nlm.nih.gov/17475910 /

97. Sehn, LH, Scott, DW, Chhanabhai, M, Berry, B, Ruskova, A, Berkahn, L, et.al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.Journal of Clinical Oncology, J Clin Oncol, 2011. 29(11): p. 1452-7., https://pubmed.ncbi.nlm.nih.gov/21383296 /

98. Paone, G, Itti, E, Haioun, C, Gaulard, P, Dupuis, J, Lin, C, et.al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2009. 36(5): p. 745-50., https://pubmed.ncbi.nlm.nih.gov/19096842 /

99. Pelosi, E, Penna, D, Douroukas, A, Bellò, M, Amati, A, Arena, V, et.al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Q J Nucl Med Mol Imaging, 2011. 55(4): p. 469-75., https://pubmed.ncbi.nlm.nih.gov/21150862 /

100. Adams, HJ, de Klerk, JM, Fijnheer, R, Heggelman, BG, Dubois, SV, Nievelstein, RA, et.al. Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?Acta Oncologica, Acta Oncol, 2015. 54(1): p. 67-72., https://pubmed.ncbi.nlm.nih.gov/25263078 /

101. Jackson, AE, Smeltzer, JP, Habermann, TM, Jones, JM, Burnette, B, Ristow, K, et.al. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.American Journal of Hematology, Am J Hematol, 2014. 89(9): p. 865-7., https://pubmed.ncbi.nlm.nih.gov/24823914 /

102. Lim, ST, Tao, M, Cheung, YB, Rajan, S, Mann, B, Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?Annals of Oncology, Ann Oncol, 2005. 16(2): p. 215-8., https://pubmed.ncbi.nlm.nih.gov/15668272 /

103. Ribrag, V, Vanel, D, Leboulleux, S, Lumbroso, J, Couanet, D, Bonniaud, G, et.al. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.European Journal of Radiology, Eur J Radiol, 2008. 66(2): p. 325-31., https://pubmed.ncbi.nlm.nih.gov/17651934 /

104. Adams, HJ, Kwee, TC, Vermoolen, MA, de Keizer, B, de Klerk, JM, Adam, JA, et.al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET.European Radiology, Eur Radiol, 2013. 23(8): p. 2271-8., https://pubmed.ncbi.nlm.nih.gov/23591618 /

105. Asenbaum, U, Nolz, R, Karanikas, G, Furtner, J, Woitek, R, Staudenherz, A, et.al. Evaluation of [18F]-FDG-based hybrid imaging combinations for assessment of bone marrow involvement in lymphoma at initial staging.Plos One, PLoS One, 2016. 11(10): p. e0164118., https://pubmed.ncbi.nlm.nih.gov/27723817 /

106. Held, G, Murawski, N, Ziepert, M, Fleckenstein, J, Pöschel, V, Zwick, C, et.al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2014. 32(11): p. 1112-8., https://pubmed.ncbi.nlm.nih.gov/24493716 /

107. International Non-Hodgkin's Lymphoma Prognostic Factors Project, A predictive model for aggressive non-Hodgkin's lymphoma.The New England Journal of Medicine, N Engl J Med, 1993. 329(14): p. 987-94., https://pubmed.ncbi.nlm.nih.gov/8141877 /

108. Ziepert, M, Hasenclever, D, Kuhnt, E, Glass, B, Schmitz, N, Pfreundschuh, M, et.al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.Journal of Clinical Oncology, J Clin Oncol, 2010. 28(14): p. 2373-80., https://pubmed.ncbi.nlm.nih.gov/20385988 /

109. Schmitz, C, Hüttmann, A, Müller, SP, Hanoun, M, Boellaard, R, Brinkmann, M, et.al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.European Journal of Cancer, Eur J Cancer, 2020. 124: p. 25-36., https://pubmed.ncbi.nlm.nih.gov/31710995 /

110. Lister, TA, Crowther, D, Sutcliffe, SB, Glatstein, E, Canellos, GP, Young, RC, et.al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.Journal of Clinical Oncology, J Clin Oncol, 1989. 7(11): p. 1630-6., https://pubmed.ncbi.nlm.nih.gov/2809679 /

111. Pfreundschuh, M, Ho, AD, Cavallin-Stahl, E, Wolf, M, Pettengell, R, Vasova, I, et.al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.The Lancet, Lancet Oncol, 2008. 9(5): p. 435-44., https://pubmed.ncbi.nlm.nih.gov/18400558 /

112. Pfreundschuh, M, Trümper, L, Osterborg, A, Pettengell, R, Trneny, M, Imrie, K, et.al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.The Lancet, Lancet Oncol, 2006. 7(5): p. 379-91., https://pubmed.ncbi.nlm.nih.gov/16648042 /

113. Advani, RH, Chen, H, Habermann, TM, Morrison, VA, Weller, EA, Fisher, RI, et.al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).British Journal of Haematology, Br J Haematol, 2010. 151(2): p. 143-51., https://pubmed.ncbi.nlm.nih.gov/20735398 /

114. Miller, TP, The limits of limited stage lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2004. 22(15): p. 2982-4., https://pubmed.ncbi.nlm.nih.gov/15210737 /

115. Zhou, Z, Sehn, LH, Rademaker, AW, Gordon, LI, Lacasce, AS, Crosby-Thompson, A, et.al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.Blood, Blood, 2014. 123(6): p. 837-42., https://pubmed.ncbi.nlm.nih.gov/24264230 /

116. Schmitz, N, Zeynalova, S, Nickelsen, M, Kansara, R, Villa, D, Sehn, LH, et.al. CNS International Prognostic Index: A risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP.Journal of Clinical Oncology, J Clin Oncol, 2016. 34(26): p. 3150-6., https://pubmed.ncbi.nlm.nih.gov/27382100 /

117. Peñalver, FJ, Sancho, JM, de la Fuente, A, Olave, MT, Martín, A, Panizo, C, et.al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).Haematologica, Haematologica, 2017. 102(2): p. 235-45., https://pubmed.ncbi.nlm.nih.gov/27846613 /

118. Song, MK, Chung, JS, Shin, HJ, Lee, SM, Lee, SE, Lee, HS, et.al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.Annals of Hematology, Ann Hematol, 2012. 91(5): p. 697-703., https://pubmed.ncbi.nlm.nih.gov/22071570/

119. Parvez, A, Tau, N, Hussey, D, Maganti, M, Metser, U, 18 F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survivalAnnals of Nuclear Medicine, Ann Nucl Med, 2018. 32(6): p. 410-6., https://pubmed.ncbi.nlm.nih.gov/29754276/

120. Song, MK, Chung, JS, Sung-Yong, O, Lee, GW, Kim, SG, Seol, YM, et.al. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.Annals of Hematology, Ann Hematol, 2010. 89(10): p. 985-91., https://pubmed.ncbi.nlm.nih.gov/20428871 /

121. Oh, MY, Oh, SB, Seoung, HG, Kim, JH, Kim, SM, Kim, TK, et.al. Clinical significance of standardized uptake value and maximum tumor diameter in patients with primary extranodal diffuse large B cell lymphoma.The Korean Journal of Hematology, Korean J Hematol, 2012. 47(3): p. 207-12., https://pubmed.ncbi.nlm.nih.gov/23071476 /

122. Sasanelli, M, Meignan, M, Haioun, C, Berriolo-Riedinger, A, Casasnovas, RO, Biggi, A, et.al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2014. 41(11): p. 2017-22., https://pubmed.ncbi.nlm.nih.gov/24902639 /

123. Ceriani, L, Gritti, G, Cascione, L, Pirosa, MC, Polino, A, Ruberto, T, et.al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.Blood Advances, Blood Adv, 2020. 4(6): p. 1082-92., https://pubmed.ncbi.nlm.nih.gov/32196557 /

124. Delaby, G, Hubaut, MA, Morschhauser, F, Besson, A, Huglo, D, Herbaux, C, et.al. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline Leukemia and Lymphoma, Leuk Lymphoma, 2020. 61(7): p. 1584-91., https://pubmed.ncbi.nlm.nih.gov/32100597 /

125. Guo, B, Tan, X, Ke, Q, Cen, H, Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.PLOS One, PLoS One, 2019. 14(1): p. e0210224., https://pubmed.ncbi.nlm.nih.gov/30625203 /

126. Xie, M, Wu, K, Liu, Y, Jiang, Q, Xie, Y, Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.Medical Oncology, Med Oncol, 2015. 32(1): p. 446., https://pubmed.ncbi.nlm.nih.gov/25511321 /

127. Gupta, N, Singh, N, To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).Nuclear Medicine Communications, Nucl Med Commun, 2020. 41(4): p. 395-404., https://pubmed.ncbi.nlm.nih.gov/32073552 /

128. Ilyas, H, Mikhaeel, NG, Dunn, JT, Rahman, F, Møller, H, Smith, D, et.al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2018. 45(7): p. 1142-54., https://pubmed.ncbi.nlm.nih.gov/29460024 /

129. Schmitz, N, Nickelsen, M, Ziepert, M, Haenel, M, Borchmann, P, Schmidt, C, et.al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).The Lancet, Lancet Oncol, 2012. 13(12): p. 1250-9., https://pubmed.ncbi.nlm.nih.gov/23168367 /

130. Decazes, P, Becker, S, Toledano, MN, Vera, P, Desbordes, P, Jardin, F, et.al. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2018. 45(10): p. 1672-9., https://pubmed.ncbi.nlm.nih.gov/29705879, /

131. Toledano, MN, Desbordes, P, Banjar, A, Gardin, I, Vera, P, Ruminy, P, et.al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2018. 45(5): p. 680-8., https://pubmed.ncbi.nlm.nih.gov/29344718 /

132. Zhang, YY, Song, L, Zhao, MX, Hu, K, A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %SUVCancer Medicine, Cancer Med, 2019. 8(11): p. 5137-47., https://pubmed.ncbi.nlm.nih.gov/31343111 /

133. Aide, N, Fruchart, C, Nganoa, C, Gac, AC, Lasnon, C, Baseline 18 F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy.European Radiology, Eur Radiol, 2020. 30(8): p. 4623-4632., https://pubmed.ncbi.nlm.nih.gov/32248365 /

134. Cottereau, AS, Nioche, C, Dirand, AS, Clerc, J, Morschhauser, F, Casasnovas, O, et.al. 18 F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of OutcomeJournal of Nuclear Medicine, J Nucl Med, 2020. 61(1): p. 40-5., https://pubmed.ncbi.nlm.nih.gov/31201248/

135. Vercellino, L, Cottereau, AS, Casasnovas, O, Tilly, H, Feugier, P, Chartier, L, et.al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy.Blood, Blood, 2020. 135(16): p. 1396-405., https://pubmed.ncbi.nlm.nih.gov/31978225 /

136. Gormsen, LC, Vendelbo, MH, Pedersen, MA, Haraldsen, A, Hjorthaug, K, Bogsrud, TV, et.al. A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT.European Journal of Nuclear Medicine and Molecular Imaging, EJNMMI Res, 2019. 9(1): p. 36., https://pubmed.ncbi.nlm.nih.gov/31054023 /

137. Barrington, SF, Meignan, M, Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden.Journal of Nuclear Medicine, J Nucl Med, 2019. 60(8): p. 1096-102., https://pubmed.ncbi.nlm.nih.gov/30954945 /

138. Boellaard, R, Delgado-Bolton, R, Oyen, WJ, Giammarile, F, Tatsch, K, Eschner, W, et.al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2015. 42(2): p. 328-54., https://pubmed.ncbi.nlm.nih.gov/25452219 /

139. Xie, M, Zhai, W, Cheng, S, Zhang, H, Xie, Y, He, W, Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.Hematology, Hematology, 2016. 21(2): p. 99-105., https://pubmed.ncbi.nlm.nih.gov/26183456 /

140. Gallicchio, R, Mansueto, G, Simeon, V, Nardelli, A, Guariglia, R, Capacchione, D, et.al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.European Journal of Haematology, Eur J Haematol, 2014. 92(5): p. 382-9., https://pubmed.ncbi.nlm.nih.gov/24428392 /

141. Pfreundschuh, M, Müller, C, Zeynalova, S, Kuhnt, E, Wiesen, MH, Held, G, et.al. Suboptimal dosing of rituximab in male and female patients with DLBCL.Blood, Blood, 2014. 123(5): p. 640-6., https://pubmed.ncbi.nlm.nih.gov/24297867 /

142. Jaeger, U, Trneny, M, Melzer, H, Praxmarer, M, Nawarawong, W, Ben Yehuda, D, et.al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.Haematologica, Haematologica, 2015. 100(7): p. 955-63., https://pubmed.ncbi.nlm.nih.gov/25911553 /

143. Müller, C, Murawski, N, Wiesen, MH, Held, G, Poeschel, V, Zeynalova, S, et.al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.Blood, Blood, 2012. 119(14): p. 3276-84., https://pubmed.ncbi.nlm.nih.gov/22337718 /

144. Habermann, TM, Wang, SS, Maurer, MJ, Morton, LM, Lynch, CF, Ansell, SM, et.al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.Blood, Blood, 2008. 112(7): p. 2694-702., https://pubmed.ncbi.nlm.nih.gov/18633131 /

145. Charbonneau, B, Maurer, MJ, Fredericksen, ZS, Zent, CS, Link, BK, Novak, AJ, et.al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.American Journal of Hematology, Am J Hematol, 2012. 87(9): p. 880-5., https://pubmed.ncbi.nlm.nih.gov/22718493 /

146. Wagner, B, Dührsen, U, Hüttmann, A, Nückel, H, Michita, RT, Rohn, H, et.al. Genetic variants of the NKG2C/HLA-E receptor-ligand axis are determinants of progression-free survival and therapy outcome in aggressive B-cell lymphoma.Cancers, Cancers (Basel), 2020. 12(11):, https://pubmed.ncbi.nlm.nih.gov/33218185 /

147. Broecker-Preuss M, Becher-Boveleth N, Müller SP, Hüttmann A, Hanoun C, Grafe H, et.al. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trialJournal of Cancer Research and Clinical Oncology, 2022. 148(10): p. 2611 - 2621., https://pubmed.ncbi.nlm.nih.gov/34708297/

148. Ellis, PM, Butow, PN, Tattersall, MH, Dunn, SM, Houssami, N, Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate.Journal of Clinical Oncology, J Clin Oncol, 2001. 19(15): p. 3554-61., https://pubmed.ncbi.nlm.nih.gov/11481363 /

149. DasMahapatra, P, Raja, P, Gilbert, J, Wicks, P, Clinical trials from the patient perspective: survey in an online patient community.BMC Health Services Research, BMC Health Serv Res, 2017. 17(1): p. 166., https://pubmed.ncbi.nlm.nih.gov/28241758 /

150. Engelbak Nielsen, Z, Eriksson, S, Schram Harsløf, LB, Petri, S, Helgesson, G, Mangset, M, et.al. Are cancer patients better off if they participate in clinical trials? A mixed methods study.BMC Cancer, BMC Cancer, 2020. 20(1): p. 401., https://pubmed.ncbi.nlm.nih.gov/32384883 /

151. Peppercorn, JM, Weeks, JC, Cook, EF, Joffe, S, Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review.The Lancet, Lancet, 2004. 363(9405): p. 263-70., https://pubmed.ncbi.nlm.nih.gov/14751698 /

152. Vist, GE, Bryant, D, Somerville, L, Birminghem, T, Oxman, AD, Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.The Cochrane Database of Systematic Reviews, Cochrane Database Syst Rev, 2008. p. MR000009., https://pubmed.ncbi.nlm.nih.gov/18677782 /

153. Liu, L, Giusti, F, Schaapveld, M, Aleman, B, Lugtenburg, P, Meijnders, P, et.al. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.British Journal of Haematology, Br J Haematol, 2017. 176(1): p. 65-75., https://pubmed.ncbi.nlm.nih.gov/27766636 /

154. Chen, CI, Skingley, P, Meyer, RM, A comparison of elderly patients with aggressive histology lymphoma who were entered or not entered on to a randomized phase II trial.Leukemia and Lymphoma, Leuk Lymphoma, 2000. 38(3-4): p. 327-34., https://pubmed.ncbi.nlm.nih.gov/10830739 /

155. Maurer, MJ, Ghesquières, H, Link, BK, Jais, JP, Habermann, TM, Thompson, CA, et.al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials.Journal of Clinical Oncology, J Clin Oncol, 2018. 36(16): p. 1603-10., https://pubmed.ncbi.nlm.nih.gov/29672223 /

156. Olszewski, AJ, Ollila, T, Reagan, JL, Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.British Journal of Haematology, Br J Haematol, 2018. 181(4): p. 495-504., https://pubmed.ncbi.nlm.nih.gov/29687879 /

157. Alig, S, Macaulay, CW, Kurtz, DM, Dührsen, U, Hüttmann, A, Schmitz, C, et.al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2021. 39(23): p. 2605-16., https://pubmed.ncbi.nlm.nih.gov/33909455 /

158. Blumenfeld, Z, von Wolff, M, GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.Human Reproduction Update, Hum Reprod Update, 2008. 14(6): p. 543-52., https://pubmed.ncbi.nlm.nih.gov/18824495 /

159. Meirow, D, Rabinovici, J, Katz, D, Or, R, Shufaro, Y, Ben-Yehuda, D, Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate.Cancer, Cancer, 2006. 107(7): p. 1634-41., https://pubmed.ncbi.nlm.nih.gov/16944540 /

160. Salama, M, Anazodo, A, Woodruff, TK, Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach.Annals of Oncology, Ann Oncol, 2019. 30(11): p. 1760-75., https://pubmed.ncbi.nlm.nih.gov/31418765 /

161. von der Weid, NX, Adult life after surviving lymphoma in childhood.Supportive Care in Cancer, Support Care Cancer, 2008. 16(4): p. 339-45., https://pubmed.ncbi.nlm.nih.gov/18196290 /

162. Sanders, JE, Hawley, J, Levy, W, Gooley, T, Buckner, CD, Deeg, HJ, et.al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation.Blood, Blood, 1996. 87(7): p. 3045-52., https://pubmed.ncbi.nlm.nih.gov/8639928 /

163. Parva, M, Lamb, K, Savior, DC, Gilman, P, Belden, M, Full-term pregnancy and vaginal delivery after treatment for non-Hodgkin's lymphoma of the cervix and lower uterine segment: a case report.Journal of Obstetrics and Gynaecology Canada, J Obstet Gynaecol Can, 2011. 33(6): p. 620-4., https://pubmed.ncbi.nlm.nih.gov/21846452 /

164. Lorusso, D, Ferrandina, G, Pagano, L, Gagliardi, ML, Scambia, G, Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery.Oncology, Oncology, 2007. 72(3-4): p. 261-4., https://pubmed.ncbi.nlm.nih.gov/18185021 /

165. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF), ertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No.015/082, November 2017), 2017., http://www.awmf.org/leitlinien/detail/ll/015-082.html

166. Elis, A, Tevet, A, Yerushalmi, R, Blickstein, D, Bairy, O, Dann, EJ, et.al. Fertility status among women treated for aggressive non-Hodgkin's lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2006. 47(4): p. 623-7., https://pubmed.ncbi.nlm.nih.gov/16690520 /

167. Meirow, D, Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers.Leukemia and Lymphoma, Leuk Lymphoma, 1999. 33(1-2): p. 65-76., https://pubmed.ncbi.nlm.nih.gov/10194122 /

168. Borgmann-Staudt, A, Rendtorff, R, Reinmuth, S, Hohmann, C, Keil, T, Schuster, FR, et.al. Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence.Bone Marrow Transplantation, Bone Marrow Transplant, 2012. 47(2): p. 271-6., https://pubmed.ncbi.nlm.nih.gov/21478918 /

169. Grigg, AP, McLachlan, R, Zaja, J, Szer, J, Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg).Bone Marrow Transplantation, Bone Marrow Transplant, 2000. 26(10): p. 1089-95., https://pubmed.ncbi.nlm.nih.gov/11108308 /

170. Jadoul, P, Donnez, J, How does bone marrow transplantation affect ovarian function and fertility?Current Opinion in Obstetrics & Gynecology, Curr Opin Obstet Gynecol, 2012. 24(3): p. 164-71., https://pubmed.ncbi.nlm.nih.gov/22510853 /

171. Teinturier, C, Hartmann, O, Valteau-Couanet, D, Benhamou, E, Bougneres, PF, Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure.Bone Marrow Transplantation, Bone Marrow Transplant, 1998. 22(10): p. 989-94., https://pubmed.ncbi.nlm.nih.gov/9849696 /

172. Wallace, WH, Thomson, AB, Kelsey, TW, The radiosensitivity of the human oocyte.Human Reproduction, Hum Reprod, 2003. 18(1): p. 117-21., https://pubmed.ncbi.nlm.nih.gov/12525451 /

173. Teh, WT, Stern, C, Chander, S, Hickey, M, The impact of uterine radiation on subsequent fertility and pregnancy outcomes.BioMed Research International, Biomed Res Int, 2014. 2014: p. 482968., https://pubmed.ncbi.nlm.nih.gov/25165706 /

174. Dittrich, R, Kliesch, S, Schüring, A, Balcerek, M, Baston-Büst, DM, Beck, R, et.al. Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM - Recommendations and statements for girls and women.Geburtshilfe und Frauenheilkunde, Geburtshilfe Frauenheilkd, 2018. 78(6): p. 567-84., https://pubmed.ncbi.nlm.nih.gov/29962516 /

175. Schüring, AN, Fehm, T, Behringer, K, Goeckenjan, M, Wimberger, P, Henes, M, et.al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation.Archives of Gynecology and Obstetrics, Arch Gynecol Obstet, 2018. 297(1): p. 241-55., https://pubmed.ncbi.nlm.nih.gov/29177593 /

176. von Wolff, M, Germeyer, A, Liebenthron, J, Korell, M, Nawroth, F, Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques.Archives of Gynecology and Obstetrics, Arch Gynecol Obstet, 2018. 297(1): p. 257-67., https://pubmed.ncbi.nlm.nih.gov/29181578 /

177. Blumenfeld, Z, Patel, B, Leiba, R, Zuckerman, T, Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.Fertility and Sterility, Fertil Steril, 2012. 98(5): p. 1266-70.e1., https://pubmed.ncbi.nlm.nih.gov/22935556 /

178. Cheng, YC, Takagi, M, Milbourne, A, Champlin, RE, Ueno, NT, Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients.The Oncologist, Oncologist, 2012. 17(2): p. 233-8., https://pubmed.ncbi.nlm.nih.gov/22282904 /

179. Donnez, J, Dolmans, MM, Fertility preservation in women.The New England Journal of Medicine, N Engl J Med, 2017. 377(17): p. 1657-65., https://pubmed.ncbi.nlm.nih.gov/29069558 /

180. Dolmans, MM, Luyckx, V, Donnez, J, Andersen, CY, Greve, T, Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue.Fertility and Sterility, Fertil Steril, 2013. 99(6): p. 1514-22., https://pubmed.ncbi.nlm.nih.gov/23541406 /

181. Shapira, M, Raanani, H, Barshack, I, Amariglio, N, Derech-Haim, S, Marciano, MN, et.al. First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination.Fertility and Sterility, Fertil Steril, 2018. 109(1): p. 48-53., https://pubmed.ncbi.nlm.nih.gov/29198847/

182. Gellert, SE, Pors, SE, Kristensen, SG, Bay-Bjørn, AM, Ernst, E, Yding Andersen, C, Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort.Journal of Assisted Reproduction and Genetics, J Assist Reprod Genet, 2018. 35(4): p. 561-70., https://pubmed.ncbi.nlm.nih.gov/29497953 /

183. Luyckx, V, Dolmans, MM, Vanacker, J, Legat, C, Fortuño Moya, C, Donnez, J, et.al. A new step toward the artificial ovary: survival and proliferation of isolated murine follicles after autologous transplantation in a fibrin scaffold.Fertility and Sterility, Fertil Steril, 2014. 101(4): p. 1149-56., https://pubmed.ncbi.nlm.nih.gov/24462059 /

184. Shapira, M, Dolmans, MM, Silber, S, Meirow, D, Evaluation of ovarian tissue transplantation: results from three clinical centers.Fertility and Sterility, Fertil Steril, 2020. 114(2): p. 388-97., https://pubmed.ncbi.nlm.nih.gov/32605799 /

185. Ferrari, S, Persico, P, Di Puppo, F, Giardina, P, Ferrari, A, Laparoscopic lateral ovarian transposition: a fertility sparing procedure.Minerva Ginecologica, Minerva Ginecol, 2009. 61(5): p. 465-8., https://pubmed.ncbi.nlm.nih.gov/19749679 /

186. Morice, P, Thiam-Ba, R, Castaigne, D, Haie-Meder, C, Gerbaulet, A, Pautier, P, et.al. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy.Human Reproduction, Hum Reprod, 1998. 13(3): p. 660-3., https://pubmed.ncbi.nlm.nih.gov/9572430 /

187. Auger, J, Sermondade, N, Eustache, F, Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.Basic and Clinical Andrology, Basic Clin Androl, 2016. 26: p. 3., https://pubmed.ncbi.nlm.nih.gov/26893905 /

188. van der Kaaij, MA, van Echten-Arends, J, Heutte, N, Meijnders, P, Abeilard-Lemoisson, E, Spina, M, et.al. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.Human Reproduction, Hum Reprod, 2014. 29(3): p. 525-33., https://pubmed.ncbi.nlm.nih.gov/24345581 /

189. Pallotti, F, Pelloni, M, Faja, F, Di Chiano, S, Di Rocco, A, Lenzi, A, et.al. Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study.Human Reproduction, Hum Reprod, 2021. 36(1): p. 16-25., https://pubmed.ncbi.nlm.nih.gov/33257989 /

190. van der Kaaij, MA, van Echten-Arends, J, Simons, AH, Kluin-Nelemans, HC, Fertility preservation after chemotherapy for Hodgkin lymphoma.Hematological Oncology, Hematol Oncol, 2010. 28(4): p. 168-79., https://pubmed.ncbi.nlm.nih.gov/20232475 /

191. Servitzoglou, M, De Vathaire, F, Oberlin, O, Patte, C, Thomas-Teinturier, C, Dose-effect relationship of alkylating agents on testicular function in male survivors of childhood lymphoma.Pediatric Hematology and Oncology, Pediatr Hematol Oncol, 2015. 32(8): p. 613-23., https://pubmed.ncbi.nlm.nih.gov/26561347 /

192. Hallak, J, Mahran, AM, Agarwal, A, Characteristics of cryopreserved semen from men with lymphoma.Journal of Assisted Reproduction and Genetics, J Assist Reprod Genet, 2000. 17(10): p. 591-4., https://pubmed.ncbi.nlm.nih.gov/11209541 /

193. Blumenauer V, Czeromin U, Fehr D, Fiedler K, Gnoth C, Krüssel JS, D-I-R Annual 2019J Reproduktionsmed Endokrinol, 2020. 15(5): p. 196-239.

194. Shiraishi, K, Matsuyama, H, Microdissection testicular sperm extraction and salvage hormonal treatment in patients with postchemotherapy azoospermia.Urology, Urology, 2014. 83(1): p. 100-6., https://pubmed.ncbi.nlm.nih.gov/24269225 /

195. Kliesch, S, Schmidt, S, Wilborn, D, Aigner, C, Albrecht, W, Bedke, J, et.al. Management of germ cell tumours of the testes in adult patients: German clinical practice guideline, part II - Recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy.Urologia Internationalis, Urol Int, 2021. 105(3-4): p. 181-91., https://pubmed.ncbi.nlm.nih.gov/33486494 /

196. Toth, B, Baston-Büst, DM, Behre, HM, Bielfeld, A, Bohlmann, M, Bühling, K, et.al. Diagnosis and treatment before assisted reproductive treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 2, hemostaseology, andrology, genetics and history of malignant disease.Geburtshilfe und Frauenheilkunde, Geburtshilfe Frauenheilkd, 2019. 79(12): p. 1293-308., https://pubmed.ncbi.nlm.nih.gov/31875859 /

197. Jungwirth A, Diemer T, Kopa Z, Krausz C, Minhas S, Tournaye H, AU Guideline on Male Infertility. In EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019, 2020., http://uroweb.org/guidelines/compilations-of-all-guidelines/

198. Hsiao, W, Stahl, PJ, Osterberg, EC, Nejat, E, Palermo, GD, Rosenwaks, Z, et.al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience.Journal of Clinical Oncology, J Clin Oncol, 2011. 29(12): p. 1607-11., https://pubmed.ncbi.nlm.nih.gov/21402606 /

199. Corona, G, Minhas, S, Giwercman, A, Bettocchi, C, Dinkelman-Smit, M, Dohle, G, et.al. Sperm recovery and ICSI outcomes in men with non-obstructive azoospermia: a systematic review and meta-analysis.Human Reproduction Update, Hum Reprod Update, 2019. 25(6): p. 733-57., https://pubmed.ncbi.nlm.nih.gov/31665451 /

200. Levi-Setti, PE, Negri, L, Baggiani, A, Morenghi, E, Albani, E, Dioguardi, CMC, et.al. Testicular sperm extraction and intracytoplasmic sperm injection outcome in cancer survivors with no available cryopreserved sperm.Journal of Assisted Reproduction and Genetics, J Assist Reprod Genet, 2020. 37(4): p. 875-82., https://pubmed.ncbi.nlm.nih.gov/31981037/

201. Récher, C, Coiffier, B, Haioun, C, Molina, TJ, Fermé, C, Casasnovas, O, et.al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.The Lancet, Lancet, 2011. 378(9806): p. 1858-67., https://pubmed.ncbi.nlm.nih.gov/22118442 /

202. Habermann, TM, Weller, EA, Morrison, VA, Gascoyne, RD, Cassileth, PA, Cohn, JB, et.al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2006. 24(19): p. 3121-7., https://pubmed.ncbi.nlm.nih.gov/16754935 /

203. Coiffier, B, Thieblemont, C, Van Den Neste, E, Lepeu, G, Plantier, I, Castaigne, S, et.al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.Blood, Blood, 2010. 116(12): p. 2040-5., https://pubmed.ncbi.nlm.nih.gov/20548096 /

204. Fisher, RI, Gaynor, ER, Dahlberg, S, Oken, MM, Grogan, TM, Mize, EM, et.al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.The New England Journal of Medicine, N Engl J Med, 1993. 328(14): p. 1002-6., https://pubmed.ncbi.nlm.nih.gov/7680764 /

205. Cunningham, D, Hawkes, EA, Jack, A, Qian, W, Smith, P, Mouncey, P, et.al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.The Lancet, Lancet, 2013. 381(9880): p. 1817-26., https://pubmed.ncbi.nlm.nih.gov/23615461 /

206. Vitolo, U, Trněný, M, Belada, D, Burke, JM, Carella, AM, Chua, N, et.al. Obinutuzumab or Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in previously untreated diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(31): p. 3529-37., https://pubmed.ncbi.nlm.nih.gov/28796588 /

207. Wästerlid, T, Biccler, JL, Brown, PN, Bøgsted, M, Enblad, G, Mészáros Jørgensen, J, et.al. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.Annals of Oncology, Ann Oncol, 2018. 29(8): p. 1882-3., https://pubmed.ncbi.nlm.nih.gov/29790897 /

208. Oiwa, K, Fujita, K, Lee, S, Morishita, T, Tsukasaki, H, Negoro, E, et.al. Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis.ESMO Open, ESMO Open, 2021. 6(4): p. 100210., https://pubmed.ncbi.nlm.nih.gov/34271313/

209. Klanova, M, Sehn, LH, Bence-Bruckler, I, Cavallo, F, Jin, J, Martelli, M, et.al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.Blood, Blood, 2019. 133(9): p. 919-26., https://pubmed.ncbi.nlm.nih.gov/30617197 /

210. Ollila, TA, Kurt, H, Waroich, J, Vatkevich, J, Sturtevant, A, Patel, NR, et.al. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.Blood, Blood, 2021. 137(8): p. 1120-4., https://pubmed.ncbi.nlm.nih.gov/32877514/

211. Boehme, V, Schmitz, N, Zeynalova, S, Loeffler, M, Pfreundschuh, M, CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).Blood, Blood, 2009. 113(17): p. 3896-902., https://pubmed.ncbi.nlm.nih.gov/19144985 /

212. Blasberg, RG, Patlak, C, Fenstermacher, JD, Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion.The Journal of Pharmacology and Experimental Therapeutics, J Pharmacol Exp Ther, 1975. 195(1): p. 73-83., https://pubmed.ncbi.nlm.nih.gov/810575 /

213. Abramson, JS, Hellmann, M, Barnes, JA, Hammerman, P, Toomey, C, Takvorian, T, et.al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.Cancer, Cancer, 2010. 116(18): p. 4283-90., https://pubmed.ncbi.nlm.nih.gov/20564149 /

214. Ferreri, AJ, Bruno-Ventre, M, Donadoni, G, Ponzoni, M, Citterio, G, Foppoli, M, et.al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.British Journal of Haematology, Br J Haematol, 2015. 168(5): p. 654-62., https://pubmed.ncbi.nlm.nih.gov/25312994/

215. Puckrin, R, El Darsa, H, Ghosh, S, Peters, A, Owen, C, Stewart, D, Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.American Journal of Hematology, Am J Hematol, 2021. 96(7): p. 764-71., https://pubmed.ncbi.nlm.nih.gov/33811794 /

216. Orellana-Noia, VM, Reed, D, McCook, AA, Sen, JM, Barlow, CM, Malecek, MK, et.al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.Blood, Blood, 2021. 139(3): p. 413-23., https://pubmed.ncbi.nlm.nih.gov/34570876/

217. Schmitz, N, Frontzek, F, CNS prophylaxis in DLBCL: Time to say goodbye?Blood, Blood, 2022. 139(3): p. 315-7., https://pubmed.ncbi.nlm.nih.gov/35050332/

218. Lewis, KL, Jakobsen, LH, Villa, D, Bobillo, S, Smedby KE, Savage, KJ, High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: An international retrospective study of 2300 high-risk patientsASH Annual Meeting and Exposition, 2021.

219. Frontzek, F, Ziepert, M, Nickelsen, M, Altmann, B, Glass, B, Haenel, M, et.al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.The Lancet, Lancet Haematol, 2021. 8(4): p. e267-77., https://pubmed.ncbi.nlm.nih.gov/33667420 /

220. Gang, AO, Strøm, C, Pedersen, M, d'Amore, F, Pedersen, LM, Bukh, A, et.al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma GroupAnnals of Oncology, 2012. 23(1): p. 147-53., https://pubmed.ncbi.nlm.nih.gov/21460380/

221. Tilly, H, Morschhauser, F, Sehn, LH, Friedberg, JW, Trněný, M, Sharman, JP, et.al. Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma.The New England Journal of Medicine, N Engl J Med, 2021. 386(4): p. 351-63., https://pubmed.ncbi.nlm.nih.gov/34904799/

222. Wästerlid, T, Hartman, L, Székely, E, Jerkeman, M, Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.Hematological Oncology, Hematol Oncol, 2017. 35(2): p. 151-7., https://pubmed.ncbi.nlm.nih.gov/26369736/

223. Friedrichs, B, Nickelsen, M, Ziepert, M, Altmann, B, Haenel, M, Viardot, A, et.al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.British Journal of Haematology, Br J Haematol, 2019. 184(5): p. 760-8., https://pubmed.ncbi.nlm.nih.gov/30520013 /

224. Dornan, D, Bennett, F, Chen, Y, Dennis, M, Eaton, D, Elkins, K, et.al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.Blood, Blood, 2009. 114(13): p. 2721-9., https://pubmed.ncbi.nlm.nih.gov/19633198/

225. Stiff, PJ, Unger, JM, Cook, JR, Constine, LS, Couban, S, Stewart, DA, et.al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.The New England Journal of Medicine, N Engl J Med, 2013. 369(18): p. 1681-90., https://pubmed.ncbi.nlm.nih.gov/24171516 /

226. Chiappella, A, Martelli, M, Angelucci, E, Brusamolino, E, Evangelista, A, Carella, AM, et.al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.The Lancet, Lancet Oncol, 2017. 18(8): p. 1076-88., https://pubmed.ncbi.nlm.nih.gov/28668386 /

227. Cortelazzo, S, Tarella, C, Gianni, AM, Ladet, M, Barbui, AM, Rossi, A, et.al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomasJournal of Clinical Oncology, J Clin Oncol, 2016. 34(33): p. 4015-22., doi.org/10.1200/JCO.2016.67.2980

228. Le Gouill, S, Milpied, NJ, Lamy, T, Delwail, V, Gressin, R, Guyota, D, et.al. First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trialJournal of Clinical Oncology, Journal of Clinical Oncology, 2011. 29(15 Suppl): p. 8003.

229. Dührsen, U, Müller, S, Hertenstein, B, Thomssen, H, Kotzerke, J, Mesters, R, et.al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial.Journal of Clinical Oncology, J Clin Oncol, 2018. 36(20): p. 2024-34., https://pubmed.ncbi.nlm.nih.gov/29750632 /

230. Haioun, C, Mounier, N, Emile, JF, Ranta, D, Coiffier, B, Tilly, H, et.al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.Annals of Oncology, Ann Oncol, 2009. 20(12): p. 1985-92., https://pubmed.ncbi.nlm.nih.gov/19567453 /

231. Kostakoglu, L, Goldsmith, SJ, Leonard, JP, Christos, P, Furman, RR, Atasever, T, et.al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.Cancer, Cancer, 2006. 107(11): p. 2678-87., https://pubmed.ncbi.nlm.nih.gov/17063502 /

232. Mikhaeel, NG, Hutchings, M, Fields, PA, O'Doherty, MJ, Timothy, AR, FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.Annals of Oncology, Ann Oncol, 2005. 16(9): p. 1514-23., https://pubmed.ncbi.nlm.nih.gov/15980161 /

233. Spaepen, K, Stroobants, S, Dupont, P, Vandenberghe, P, Thomas, J, de Groot, T, et.al. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.Annals of Oncology, Ann Oncol, 2002. 13(9): p. 1356-63., https://pubmed.ncbi.nlm.nih.gov/12196360 /

234. Hanaoka, K, Hosono, M, Usami, K, Tatsumi, Y, Yamazoe, Y, Komeya, Y, et.al. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.Nuclear Medicine Communications, Nucl Med Commun, 2011. 32(8): p. 678-83., https://pubmed.ncbi.nlm.nih.gov/21499162 /

235. Hüttmann, A, Müller, S, Jöckel, KH, Dührsen, U, Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2010. 28(27): p. e488-9; author reply e490-1., https://pubmed.ncbi.nlm.nih.gov/20644097 /

236. Jacene, HA, Ishimori, T, Engles, JM, Leboulleux, S, Stearns, V, Wahl, RL, Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies.Journal of Nuclear Medicine, J Nucl Med, 2006. 47(6): p. 950-6., https://pubmed.ncbi.nlm.nih.gov/16741304 /

237. Lin, C, Itti, E, Haioun, C, Petegnief, Y, Luciani, A, Dupuis, J, et.al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.Journal of Nuclear Medicine, J Nucl Med, 2007. 48(10): p. 1626-32., https://pubmed.ncbi.nlm.nih.gov/17873129 /

238. Meignan, M, Gallamini, A, Meignan, M, Gallamini, A, Haioun, C, Report on the first international workshop on interim-PET-scan in lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2009. 50(8): p. 1257-60., https://pubmed.ncbi.nlm.nih.gov/19544140 /

239. Rekowski, J, Hüttmann, A, Schmitz, C, Müller, SP, Kurch, L, Kotzerke, J, et.al. Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: Comparison of the Deauville 5-Point Scale and the SUVJournal of Nuclear Medicine, J Nucl Med, 2021. 62(1): p. 37-42., https://pubmed.ncbi.nlm.nih.gov/32385164 /

240. Mikhaeel, NG, Cunningham, D, Counsell, N, McMillan, A, Radford, JA, Ardeshna, KM, et.al. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.British Journal of Haematology, Br J Haematol, 2021. 192(3): p. 504-13., https://pubmed.ncbi.nlm.nih.gov/32621535 /

241. Casasnovas, RO, Ysebaert, L, Thieblemont, C, Bachy, E, Feugier, P, Delmer, A, et.al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.Blood, Blood, 2017. 130(11): p. 1315-1326., https://pubmed.ncbi.nlm.nih.gov/28701367 /

242. Kasamon, YL, Wahl, RL, Ziessman, HA, Blackford, AL, Goodman, SN, Fidyk, CA, et.al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.Biology of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 2009. 15(2): p. 242-8., https://pubmed.ncbi.nlm.nih.gov/19167684 /

243. Pardal, E, Coronado, M, Martín, A, Grande, C, Marín-Niebla, A, Panizo, C, et.al. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.British Journal of Haematology, Br J Haematol, 2014. 167(3): p. 327-36., https://pubmed.ncbi.nlm.nih.gov/25066542 /

244. Stewart, DA, Kloiber, R, Owen, C, Bahlis, NJ, Duggan, P, Mansoor, A, et.al. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2014. 55(9): p. 2064-70., https://pubmed.ncbi.nlm.nih.gov/24188476 /

245. Swinnen, LJ, Li, H, Quon, A, Gascoyne, R, Hong, F, Ranheim, EA, et.al. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).British Journal of Haematology, Br J Haematol, 2015. 170(1): p. 56-65., https://pubmed.ncbi.nlm.nih.gov/25823885 /

246. Sehn, LH, Hary, ELG, Gill, KK, Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC).Blood, Blood, 2014. 124: p. 392.

247. Sehn, LH, Savage, KJ, Hoskins, P, Limited-stage diffuse large B-cell lymphoma (DLBCL) patients with a negative PET scan following three cycles of R-CHOP can be effectively treated with abbreviated chemoimmunotherapy alone.Blood, Blood, 2007. 110: p. 787.

248. Gómez León, N, Delgado-Bolton, RC, Del Campo Del Val, L, Cabezas, B, Arranz, R, García, M, et.al. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.Clinical Nuclear Medicine, Clin Nucl Med, 2017. 42(8): p. 595-602., https://pubmed.ncbi.nlm.nih.gov/28604477 /

249. Barrington, SF, Mikhaeel, NG, Kostakoglu, L, Meignan, M, Hutchings, M, Müeller, SP, et.al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.Journal of Clinical Oncology, J Clin Oncol, 2014. 32(27): p. 3048-58., https://pubmed.ncbi.nlm.nih.gov/25113771 /

250. Juweid, ME, Stroobants, S, Hoekstra, OS, Mottaghy, FM, Dietlein, M, Guermazi, A, et.al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2007. 25(5): p. 571-8., https://pubmed.ncbi.nlm.nih.gov/17242397 /

251. Kostakoglu, L, Martelli, M, Sehn, LH, Belada, D, Carella, AM, Chua, N, et.al. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.Blood Advances, Blood Adv, 2021. 5(5): p. 1283-90., https://pubmed.ncbi.nlm.nih.gov/33651099 /

252. Pregno, P, Chiappella, A, Bellò, M, Botto, B, Ferrero, S, Franceschetti, S, et.al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.Blood, Blood, 2012. 119(9): p. 2066-73., https://pubmed.ncbi.nlm.nih.gov/22234681 /

253. Safar, V, Dupuis, J, Itti, E, Jardin, F, Fruchart, C, Bardet, S, et.al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.Journal of Clinical Oncology, J Clin Oncol, 2012. 30(2): p. 184-90., https://pubmed.ncbi.nlm.nih.gov/22162590 /

254. Bishton, MJ, Hughes, S, Richardson, F, James, E, Bessell, E, Sovani, V, et.al. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.British Journal of Haematology, Br J Haematol, 2016. 172(2): p. 246-54., https://pubmed.ncbi.nlm.nih.gov/26577576 /

255. Kanemasa, Y, Shimoyama, T, Sasaki, Y, Tamura, M, Sawada, T, Omuro, Y, et.al. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.Medical Oncology, Med Oncol, 2017. 34(2): p. 29., https://pubmed.ncbi.nlm.nih.gov/28083854 /

256. Freeman, CL, Savage, KJ, Villa, DR, Scott, DW, Srour, L, Gerrie, AS, et.al. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.Blood, Blood, 2021. 137(7): p. 929-38., https://pubmed.ncbi.nlm.nih.gov/32871586 /

257. Pfreundschuh, M, Christofyllakis, K, Altmann, B, Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHLJournal of Clinical Oncology, J Clin Onc, 2017. 35: p. 7506.

258. Pfreundschuh, M, Murawski, N, Christofyllakis, K, Excellent outcome of elderly patients with favourable-prognosis DLBCL treated with 4 cycles chop/chlip-14 plus 8 applications of rituximab and a pet-based intensification strategy that includes involved-site radiotherapy (IS-RT): results of the first 120 patients of the optimal>60 trial of the dshnhlBlood, Blood, 2017. 130:

259. Horning, SJ, Weller, E, Kim, K, Earle, JD, O'Connell, MJ, Habermann, TM, et.al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.Journal of Clinical Oncology, J Clin Oncol, 2004. 22(15): p. 3032-8., https://pubmed.ncbi.nlm.nih.gov/15210738/

260. Bonnet, C, Fillet, G, Mounier, N, Ganem, G, Molina, TJ, Thiéblemont, C, et.al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.Journal of Clinical Oncology, J Clin Oncol, 2007. 25(7): p. 787-92., https://pubmed.ncbi.nlm.nih.gov/17228021/

261. Miller, TP, Dahlberg, S, Cassady, JR, Adelstein, DJ, Spier, CM, Grogan, TM, et.al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.The New England Journal of Medicine, N Engl J Med, 1998. 339(1): p. 21-6., https://pubmed.ncbi.nlm.nih.gov/9647875 /

262. Stephens, DM, Li, H, LeBlanc, ML, Puvvada, SD, Persky, D, Friedberg, JW, et.al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-Cell lymphoma: Final and long-term analysis of Southwest Oncology Group Study S8736.Journal of Clinical Oncology, J Clin Oncol, 2016. 34(25): p. 2997-3004., https://pubmed.ncbi.nlm.nih.gov/27382104/

263. Reyes, F, Lepage, E, Ganem, G, Molina, TJ, Brice, P, Coiffier, B, et.al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.The New England Journal of Medicine, N Engl J Med, 2005. 352(12): p. 1197-205., https://pubmed.ncbi.nlm.nih.gov/15788496/

264. Pfreundschuh, M, Murawski, N, Zimpert, M, Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLAJournal of Clinical Oncology, J Clin Oncol, 2018. 36: p. 7574.

265. Pfreundschuh, M, Kuhnt, E, Trümper, L, Osterborg, A, Trneny, M, Shepherd, L, et.al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.The Lancet, Lancet Oncol, 2011. 12(11): p. 1013-22., https://pubmed.ncbi.nlm.nih.gov/21940214 /

266. Dabaja, BS, Vanderplas, AM, Crosby-Thompson, AL, Abel, GA, Czuczman, MS, Friedberg, JW, et.al. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.Cancer, Cancer, 2015. 121(7): p. 1032-9., https://pubmed.ncbi.nlm.nih.gov/25492236 /

267. Kwon, J, Kim, IH, Kim, BH, Kim, TM, Heo, DS, Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2015. 92(1): p. 91-8., https://pubmed.ncbi.nlm.nih.gov/25721091 /

268. Parikh, RR, Yahalom, J, Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.Leukemia and Lymphoma, Leuk Lymphoma, 2017. 58(3): p. 614-22., https://pubmed.ncbi.nlm.nih.gov/27685446 /

269. Cassidy, RJ, Jegadeesh, N, Switchenko, J, Danish, H, Esiashvili, N, Flowers, CR, et.al. The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.Leukemia and Lymphoma, Leuk Lymphoma, 2016. 57(8): p. 1876-82., https://pubmed.ncbi.nlm.nih.gov/26759182 /

270. Held, G, Zeynalova, S, Murawski, N, Ziepert, M, Kempf, B, Viardot, A, et.al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.Journal of Clinical Oncology, J Clin Oncol, 2013. 31(32): p. 4115-22., https://pubmed.ncbi.nlm.nih.gov/24062391 /

271. Bruno Ventre, M, Ferreri, AJ, Gospodarowicz, M, Govi, S, Messina, C, Porter, D, et.al. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).The Oncologist, Oncologist, 2014. 19(3): p. 291-8., https://pubmed.ncbi.nlm.nih.gov/24567283 /

272. Messina, C, Ferreri, AJ, Govi, S, Bruno-Ventre, M, Gracia Medina, EA, Porter, D, et.al. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).British Journal of Haematology, Br J Haematol, 2014. 164(6): p. 834-40., https://pubmed.ncbi.nlm.nih.gov/24383942 /

273. Ma, S, Zhang, Y, Li, Z, Yan, H, Xia, L, Shi, W, et.al. Role of radiation therapy differs between stages in primary bone large b-Cell lymphoma in rituximab era: A population-based analysis.Frontiers in Oncology, Front Oncol, 2020. 10: p. 1157., https://pubmed.ncbi.nlm.nih.gov/32760674 /

274. Ramadan, KM, Shenkier, T, Sehn, LH, Gascoyne, RD, Connors, JM, A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.Annals of Oncology, Ann Oncol, 2007. 18(1): p. 129-35., https://pubmed.ncbi.nlm.nih.gov/17018705 /

275. Tao, R, Allen, PK, Rodriguez, A, Shihadeh, F, Pinnix, CC, Arzu, I, et.al. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2015. 92(1): p. 122-9., https://pubmed.ncbi.nlm.nih.gov/25754633 /

276. Girinsky, T, Auperin, A, Ribrag, V, Elleuch, M, Ferme, C, Bonniaud, G, et.al. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patientsInternational Journal of Radiation Oncology, Biology, Physics, 2014. 89(5): p. 1047-52., https://pubmed.ncbi.nlm.nih.gov/25035208/

277. Lee, YK, Cook, G, Flower, MA, Rowbottom, C, Shahidi, M, Sharma, B, et.al. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma.Radiotherapy and Oncology, Radiother Oncol, 2004. 73(3): p. 277-83., https://pubmed.ncbi.nlm.nih.gov/15588871 /

278. Terezakis, SA, Hunt, MA, Kowalski, A, McCann, P, Schmidtlein, CR, Reiner, A, et.al. [18F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2011. 81(3): p. 615-22., https://pubmed.ncbi.nlm.nih.gov/20933343 /

279. Terezakis, SA, Schöder, H, Kowalski, A, McCann, P, Lim, R, Turlakov, A, et.al. A prospective study of 18FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2014. 89(2): p. 376-83., https://pubmed.ncbi.nlm.nih.gov/24726287 /

280. Mikhaeel, NG, Milgrom, SA, Terezakis, S, Berthelsen, AK, Hodgson, D, Eich, HT, et.al. The optimal use of imaging in radiation therapy for lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG).International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2019. 104(3): p. 501-12., https://pubmed.ncbi.nlm.nih.gov/30763664 /

281. Wirth, A, Mikhaeel, NG, Aleman, BMP, Pinnix, CC, Constine, LS, Ricardi, U, et.al. Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group guidelines.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2020. 107(5): p. 909-33., https://pubmed.ncbi.nlm.nih.gov/32272184 /

282. Kriz, J, Spickermann, M, Lehrich, P, Schmidberger, H, Reinartz, G, Eich, H, et.al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.Strahlentherapie und Onkologie, Strahlenther Onkol, 2015. 191(9): p. 717-25., https://pubmed.ncbi.nlm.nih.gov/25876905 /

283. Paumier, A, Ghalibafian, M, Gilmore, J, Beaudre, A, Blanchard, P, el Nemr, M, et.al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2012. 82(4): p. 1522-7., https://pubmed.ncbi.nlm.nih.gov/21705151 /

284. Rechner, LA, Maraldo, MV, Vogelius, IR, Zhu, XR, Dabaja, BS, Brodin, NP, et.al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath holdRadiotherapy and Oncology, 2017. 125(1): p. 41-7.

285. Edvardsson, A, Kügele, M, Alkner, S, Enmark, M, Nilsson, J, Kristensen, I, et.al. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy.Acta Oncologica, Acta Oncol, 2019. 58(1): p. 95-104., https://pubmed.ncbi.nlm.nih.gov/30280626 /

286. Charpentier, AM, Conrad, T, Sykes, J, Ng, A, Zhou, R, Parent, A, et.al. Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose.Practical Radiation Oncology, Pract Radiat Oncol, 2014. 4(3): p. 174-80., https://pubmed.ncbi.nlm.nih.gov/24766684 /

287. Petersen, PM, Aznar, MC, Berthelsen, AK, Loft, A, Schut, DA, Maraldo, M, et.al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold.Acta Oncologica, Acta Oncol, 2015. 54(1): p. 60-6., https://pubmed.ncbi.nlm.nih.gov/25025999/

288. Aznar, MC, Maraldo, MV, Schut, DA, Lundemann, M, Brodin, NP, Vogelius, IR, et.al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2015. 92(1): p. 169-74., https://pubmed.ncbi.nlm.nih.gov/25754634 /

289. Starke, A, Bowden, J, Lynn, R, Hall, K, Hudson, K, Rato, A, et.al. Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma.Radiotherapy and Oncology, Radiother Oncol, 2018. 129(3): p. 449-55., https://pubmed.ncbi.nlm.nih.gov/30245037 /

290. Everett, AS, Hoppe, BS, Louis, D, McDonald, AM, Morris, CG, Mendenhall, NP, et.al. Comparison of techniques for involved-site radiation therapy in patients with lower mediastinal lymphoma.Practical Radiation Oncology, Pract Radiat Oncol, 2019. 9(6): p. 426-34., https://pubmed.ncbi.nlm.nih.gov/31128302 /

291. Voong, KR, McSpadden, K, Pinnix, CC, Shihadeh, F, Reed, V, Salehpour, MR, et.al. Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma.Radiation Oncology, Radiat Oncol, 2014. 9: p. 94., https://pubmed.ncbi.nlm.nih.gov/24735767 /

292. Girinsky, T, Pichenot, C, Beaudre, A, Ghalibafian, M, Lefkopoulos, D, Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2006. 64(1): p. 218-26., https://pubmed.ncbi.nlm.nih.gov/16169675 /

293. Cella, L, Liuzzi, R, Magliulo, M, Conson, M, Camera, L, Salvatore, M, et.al. Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques.Radiation Oncology, Radiat Oncol, 2010. 5: p. 33., https://pubmed.ncbi.nlm.nih.gov/20459790 /

294. Antoni, D, Natarajan-Ame, S, Meyer, P, Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin diseaseInternational Journal of Radiation Oncology, Biology, Physics, Radiat Oncol, 2013. 8: p. 112., https://pubmed.ncbi.nlm.nih.gov/23638873/

295. Chera, BS, Rodriguez, C, Morris, CG, Louis, D, Yeung, D, Li, Z, et.al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2009. 75(4): p. 1173-80., https://pubmed.ncbi.nlm.nih.gov/19386423 /

296. Cella, L, Conson, M, Pressello, MC, Molinelli, S, Schneider, U, Donato, V, et.al. Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms.Radiation Oncology, Radiat Oncol, 2013. 8: p. 22., https://pubmed.ncbi.nlm.nih.gov/23360559 /

297. De Sanctis, V, Bolzan, C, D'Arienzo, M, Bracci, S, Fanelli, A, Cox, MC, et.al. Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?Radiation Oncology, Radiat Oncol, 2012. 7: p. 129., https://pubmed.ncbi.nlm.nih.gov/22857015 /

298. Filippi, AR, Ragona, R, Piva, C, Scafa, D, Fiandra, C, Fusella, M, et.al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2015. 92(1): p. 161-8., https://pubmed.ncbi.nlm.nih.gov/25863763 /

299. Maraldo, MV, Brodin, NP, Aznar, MC, Vogelius, IR, Munck af Rosenschöld, P, Petersen, PM, et.al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.Annals of Oncology, Ann Oncol, 2013. 24(8): p. 2113-8., https://pubmed.ncbi.nlm.nih.gov/23619032 /

300. Schneider, U, Sumila, M, Robotka, J, Weber, D, Gruber, G, Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study.Radiation Oncology, Radiat Oncol, 2014. 9: p. 58., https://pubmed.ncbi.nlm.nih.gov/24548307 /

301. Weber, DC, Johanson, S, Peguret, N, Cozzi, L, Olsen, DR, Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2011. 81(2): p. 490-7., https://pubmed.ncbi.nlm.nih.gov/20800383 /

302. Pepper, NB, Oertel, M, Kittel, C, Kröger, KJ, Elsayad, K, Haverkamp, U, et.al. Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma.Strahlentherapie und Onkologie, Strahlenther Onkol, 2021. 197(1): p. 56-62., https://pubmed.ncbi.nlm.nih.gov/32945894/

303. Besson, N, Pernin, V, Zefkili, S, Kirova, YM, Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-centre experience and review of the literature.The British Journal of Radiology, Br J Radiol, 2016. 89(1059): p. 20150409., https://pubmed.ncbi.nlm.nih.gov/26744079 /

304. Hoppe, BS, Flampouri, S, Su, Z, Latif, N, Dang, NH, Lynch, J, et.al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2012. 84(2): p. 449-55., https://pubmed.ncbi.nlm.nih.gov/22386373 /

305. Maraldo, MV, Brodin, NP, Aznar, MC, Vogelius, IR, Munck Af Rosenschöld, P, Petersen, PM, et.al. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy.Radiotherapy and Oncology, Radiother Oncol, 2014. 110(3): p. 441-7., https://pubmed.ncbi.nlm.nih.gov/24188865 /

306. Horn, S, Fournier-Bidoz, N, Pernin, V, Peurien, D, Vaillant, M, Dendale, R, et.al. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy.Cancer Radiotherapie, Cancer Radiother, 2016. 20(2): p. 98-103., https://pubmed.ncbi.nlm.nih.gov/26992750 /

307. Sachsman, S, Hoppe, BS, Mendenhall, NP, Holtzman, A, Li, Z, Slayton, W, et.al. Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2015. 56(7): p. 2019-24., https://pubmed.ncbi.nlm.nih.gov/25315071/

308. Baues, C, Marnitz, S, Engert, A, Baus, W, Jablonska, K, Fogliata, A, et.al. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation: A planning comparison of deep inspiration breath hold intensity modulation radiotherapy and intensity modulated proton therapy.Radiation Oncology, Radiat Oncol, 2018. 13(1): p. 122., https://pubmed.ncbi.nlm.nih.gov/29970105 /

309. König, L, Bougatf, N, Hörner-Rieber, J, Chaudhri, N, Mielke, T, Klüter, S, et.al. Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison.Strahlentherapie und Onkologie, Strahlenther Onkol, 2019. 195(7): p. 677-87., https://pubmed.ncbi.nlm.nih.gov/30972453 /

310. Sachsman, S, Flampouri, S, Li, Z, Lynch, J, Mendenhall, NP, Hoppe, BS, Proton therapy in the management of non-Hodgkin lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2015. 56(9): p. 2608-12., https://pubmed.ncbi.nlm.nih.gov/25669925 /

311. Taparra, K, Lester, SC, Harmsen, WS, Petersen, M, Funk, RK, Blanchard, MJ, et.al. Reducing heart dose with protons and cardiac substructure sparing for mediastinal lymphoma treatment.International Journal of Particle Therapy, Int J Part Ther, 2020. 7(1): p. 1-12., https://pubmed.ncbi.nlm.nih.gov/33094130 /

312. Li, J, Dabaja, B, Reed, V, Allen, PK, Cai, H, Amin, MV, et.al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2011. 81(1): p. 167-74., https://pubmed.ncbi.nlm.nih.gov/20643518 /

313. Toltz, A, Shin, N, Mitrou, E, Laude, C, Freeman, CR, Seuntjens, J, et.al. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential.Journal of Applied Clinical Medical Physics, J Appl Clin Med Phys, 2015. 16(5): p. 167-78., https://pubmed.ncbi.nlm.nih.gov/26699298 /

314. Dabaja, BS, Hoppe, BS, Plastaras, JP, Newhauser, W, Rosolova, K, Flampouri, S, et.al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.Blood, Blood, 2018. 132(16): p. 1635-46., https://pubmed.ncbi.nlm.nih.gov/30108066 /

315. Illidge, T, Specht, L, Yahalom, J, Aleman, B, Berthelsen, AK, Constine, L, et.al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2014. 89(1): p. 49-58., https://pubmed.ncbi.nlm.nih.gov/24725689 /

316. Lowry, L, Smith, P, Qian, W, Falk, S, Benstead, K, Illidge, T, et.al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.Radiotherapy and Oncology, Radiother Oncol, 2011. 100(1): p. 86-92., https://pubmed.ncbi.nlm.nih.gov/21664710 /

317. Tubiana, M, Carde, P, Burgers, JM, Cosset, JM, Van Glabbeke, M, Somers, R, Prognostic factors in non-Hodgkin's lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 1986. 12(4): p. 503-14., https://pubmed.ncbi.nlm.nih.gov/3516950 /

318. Pfreundschuh, M, Schubert, J, Ziepert, M, Schmits, R, Mohren, M, Lengfelder, E, et.al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).The Lancet, Lancet Oncol, 2008. 9(2): p. 105-16., https://pubmed.ncbi.nlm.nih.gov/18226581 /

319. Kelsey, CR, Broadwater, G, James, O, Chino, J, Diehl, L, Beaven, AW, et.al. Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2019. 105(1): p. 96-101., https://pubmed.ncbi.nlm.nih.gov/30858144 /

320. Pfreundschuh, MG, Trümper, L, Ma, D, Österborg, A, Pettengell, R, Trneny, M, et.al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysisJournal of Clinical Oncology, 2004. 22(no. 14_suppl): p. 6500.

321. Peyrade, F, Bologna, S, Delwail, V, Emile, JF, Pascal, L, Fermé, C, et.al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.The Lancet, Lancet Haematol, 2017. 4(1): p. e46-55., https://pubmed.ncbi.nlm.nih.gov/28041583/

322. Lakshmaiah, KC, Asati, V, Babu K, G, D, L, Jacob, LA, M C, SB, et.al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.European Journal of Haematology, Eur J Haematol, 2018. 100(6): p. 644-8., https://pubmed.ncbi.nlm.nih.gov/29569279/

323. Rozental, A, Gafter-Gvili, A, Vidal, L, Raanani, P, Gurion, R, The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.Hematological Oncology, Hematol Oncol, 2019. 37(1): p. 27-34., https://pubmed.ncbi.nlm.nih.gov/30216478 /

324. Witzens-Harig, M, Benner, A, McClanahan, F, Klemmer, J, Brandt, J, Brants, E, et.al. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.British Journal of Haematology, Br J Haematol, 2015. 171(5): p. 710-9., https://pubmed.ncbi.nlm.nih.gov/26449739 /

325. Thieblemont, C, Tilly, H, Gomes da Silva, M, Casasnovas, RO, Fruchart, C, Morschhauser, F, et.al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.Journal of clinical Oncology, J Clin Oncol, 2017. 35(22): p. 2473-81., https://pubmed.ncbi.nlm.nih.gov/28426350 /

326. Crump, M, Leppä, S, Fayad, L, Lee, JJ, Di Rocco, A, Ogura, M, et.al. Randomized, double-blind, phase III trial of Enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2016. 34(21): p. 2484-92., https://pubmed.ncbi.nlm.nih.gov/27217449/

327. Witzig, TE, Tobinai, K, Rigacci, L, Ikeda, T, Vanazzi, A, Hino, M, et.al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.Annals of Oncology, Ann Oncol, 2018. 29(3): p. 707-14., https://pubmed.ncbi.nlm.nih.gov/29253068 /

328. Oberic, L, Peyrade, F, Puyade, M, Bonnet, C, Dartigues-Cuillères, P, Fabiani, B, et.al. Subcutaneous Rituximab-miniCHOP compared with subcutaneous Rituximab-miniCHOP plus Lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older.Journal of Clinical Oncology, J Clin Oncol, 2021. 39(11): p. 1203-13., https://pubmed.ncbi.nlm.nih.gov/33444079 /

329. Thieblemont, C, Grossoeuvre, A, Houot, R, Broussais-Guillaumont, F, Salles, G, Traullé, C, et.al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome.Annals of Oncology, Ann Oncol, 2008. 19(4): p. 774-9., https://pubmed.ncbi.nlm.nih.gov/18065404/

330. Lichtman, SM, Boparai, MK, Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy.Current Treatment Options in Oncology, Curr Treat Options Oncol, 2008. 9(2-3): p. 191-203., https://pubmed.ncbi.nlm.nih.gov/18663583 /

331. Peyrade, F, Jardin, F, Thieblemont, C, Thyss, A, Emile, JF, Castaigne, S, et.al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.The Lancet, Lancet Oncol, 2011. 12(5): p. 460-8., https://pubmed.ncbi.nlm.nih.gov/21482186 /

332. Storti, S, Spina, M, Pesce, EA, Salvi, F, Merli, M, Ruffini, A, et.al. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Haematologica, Haematologica, 2018. 103(8): p. 1345-1350., https://pubmed.ncbi.nlm.nih.gov/29748444 /

333. Weidmann, E, Neumann, A, Fauth, F, Atmaca, A, Al-Batran, SE, Pauligk, C, et.al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.Annals of Oncology, Ann Oncol, 2011. 22(8): p. 1839-44., https://pubmed.ncbi.nlm.nih.gov/21257672 /

334. Windebank, AJ, Grisold, W, Chemotherapy-induced neuropathy.Journal of the Peripheral Nervous System, J Peripher Nerv Syst, 2008. 13(1): p. 27-46., https://pubmed.ncbi.nlm.nih.gov/18346229 /

335. Rummel, MJ, Niederle, N, Maschmeyer, G, Banat, GA, von Grünhagen, U, Losem, C, et.al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.The Lancet, Lancet, 2013. 381(9873): p. 1203-10., https://pubmed.ncbi.nlm.nih.gov/23433739 /

336. Sawaki, A, Miyazaki, K, Yamaguchi, M, Takeuchi, T, Kobayashi, K, Imai, H, et.al. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.International Journal of Hematology, Int J Hematol, 2020. 111(5): p. 686-91., https://pubmed.ncbi.nlm.nih.gov/31993939 /

337. Hatzl, S, Posch, F, Rezai, A, Gornicec, M, Beham-Schmid, C, Magnes, T, et.al. Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy.Supportive Care in Cancer, Support Care Cancer, 2021. 29(9): p. 5197-207., https://pubmed.ncbi.nlm.nih.gov/33625586 /

338. Moccia, AA, Schaff, K, Freeman, C, Hoskins, PJ, Klasa, RJ, Savage, KJ, et.al. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.Blood Advances, Blood Adv, 2021. 5(5): p. 1483-9., https://pubmed.ncbi.nlm.nih.gov/33683338 /

339. Fridrik, MA, Jaeger, U, Petzer, A, Willenbacher, W, Keil, F, Lang, A, et.al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group (Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT)(NHL-14).European Journal of Cancer, Eur J Cancer, 2016. 58: p. 112-21., https://pubmed.ncbi.nlm.nih.gov/26990931 /

340. Mian, M, Wasle, I, Gamerith, G, Mondello, P, Melchardt, T, Jäger, T, et.al. R-CHOP versus R-COMP: are they really equally effective?Clinical Oncology, Clin Oncol (R Coll Radiol), 2014. 26(10): p. 648-52., https://pubmed.ncbi.nlm.nih.gov/24929649 /

341. Sancho, JM, Fernandez-Alvarez, R, Gual-Capllonch, F, Gonzalez-Garcia, E, Grande, C, Gutierrez, N, et.al. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.Cancer medicine, Cancer Med, 2021. 10(4): p. 1314-26., https://pubmed.ncbi.nlm.nih.gov/33492774 /

342. Limat, S, Daguindau, E, Cahn, JY, Nerich, V, Brion, A, Perrin, S, et.al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.Journal of Clinical Pharmacy and Therapeutics, J Clin Pharm Ther, 2014. 39(2): p. 168-74., https://pubmed.ncbi.nlm.nih.gov/24384030 /

343. Rohlfing, S, Aurich, M, Schöning, T, Ho, AD, Witzens-Harig, M, Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.Clinical Lymphoma, Myeloma and Leukemia, Clin Lymphoma Myeloma Leuk, 2015. 15(8): p. 458-63., https://pubmed.ncbi.nlm.nih.gov/25899891 /

344. Annibali, O, Chiodi, F, Cenfra, N, Sarlo, C, Mega, S, Cavallari, I, et.al. 'Real Life' experience in a 'difficult to treat' patient population of non-Hodgkin lymphomas using the R-COMP regimen.Leukemia and Lymphoma, Leuk Lymphoma, 2016. 57(12): p. 2919-22., https://pubmed.ncbi.nlm.nih.gov/27063923 /

345. Rigacci, L, Annibali, O, Kovalchuk, S, Bonifacio, E, Pregnolato, F, Angrilli, F, et.al. Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.Hematological Oncology, Hematol Oncol, 2020. 38(4): p. 478-86., https://pubmed.ncbi.nlm.nih.gov/32542788 /

346. Wright, GW, Huang, DW, Phelan, JD, Coulibaly, ZA, Roulland, S, Young, RM, et.al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications.Cancer Cell, Cancer Cell, 2020. 37(4): p. 551-68.e14., https://pubmed.ncbi.nlm.nih.gov/32289277/

347. Bojarczuk, K, Wienand, K, Ryan, JA, Chen, L, Villalobos-Ortiz, M, Mandato, E, et.al. Targeted inhibition of PI3Ka/d is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.Blood, Blood, 2019. 133(1): p. 70-80., https://pubmed.ncbi.nlm.nih.gov/30322870 /

348. Swerdlow, SH, Campo, E, Pileri, SA, Harris, NL, Stein, H, Siebert, R, et.al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood, Blood, 2016. 127(20): p. 2375-90., https://pubmed.ncbi.nlm.nih.gov/26980727 /

349. Abramson, JS, The spectrum of double hit lymphomasHematology/Oncology Clinics of North America, Hematol Oncol Clin North Am, 2016. 30(6): p. 1239-49., https://pubmed.ncbi.nlm.nih.gov/27888878 /

350. Abramson, JS, Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?Cancer, Cancer, 2019. 125(18): p. 3111-20., https://pubmed.ncbi.nlm.nih.gov/31287161 /

351. Davies, A, Double-hit lymphoma: So what?Hematological Oncology, Hematol Oncol, 2019. 37 Suppl 1(Suppl 1): p. 19-23., https://pubmed.ncbi.nlm.nih.gov/31187528 /

352. Johnson, NA, Savage, KJ, Ludkovski, O, Ben-Neriah, S, Woods, R, Steidl, C, et.al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.Blood, Blood, 2009. 114(11): p. 2273-9., https://pubmed.ncbi.nlm.nih.gov/19597184 /

353. Le Gouill, S, Talmant, P, Touzeau, C, Moreau, A, Garand, R, Juge-Morineau, N, et.al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.Haematologica, Haematologica, 2007. 92(10): p. 1335-42., https://pubmed.ncbi.nlm.nih.gov/18024371 /

354. Niitsu, N, Okamoto, M, Miura, I, Hirano, M, Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.Leukemia, Leukemia, 2009. 23(4): p. 777-83., https://pubmed.ncbi.nlm.nih.gov/19151788 /

355. Snuderl, M, Kolman, OK, Chen, YB, Hsu, JJ, Ackerman, AM, Dal Cin, P, et.al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.The American Journal of Surgical Pathology, Am J Surg Pathol, 2010. 34(3): p. 327-40., https://pubmed.ncbi.nlm.nih.gov/20118770 /

356. Rosenwald, A, Bens, S, Advani, R, Barrans, S, Copie-Bergman, C, Elsensohn, MH, et.al. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker ConsortiumJournal of Clinical Oncology, J Clin Oncol, 2019. 37(35): p. 3359-68., https://pubmed.ncbi.nlm.nih.gov/31498031/

357. Rosenwald, A, Sehn, LH, Maucort-Boulch, D, Prognostic significance of MYC single, double, triple hit and MYC-translocation partner status in diffuse large B-cell lymphoma - a study by the Lunenburg Lymphoma Biomarker Consortium (LLBC)Blood, Blood, 2018. 132(Suppl 1): p. 344.

358. Howlett, C, Snedecor, SJ, Landsburg, DJ, Svoboda, J, Chong, EA, Schuster, SJ, et.al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.British Journal of Haematology, Br J Haematol, 2015. 170(4): p. 504-14., https://pubmed.ncbi.nlm.nih.gov/25907897 /

359. Landsburg, DJ, Falkiewicz, MK, Maly, J, Blum, KA, Howlett, C, Feldman, T, et.al. Outcomes of patients with double-hit lymphoma who achieve first complete remission.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(20): p. 2260-7., https://pubmed.ncbi.nlm.nih.gov/28475457 /

360. Petrich, AM, Gandhi, M, Jovanovic, B, Castillo, JJ, Rajguru, S, Yang, DT, et.al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.Blood, Blood, 2014. 124(15): p. 2354-61., https://pubmed.ncbi.nlm.nih.gov/25161267 /

361. Schommers, P, Hentrich, M, Hoffmann, C, Gillor, D, Zoufaly, A, Jensen, B, et.al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort.British Journal of Haematology, Br J Haematol, 2015. 168(6): p. 806-10., https://pubmed.ncbi.nlm.nih.gov/25403997 /

362. Ribera, JM, Oriol, A, Morgades, M, González-Barca, E, Miralles, P, López-Guillermo, A, et.al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.British Journal of Haematology, Br J Haematol, 2008. 140(4): p. 411-9., https://pubmed.ncbi.nlm.nih.gov/18162120 /

363. Wyen, C, Jensen, B, Hentrich, M, Siehl, J, Sabranski, M, Esser, S, et.al. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.AIDS, AIDS, 2012. 26(4): p. 457-64., https://pubmed.ncbi.nlm.nih.gov/22112600 /

364. Boué, F, Gabarre, J, Gisselbrecht, C, Reynes, J, Cheret, A, Bonnet, F, et.al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2006. 24(25): p. 4123-8., https://pubmed.ncbi.nlm.nih.gov/16896005 /

365. Barta, SK, Xue, X, Wang, D, Tamari, R, Lee, JY, Mounier, N, et.al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.Blood, Blood, 2013. 122(19): p. 3251-62., https://pubmed.ncbi.nlm.nih.gov/24014242 /

366. Kaplan, LD, Lee, JY, Ambinder, RF, Sparano, JA, Cesarman, E, Chadburn, A, et.al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.Blood, Blood, 2005. 106(5): p. 1538-43., https://pubmed.ncbi.nlm.nih.gov/15914552 /

367. Bartlett, NL, Wilson, WH, Jung, SH, Hsi, ED, Maurer, MJ, Pederson, LD, et.al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase III intergroup trial alliance/CALGB 50303.Journal of Clinical Oncology, J Clin Oncol, 2019. 37(21): p. 1790-9., https://pubmed.ncbi.nlm.nih.gov/30939090 /

368. Bohlius, J, Schmidlin, K, Costagliola, D, Fätkenheuer, G, May, M, Caro-Murillo, AM, et.al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.Antiviral Therapy, Antivir Ther, 2009. 14(8): p. 1065-74., https://pubmed.ncbi.nlm.nih.gov/20032536 /

369. Barta, SK, Samuel, MS, Xue, X, Wang, D, Lee, JY, Mounier, N, et.al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.Annals of Oncology, Ann Oncol, 2015. 26(5): p. 958-66., https://pubmed.ncbi.nlm.nih.gov/25632071 /

370. Welz, T, Wyen, C, Hensel, M, Drug interactions in the treatment of malignancy in HIV-infected patients.Oncology Research and Treatment, Oncol Res Treat, 2017. 40(3): p. 120-7., https://pubmed.ncbi.nlm.nih.gov/28253501 /

371. Armitage, JO, Weisenburger, DD, New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.Journal of Clinical Oncology, J Clin Oncol, 1998. 16(8): p. 2780-95., https://pubmed.ncbi.nlm.nih.gov/9704731 /

372. Campo, E, Swerdlow, SH, Harris, NL, Pileri, S, Stein, H, Jaffe, ES, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.Blood, Blood, 2011. 117(19): p. 5019-32., https://pubmed.ncbi.nlm.nih.gov/21300984 /

373. Chapuy, B, Stewart, C, Dunford, AJ, Kim, J, Wienand, K, Kamburov, A, et.al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.Blood, Blood, 2019. 134(26): p. 2369-82., https://pubmed.ncbi.nlm.nih.gov/31697821 /

374. Rosenwald, A, Wright, G, Leroy, K, Yu, X, Gaulard, P, Gascoyne, RD, et.al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.The Journal of Experimental Medicine, J Exp Med, 2003. 198(6): p. 851-62., https://pubmed.ncbi.nlm.nih.gov/12975453 /

375. Savage, KJ, Monti, S, Kutok, JL, Cattoretti, G, Neuberg, D, De Leval, L, et.al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.Blood, Blood, 2003. 102(12): p. 3871-9., https://pubmed.ncbi.nlm.nih.gov/12933571 /

376. Cazals-Hatem, D, Lepage, E, Brice, P, Ferrant, A, d'Agay, MF, Baumelou, E, et.al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study.The American Journal of Surgical Pathology, Am J Surg Pathol, 1996. 20(7): p. 877-88., https://pubmed.ncbi.nlm.nih.gov/8669537 /

377. Savage, KJ, Al-Rajhi, N, Voss, N, Paltiel, C, Klasa, R, Gascoyne, RD, et.al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.Annals of Oncology, Ann Oncol, 2006. 17(1): p. 123-30., https://pubmed.ncbi.nlm.nih.gov/16236753 /

378. Jaffe, E, Harris, NL, Vardiman, J, Arber, D, Campo, E, Hematopathology, 2010. 1st Edition:

379. Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, Mauch PM, Non-Hodgkin LymphomasLippincott Williams & Wilkins, 2010. 2nd ed.:

380. van Besien, K, Kelta, M, Bahaguna, P, Primary mediastinal B-cell lymphoma: a review of pathology and management.Journal of Clinical Oncology, J Clin Oncol, 2001. 19(6): p. 1855-64., https://pubmed.ncbi.nlm.nih.gov/11251018 /

381. Jacobson, JO, Aisenberg, AC, Lamarre, L, Willett, CG, Linggood, RM, Miketic, LM, et.al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy.Cancer, Cancer, 1988. 62(9): p. 1893-8., https://pubmed.ncbi.nlm.nih.gov/3167803 /

382. Hamlin, PA, Portlock, CS, Straus, DJ, Noy, A, Singer, A, Horwitz, SM, et.al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.British Journal of Haematology, Br J Haematol, 2005. 130(5): p. 691-9., https://pubmed.ncbi.nlm.nih.gov/16115124 /

383. Lees, C, Keane, C, Gandhi, MK, Gunawardana, J, Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.British Journal of Haematology, Br J Haematol, 2019. 185(1): p. 25-41., https://pubmed.ncbi.nlm.nih.gov/30740662 /

384. Held, G, Thurner, L, Poeschel, V, Berdel, C, Ott, G, Schmidt, C, et.al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma AllianceEHA Library, EHA Library, 2020.

385. Dunleavy, K, Pittaluga, S, Maeda, LS, Advani, R, Chen, CC, Hessler, J, et.al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.The New England Journal of Medicine, N Engl J Med, 2013. 368(15): p. 1408-16., https://pubmed.ncbi.nlm.nih.gov/23574119 /

386. Mottok, A, Hung, SS, Chavez, EA, Woolcock, B, Telenius, A, Chong, LC, et.al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.Blood, Blood, 2019. 134(10): p. 802-813., https://pubmed.ncbi.nlm.nih.gov/31292115 /

387. Laurent, C, Baron, M, Amara, N, Haioun, C, Dandoit, M, Maynadié, M, et.al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(18): p. 2008-17., https://pubmed.ncbi.nlm.nih.gov/28459613 /

388. Yuan, J, Wright, G, Rosenwald, A, Steidl, C, Gascoyne, RD, Connors, JM, et.al. Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling.The American Journal of Surgical Pathology, Am J Surg Pathol, 2015. 39(10): p. 1322-30., https://pubmed.ncbi.nlm.nih.gov/26135560 /

389. Sarkozy, C, Molina, T, Ghesquières, H, Michallet, AS, Dupuis, J, Damotte, D, et.al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association.Haematologica, Haematologica, 2017. 102(1): p. 150-9., https://pubmed.ncbi.nlm.nih.gov/27758822 /

390. Traverse-Glehen, A, Pittaluga, S, Gaulard, P, Sorbara, L, Alonso, MA, Raffeld, M, et.al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.The American Journal of Surgical Pathology, Am J Surg Pathol, 2005. 29(11): p. 1411-21., https://pubmed.ncbi.nlm.nih.gov/16224207 /

391. Gleeson, M, Hawkes, EA, Cunningham, D, Chadwick, N, Counsell, N, Lawrie, A, et.al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.British Journal of Haematology, Br J Haematol, 2016. 175(4): p. 668-72., https://pubmed.ncbi.nlm.nih.gov/27477167 /

392. Rieger, M, Österborg, A, Pettengell, R, White, D, Gill, D, Walewski, J, et.al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.Annals of Oncology, Ann Oncol, 2011. 22(3): p. 664-70., https://pubmed.ncbi.nlm.nih.gov/20724576 /

393. Pohlen, M, Gerth, HU, Liersch, R, Koschmieder, S, Mesters, RM, Kessler, T, et.al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.American Journal of Hematology, Am J Hematol, 2011. 86(12): p. E61-4., https://pubmed.ncbi.nlm.nih.gov/21898532/

394. Zinzani, PL, Martelli, M, Bertini, M, Gianni, AM, Devizzi, L, Federico, M, et.al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.Haematologica, Haematologica, 2002. 87(12): p. 1258-64., https://pubmed.ncbi.nlm.nih.gov/12495899 /

395. Zinzani, PL, Stefoni, V, Finolezzi, E, Brusamolino, E, Cabras, MG, Chiappella, A, et.al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.Clinical Lymphoma and Myeloma, Clin Lymphoma Myeloma, 2009. 9(5): p. 381-5., https://pubmed.ncbi.nlm.nih.gov/19858058 /

396. Cheson, BD, Horning, SJ, Coiffier, B, Shipp, MA, Fisher, RI, Connors, JM, et.al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.Journal of Clinical Oncology, J Clin Oncol, 1999. 17(4): p. 1244., https://pubmed.ncbi.nlm.nih.gov/10561185 /

397. Hayden, AR, Tonseth, P, Lee, DG, Villa, D, Gerrie, AS, Scott, DW, et.al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.Blood, Blood, 2020. 136(24): p. 2803-11., https://pubmed.ncbi.nlm.nih.gov/32603413 /

398. Yahalom, J, Illidge, T, Specht, L, Hoppe, RT, Li, YX, Tsang, R, et.al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2015. 92(1): p. 11-31., https://pubmed.ncbi.nlm.nih.gov/25863750 /

399. Aoki, T, Shimada, K, Suzuki, R, Izutsu, K, Tomita, A, Maeda, Y, et.al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma.Blood Cancer Journal, Blood Cancer J, 2015. 5: p. e372., https://pubmed.ncbi.nlm.nih.gov/26636287 /

400. Kuruvilla, J, Pintilie, M, Tsang, R, Nagy, T, Keating, A, Crump, M, Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2008. 49(7): p. 1329-36., https://pubmed.ncbi.nlm.nih.gov/18604722 /

401. Herrera, AF, Chen, L, Khajavian, S, Chase, M, Darrah, J, Maloney, D, et.al. Allogeneic stem cell transplantation provides durable remission in patients with primary mediastinal large B cell lymphoma.Biology of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 2019. 25(12): p. 2383-7., https://pubmed.ncbi.nlm.nih.gov/31394277 /

402. Kondo, E, Shimizu-Koresawa, R, Chihara, D, Mizuta, S, Izutsu, K, Ikegame, K, et.al. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry.British Journal of Haematology, Br J Haematol, 2019. 186(6): p. e219-23., https://pubmed.ncbi.nlm.nih.gov/31355916 /

403. Green, MR, Monti, S, Rodig, SJ, Juszczynski, P, Currie, T, O'Donnell, E, et.al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Blood, Blood, 2010. 116(17): p. 3268-77., https://pubmed.ncbi.nlm.nih.gov/20628145 /

404. Zinzani, PL, Ribrag, V, Moskowitz, CH, Michot, JM, Kuruvilla, J, Balakumaran, A, et.al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.Blood, Blood, 2017. 130(3): p. 267-70., https://pubmed.ncbi.nlm.nih.gov/28490569/

405. Zinzani, PL, Santoro, A, Gritti, G, Brice, P, Barr, PM, Kuruvilla, J, et.al. Nivolumab combined with Brentuximab Vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: Efficacy and safety from the phase II Checkmate 436 study.Journal of Clinical Oncology, J Clin Oncol, 2019. 37(33): p. 3081-9., https://pubmed.ncbi.nlm.nih.gov/31398081 /

406. Abramson, JS, Palomba, ML, Gordon, LI, Lunning, MA, Wang, M, Arnason, J, et.al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.The Lancet, Lancet, 2020. 396(10254): p. 839-52., https://pubmed.ncbi.nlm.nih.gov/32888407 /

407. Neelapu, SS, Locke, FL, Bartlett, NL, Lekakis, LJ, Miklos, DB, Jacobson, CA, et.al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.The New England Journal of Medicine, N Engl J Med, 2017. 377(26): p. 2531-44., https://pubmed.ncbi.nlm.nih.gov/29226797 /

408. Kochenderfer, JN, Dudley, ME, Kassim, SH, Somerville, RP, Carpenter, RO, Stetler-Stevenson, M, et.al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.Journal of Clinical Oncology, J Clin Oncol, 2015. 33(6): p. 540-9., https://pubmed.ncbi.nlm.nih.gov/25154820 /

409. Pinnix, CC, Smith, GL, Milgrom, S, Osborne, EM, Reddy, JP, Akhtari, M, et.al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2015. 92(1): p. 175-82., https://pubmed.ncbi.nlm.nih.gov/25863764 /

410. Evens, AM, Kanakry, JA, Sehn, LH, Kritharis, A, Feldman, T, Kroll, A, et.al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.American Journal of Hematology, Am J Hematol, 2015. 90(9): p. 778-83., https://pubmed.ncbi.nlm.nih.gov/26044261 /

411. García, JF, Mollejo, M, Fraga, M, Forteza, J, Muniesa, JA, Pérez-Guillermo, M, et.al. Large B-cell lymphoma with Hodgkin's features.Histopathology, Histopathology, 2005. 47(1): p. 101-10., https://pubmed.ncbi.nlm.nih.gov/15982329 /

412. Sarkozy, C, Chong, L, Takata, K, Chavez, EA, Miyata-Takata, T, Duns, G, et.al. Gene expression profiling of gray zone lymphoma.Blood Advances, Blood Adv, 2020. 4(11): p. 2523-35., https://pubmed.ncbi.nlm.nih.gov/32516416 /

413. Sarkozy, C, Hung, SS, Chavez, EA, Duns, G, Takata, K, Chong, LC, et.al. Mutational landscape of gray zone lymphoma.Blood, Blood, 2021. 137(13): p. 1765-76., https://pubmed.ncbi.nlm.nih.gov/32961552 /

414. Wilson, WH, Pittaluga, S, Nicolae, A, Camphausen, K, Shovlin, M, Steinberg, SM, et.al. A prospective study of mediastinal gray-zone lymphoma.Blood, Blood, 2014. 124(10): p. 1563-9., https://pubmed.ncbi.nlm.nih.gov/25024303 /

415. Hancock, SL, Tucker, MA, Hoppe, RT, Breast cancer after treatment of Hodgkin's disease.Journal of the National Cancer Institute, J Natl Cancer Inst, 1993. 85(1): p. 25-31., https://pubmed.ncbi.nlm.nih.gov/8416252 /

416. Henderson, TO, Amsterdam, A, Bhatia, S, Hudson, MM, Meadows, AT, Neglia, JP, et.al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer.Annals of Internal Medicine, Ann Intern Med, 2010. 152(7): p. 444-55; W144-54., https://pubmed.ncbi.nlm.nih.gov/20368650 /

417. Ng, AK, Bernardo, MV, Weller, E, Backstrand, K, Silver, B, Marcus, KC, et.al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.Blood, Blood, 2002. 100(6): p. 1989-96., https://pubmed.ncbi.nlm.nih.gov/12200357 /

418. Schaapveld, M, Aleman, BM, van Eggermond, AM, Janus, CP, Krol, AD, van der Maazen, RW, et.al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma.The New England Journal of Medicine, N Engl J Med, 2015. 373(26): p. 2499-511., https://pubmed.ncbi.nlm.nih.gov/26699166 /

419. De Bruin, ML, Sparidans, J, van't Veer, MB, Noordijk, EM, Louwman, MW, Zijlstra, JM, et.al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.Journal of Clinical Oncology, J Clin Oncol, 2009. 27(26): p. 4239-46., https://pubmed.ncbi.nlm.nih.gov/19667275 /

420. Travis, LB, Hill, DA, Dores, GM, Gospodarowicz, M, van Leeuwen, FE, Holowaty, E, et.al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.Journal of the American Medical Association, JAMA, 2003. 290(4): p. 465-75., https://pubmed.ncbi.nlm.nih.gov/12876089 /

421. Howell, SJ, Searle, C, Goode, V, Gardener, T, Linton, K, Cowan, RA, et.al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage.British Journal of Cancer, Br J Cancer, 2009. 101(4): p. 582-8., https://pubmed.ncbi.nlm.nih.gov/19672261 /

422. Lee, L, Pintilie, M, Hodgson, DC, Goss, PE, Crump, M, Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma.Annals of Oncology, Ann Oncol, 2008. 19(1): p. 62-7., https://pubmed.ncbi.nlm.nih.gov/17878177 /

423. Schellong, G, Riepenhausen, M, Ehlert, K, Brämswig, J, Dörffel, W, Schmutzler, RK, et.al. Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up.Deutsches Arzteblatt International, Dtsch Arztebl Int, 2014. 111(1-2): p. 3-9., https://pubmed.ncbi.nlm.nih.gov/24565270 /

424. Swerdlow, AJ, Cooke, R, Bates, A, Cunningham, D, Falk, SJ, Gilson, D, et.al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.Journal of Clinical Oncology, J Clin Oncol, 2012. 30(22): p. 2745-52., https://pubmed.ncbi.nlm.nih.gov/22734026 /

425. Møller, MB, Pedersen, NT, Christensen, BE, Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.British Journal of Haematology, Br J Haematol, 2004. 124(2): p. 151-9., https://pubmed.ncbi.nlm.nih.gov/14687024 /

426. Freeman, C, Berg, JW, Cutler, SJ, Occurrence and prognosis of extranodal lymphomas.Cancer, Cancer, 1972. 29(1): p. 252-60., https://pubmed.ncbi.nlm.nih.gov/5007387 /

427. Otter, R, Gerrits, WB, vd Sandt, MM, Hermans, J, Willemze, R, Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry.European Journal of Cancer and Clinical Oncology, Eur J Cancer Clin Oncol, 1989. 25(8): p. 1203-10., https://pubmed.ncbi.nlm.nih.gov/2767109 /

428. Cheah, CY, Wirth, A, Seymour, JF, Primary testicular lymphoma.Blood, Blood, 2014. 123(4): p. 486-93., https://pubmed.ncbi.nlm.nih.gov/24282217 /

429. Li, D, Xie, P, Mi, C, Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.Pathology, Research and Practice, Pathol Res Pract, 2010. 206(9): p. 611-5., https://pubmed.ncbi.nlm.nih.gov/20627604 /

430. Booman, M, Douwes, J, Glas, AM, de Jong, D, Schuuring, E, Kluin, PM, Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics.The Journal of Pathology, J Pathol, 2006. 210(2): p. 163-71., https://pubmed.ncbi.nlm.nih.gov/16823896/

431. Go, RS, Gundrum, JD, Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement.American Journal of Hematology, Am J Hematol, 2009. 84(11): p. 762-3., https://pubmed.ncbi.nlm.nih.gov/19856427 /

432. Takahashi, H, Tomita, N, Yokoyama, M, Tsunoda, S, Yano, T, Murayama, K, et.al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.Cancer, Cancer, 2012. 118(17): p. 4166-72., https://pubmed.ncbi.nlm.nih.gov/22213346 /

433. Zucca, E, Conconi, A, Mughal, TI, Sarris, AH, Seymour, JF, Vitolo, U, et.al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.Journal of Clinical Oncology, J Clin Oncol, 2003. 21(1): p. 20-7., https://pubmed.ncbi.nlm.nih.gov/12506165 /

434. Fonseca, R, Habermann, TM, Colgan, JP, O'Neill, BP, White, WL, Witzig, TE, et.al. Testicular lymphoma is associated with a high incidence of extranodal recurrence.Cancer, Cancer, 2000. 88(1): p. 154-61., https://pubmed.ncbi.nlm.nih.gov/10618618 /

435. Seymour, JF, Solomon, B, Wolf, MM, Janusczewicz, EH, Wirth, A, Prince, HM, Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors.Clinical Lymphoma, Clin Lymphoma, 2001. 2(2): p. 109-15., https://pubmed.ncbi.nlm.nih.gov/11707851 /

436. Tondini, C, Ferreri, AJ, Siracusano, L, Valagussa, P, Giardini, R, Rampinelli, I, et.al. Diffuse large-cell lymphoma of the testis.Journal of Clinical Oncology, J Clin Oncol, 1999. 17(9): p. 2854-8., https://pubmed.ncbi.nlm.nih.gov/10561362 /

437. Visco, C, Medeiros, LJ, Mesina, OM, Rodriguez, MA, Hagemeister, FB, McLaughlin, P, et.al. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?Clinical Lymphoma, Clin Lymphoma, 2001. 2(1): p. 40-6., https://pubmed.ncbi.nlm.nih.gov/11707869 /

438. Kridel, R, Telio, D, Villa, D, Sehn, LH, Gerrie, AS, Shenkier, T, et.al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.British Journal of Haematology, Br J Haematol, 2017. 176(2): p. 210-21., https://pubmed.ncbi.nlm.nih.gov/27739058 /

439. Linassier, C, Desablens, B, Lefrancq, T, Le Prise, PY, Harousseau, JL, Jacob, C, et.al. Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.Clinical Lymphoma, Clin Lymphoma, 2002. 3(3): p. 167-72., https://pubmed.ncbi.nlm.nih.gov/12521394 /

440. Avilés, A, Neri, N, Huerta-Guzmán, J, Pérez, F, Fernández, R, Testicular lymphoma: organ-specific treatment did not improve outcome.Oncology, Oncology, 2004. 67(3-4): p. 211-4., https://pubmed.ncbi.nlm.nih.gov/15557780 /

441. Vitolo, U, Chiappella, A, Ferreri, AJ, Martelli, M, Baldi, I, Balzarotti, M, et.al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.Journal of Clinical Oncology, J Clin Oncol, 2011. 29(20): p. 2766-72., https://pubmed.ncbi.nlm.nih.gov/21646602 /

442. Park, BB, Kim, JG, Sohn, SK, Kang, HJ, Lee, SS, Eom, HS, et.al. Consideration of aggressive therapeutic strategies for primary testicular lymphoma.American Journal of Hematology, Am J Hematol, 2007. 82(9): p. 840-5., https://pubmed.ncbi.nlm.nih.gov/17563078 /

443. Eyre, TA, Djebbari, F, Kirkwood, AA, Collins, GP, Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.Haematologica, Haematologica, 2020. 105(7): p. 1914-24., https://pubmed.ncbi.nlm.nih.gov/31488560/

444. Orellana-Noia VM, Reed DR, Sen JM, Barlow C, Malecek MK, Kahl BS, et.al. CNS prophylaxis during front-line therapy in aggressive non-Hodgkin lymphomas: Real-world outcomes and practice patterns from 19 US academic institutionsBlood, Blood, 2020. 136(Supplement): p. 27-8., https://doi.org/10.1182/blood-2020-134798

445. Bobillo, S, Joffe, E, Sermer, D, Mondello, P, Ghione, P, Caron, PC, et.al. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.Blood Cancer Journal, Blood Cancer J, 2021. 11(6): p. 113., https://pubmed.ncbi.nlm.nih.gov/34135307/

446. Zouhair, A, Weber, D, Belkacémi, Y, Ketterer, N, Dietrich, PY, Villà, S, et.al. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2002. 52(3): p. 652-6., https://pubmed.ncbi.nlm.nih.gov/11849786 /

447. Lewin, KJ, Ranchod, M, Dorfman, RF, Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease.Cancer, Cancer, 1978. 42(2): p. 693-707., https://pubmed.ncbi.nlm.nih.gov/354774 /

448. Musshoff, K, Schmidt-Vollmer, H, Proceedings: Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification.Zeitschrift fur Krebsforschung und klinische Onkologie, Z Krebsforsch Klin Onkol Cancer Res Clin Oncol, 1975. 83(4): p. 323-41., https://pubmed.ncbi.nlm.nih.gov/125960 /

449. Radaszkiewicz, T, Dragosics, B, Bauer, P, Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis.Gastroenterology, Gastroenterology, 1992. 102(5): p. 1628-38., https://pubmed.ncbi.nlm.nih.gov/1568573 /

450. Koch, P, del Valle, F, Berdel, WE, Willich, NA, Reers, B, Hiddemann, W, et.al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.Journal of Clinical Oncology, J Clin Oncol, 2001. 19(18): p. 3861-73., https://pubmed.ncbi.nlm.nih.gov/11559724 /

451. Brands, F, Mönig, SP, Raab, M, Treatment and prognosis of gastric lymphoma.The European Journal of Surgery, Eur J Surg, 1997. 163(11): p. 803-13., https://pubmed.ncbi.nlm.nih.gov/9414040 /

452. de Jong, D, Aleman, BM, Taal, BG, Boot, H, Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey.Annals of Oncology, Ann Oncol, 1999. 10(3): p. 275-80., https://pubmed.ncbi.nlm.nih.gov/10355570 /

453. Avilés, A, Nambo, MJ, Neri, N, Huerta-Guzmán, J, Cuadra, I, Alvarado, I, et.al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial.Annals of Surgery, Ann Surg, 2004. 240(1): p. 44-50., https://pubmed.ncbi.nlm.nih.gov/15213617 /

454. Koch, P, del Valle, F, Berdel, WE, Willich, NA, Reers, B, Hiddemann, W, et.al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92.Journal of Clinical Oncology, J Clin Oncol, 2001. 19(18): p. 3874-83., https://pubmed.ncbi.nlm.nih.gov/11559725 /

455. Koch, P, Probst, A, Berdel, WE, Willich, NA, Reinartz, G, Brockmann, J, et.al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).Journal of Clinical Oncology, J Clin Oncol, 2005. 23(28): p. 7050-9., https://pubmed.ncbi.nlm.nih.gov/16129843 /

456. Chan, JK, Ng, CS, Isaacson, PG, Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach.The American Journal of Pathology, Am J Pathol, 1990. 136(5): p. 1153-64., https://pubmed.ncbi.nlm.nih.gov/2349966 /

457. Couto, ME, Oliveira, I, Domingues, N, Viterbo, L, Martins, Â, Moreira, I, et.al. Gastric diffuse large B-cell lymphoma: A single-center 9-year experience.Indian Journal of Hematology & Blood Transfusion, Indian J Hematol Blood Transfus, 2021. 37(3): p. 1-5., https://pubmed.ncbi.nlm.nih.gov/33424149 /

458. Tanaka, T, Shimada, K, Yamamoto, K, Hirooka, Y, Niwa, Y, Sugiura, I, et.al. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.Annals of Hematology, Ann Hematol, 2012. 91(3): p. 383-90., https://pubmed.ncbi.nlm.nih.gov/21822617 /

459. Kang, HJ, Lee, HH, Jung, SE, Park, KS, O, JH, Jeon, YW, et.al. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.PLOS One, PLoS One, 2020. 15(9): p. e0238807., https://pubmed.ncbi.nlm.nih.gov/32960887 /

460. Morgner, A, Miehlke, S, Fischbach, W, Schmitt, W, Müller-Hermelink, H, Greiner, A, et.al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.Journal of Clinical Oncology, J Clin Oncol, 2001. 19(7): p. 2041-8., https://pubmed.ncbi.nlm.nih.gov/11283137 /

461. Ferreri, AJ, Govi, S, Raderer, M, Mulè, A, Andriani, A, Caracciolo, D, et.al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial.Blood, Blood, 2012. 120(18): p. 3858-60., https://pubmed.ncbi.nlm.nih.gov/23118214 /

462. Park, HS, Kim, YJ, Yang, WI, Suh, CO, Lee, YC, Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma.World Journal of Gastroenterology, World J Gastroenterol, 2010. 16(17): p. 2158-62., https://pubmed.ncbi.nlm.nih.gov/20440857 /

463. Messina, C, Christie, D, Zucca, E, Gospodarowicz, M, Ferreri, AJ, Primary and secondary bone lymphomas.Cancer Treatment Reviews, Cancer Treat Rev, 2015. 41(3): p. 235-46., https://pubmed.ncbi.nlm.nih.gov/25698636 /

464. Ollila, TA, Olszewski, AJ, Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence., Curr Treat Options Oncol, 2018. 19 (8)(8): p. 38., https://pubmed.ncbi.nlm.nih.gov/29931605/

465. Beal, K, Allen, L, Yahalom, J, Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.Cancer, Cancer, 2006. 106(12): p. 2652-6., https://pubmed.ncbi.nlm.nih.gov/16700039 /

466. Govi, S, Christie, D, Messina, C, Bruno Ventre, M, Gracia Medina, EA, Porter, D, et.al. The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone.Annals of Oncology, Ann Oncol, 2014. 25(1): p. 176-81., https://pubmed.ncbi.nlm.nih.gov/24287938 /

467. Jennings, WC, Baker, RS, Murray, SS, Howard, CA, Parker, DE, Peabody, LF, et.al. Primary breast lymphoma: the role of mastectomy and the importance of lymph node status.Annals of Surgery, Ann Surg, 2007. 245(5): p. 784-9., https://pubmed.ncbi.nlm.nih.gov/17457172 /

468. Radkani, P, Joshi, D, Paramo, JC, Mesko, TW, Primary breast lymphoma: 30 years of experience with diagnosis and treatment at a single medical center.Journal of the American Medical Association, JAMA Surg, 2014. 149(1): p. 91-3., https://pubmed.ncbi.nlm.nih.gov/24257833 /

469. Ryan, G, Martinelli, G, Kuper-Hommel, M, Tsang, R, Pruneri, G, Yuen, K, et.al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.Annals of Oncology, Ann Oncol, 2008. 19(2): p. 233-41., https://pubmed.ncbi.nlm.nih.gov/17932394 /

470. Avilés, A, Castañeda, C, Neri, N, Cleto, S, Nambo, MJ, Rituximab and dose dense chemotherapy in primary breast lymphoma.Haematologica, Haematologica, 2007. 92(8): p. 1147-8., https://pubmed.ncbi.nlm.nih.gov/17650450 /

471. Hosein, PJ, Maragulia, JC, Salzberg, MP, Press, OW, Habermann, TM, Vose, JM, et.al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.British Journal of Haematology, Br J Haematol, 2014. 165(3): p. 358-63., https://pubmed.ncbi.nlm.nih.gov/24467658 /

472. Jeanneret-Sozzi, W, Taghian, A, Epelbaum, R, Poortmans, P, Zwahlen, D, Amsler, B, et.al. Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study.BMC Cancer, BMC Cancer, 2008. 8: p. 86., https://pubmed.ncbi.nlm.nih.gov/18380889 /

473. Yhim, HY, Kang, HJ, Choi, YH, Kim, SJ, Kim, WS, Chae, YS, et.al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.BMC Cancer, BMC Cancer, 2010. 10: p. 321., https://pubmed.ncbi.nlm.nih.gov/20569446 /

474. Yhim, HY, Kim, JS, Kang, HJ, Kim, SJ, Kim, WS, Choi, CW, et.al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.International Journal of Cancer, Int J Cancer, 2012. 131(1): p. 235-43., https://pubmed.ncbi.nlm.nih.gov/21823120/

475. Yhim, HY, Yoon, DH, Kim, SJ, Yang, DH, Eom, HS, Kim, KH, et.al. First-line treatment for primary breast diffuse large B-cell lymphoma using immunochemotherapy and central nervous system prophylaxis: A multicenter phase 2 trial.Cancers, Cancers (Basel), 2020. 12(8):, https://pubmed.ncbi.nlm.nih.gov/32781541/

476. Puckrin, R, El Darsa, H, Ghosh, S, Peters, A, Stewart, DA, Lack of effectiveness of intravenous high-dose Methotrexate for prevention of CNS relapse in patients with high-risk DLCBL: A retrospective analysis from Alberta, CanadaBlood, Blood, 2020. 136: p. 26-7.

477. Willemze, R, Cerroni, L, Kempf, W, Berti, E, Facchetti, F, Swerdlow, SH, et.al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.Blood, Blood, 2019. 133(16): p. 1703-14., https://pubmed.ncbi.nlm.nih.gov/30635287 /

478. Paulli, M, Lucioni, M, Maffi, A, Croci, GA, Nicola, M, Berti, E, Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.Giornale Italiano Di Dermatologia E Venereologia, G Ital Dermatol Venereol, 2012. 147(6): p. 589-602., https://pubmed.ncbi.nlm.nih.gov/23149705 /

479. Atiq, N, Kibbelaar, RE, de Vries, F, Hoogendoorn, M, An 88-year-old woman with an ulcerous tumour on the leg. Primary cutaneous diffuse large-B-cell lymphoma, leg type.The Netherlands Journal of Medicine, Neth J Med, 2016. 74(2): p. 93-5., https://pubmed.ncbi.nlm.nih.gov/26951356 /

480. Dongre, A, Kar, S, Gondse, S, Gangane, N, Mehra, BK, Primary cutaneous diffuse large B cell lymphoma, leg type.Indian Journal of Dermatology, Venereology and Leprology, Indian J Dermatol Venereol Leprol, 2011. 77(2): p. 212-4., https://pubmed.ncbi.nlm.nih.gov/21393962 /

481. Massone, C, Fink-Puches, R, Wolf, I, Zalaudek, I, Cerroni, L, Atypical clinicopathologic presentation of primary cutaneous diffuse large B-cell lymphoma, leg type.Journal of the American Academy of Dermatology, J Am Acad Dermatol, 2015. 72(6): p. 1016-20., https://pubmed.ncbi.nlm.nih.gov/25824272 /

482. Salem, AB, Nfoussi, H, Kchir, N, Ureteral spread of a primary cutaneous diffuse large B-cell lymphoma, leg type.Indian Journal of Urology, Indian J Urol, 2014. 30(2): p. 222-4., https://pubmed.ncbi.nlm.nih.gov/24744525 /

483. Hembury, TA, Lee, B, Gascoyne, RD, Macpherson, N, Yang, B, House, N, et.al. Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases.American Journal of Clinical Pathology, Am J Clin Pathol, 2002. 117(4): p. 574-80., https://pubmed.ncbi.nlm.nih.gov/11939732 /

484. Delecluse, HJ, Anagnostopoulos, I, Dallenbach, F, Hummel, M, Marafioti, T, Schneider, U, et.al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.Blood, Blood, 1997. 89(4): p. 1413-20., https://pubmed.ncbi.nlm.nih.gov/9028965 /

485. Swerdlow, SC, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, WHO classification of tumours of haematopoietic and lymphoid tissuesWorld Health Organization, 2017. Revised 4th edition:

486. Loghavi, S, Alayed, K, Aladily, TN, Zuo, Z, Ng, SB, Tang, G, et.al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.Journal of Hematology and Oncology, J Hematol Oncol, 2015. 8: p. 65., https://pubmed.ncbi.nlm.nih.gov/26055271 /

487. Valera, A, Balagué, O, Colomo, L, Martínez, A, Delabie, J, Taddesse-Heath, L, et.al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.The American Journal of Surgical Pathology, Am J Surg Pathol, 2010. 34(11): p. 1686-94., https://pubmed.ncbi.nlm.nih.gov/20962620 /

488. Morscio, J, Dierickx, D, Nijs, J, Verhoef, G, Bittoun, E, Vanoeteren, X, et.al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.The American Journal of Surgical Pathology, Am J Surg Pathol, 2014. 38(7): p. 875-86., https://pubmed.ncbi.nlm.nih.gov/24832164 /

489. Castillo, JJ, Bibas, M, Miranda, RN, The biology and treatment of plasmablastic lymphoma.Blood, Blood, 2015. 125(15): p. 2323-30., https://pubmed.ncbi.nlm.nih.gov/25636338 /

490. Liu, Z, Filip, I, Gomez, K, Engelbrecht, D, Meer, S, Lalloo, PN, et.al. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.Blood Cancer Discovery, Blood Cancer Discov, 2020. 1(1): p. 112-25., https://pubmed.ncbi.nlm.nih.gov/33225311 /

491. Frontzek, F, Staiger, AM, Zapukhlyak, M, Xu, W, Bonzheim, I, Borgmann, V, et.al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.Nature Communications, Nat Commun, 2021. 12(1): p. 5183., https://pubmed.ncbi.nlm.nih.gov/34465776/

492. Castillo, JJ, Furman, M, Beltrán, BE, Bibas, M, Bower, M, Chen, W, et.al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.Cancer, Cancer, 2012. 118(21): p. 5270-7., https://pubmed.ncbi.nlm.nih.gov/22510767 /

493. Tchernonog, E, Faurie, P, Coppo, P, Monjanel, H, Bonnet, A, Algarte Génin, M, et.al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.Annals of Oncology, Ann Oncol, 2017. 28(4): p. 843-8., https://pubmed.ncbi.nlm.nih.gov/28031174 /

494. Teruya-Feldstein, J, Chiao, E, Filippa, DA, Lin, O, Comenzo, R, Coleman, M, et.al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients.Annals of Oncology, Ann Oncol, 2004. 15(11): p. 1673-9., https://pubmed.ncbi.nlm.nih.gov/15520070 /

495. Patel, K, Oki, Y, Qazilbash, M, Muzzafar, T, Weber, DM, Fowler, N, et.al. Plasmablastic Lymphoma: 28 Patient Single Institution Experience - ASH 2013Blood, Blood, 2013. 2013:

496. Castillo, JJ, Winer, ES, Stachurski, D, Perez, K, Jabbour, M, Milani, C, et.al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.The Oncologist, Oncologist, 2010. 15(3): p. 293-9., https://pubmed.ncbi.nlm.nih.gov/20167839 /

497. Liu, JJ, Zhang, L, Ayala, E, Field, T, Ochoa-Bayona, JL, Perez, L, et.al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review.Leukemia Research, Leuk Res, 2011. 35(12): p. 1571-7., https://pubmed.ncbi.nlm.nih.gov/21752466 /

498. Cattaneo, C, Re, A, Ungari, M, Peli, A, Casari, S, Castelnuovo, F, et.al. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience.Leukemia and Lymphoma, Leuk Lymphoma, 2015. 56(1): p. 267-9., https://pubmed.ncbi.nlm.nih.gov/24712980 /

499. Cattaneo, C, Finel, H, McQuaker, G, Vandenberghe, E, Rossi, G, Dreger, P, Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience.Biology of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 2015. 21(6): p. 1146-7., https://pubmed.ncbi.nlm.nih.gov/25783635 /

500. Castillo, JJ, Reagan, JL, Sikov, WM, Winer, ES, Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.British Journal of Haematology, Br J Haematol, 2015. 169(3): p. 352-5., https://pubmed.ncbi.nlm.nih.gov/25612847 /

501. Dittus, C, Grover, N, Ellsworth, S, Tan, X, Park, SI, Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.Leukemia and Lymphoma, Leuk Lymphoma, 2018. 59(9): p. 2121-7., https://pubmed.ncbi.nlm.nih.gov/29303024 /

502. Wahlin, BE, Yri, OE, Kimby, E, Holte, H, Delabie, J, Smeland, EB, et.al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times.British Journal of Haematology, Br J Haematol, 2012. 156(2): p. 225-33., https://pubmed.ncbi.nlm.nih.gov/22126847/

503. Link, BK, Maurer, MJ, Nowakowski, GS, Ansell, SM, Macon, WR, Syrbu, SI, et.al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.Journal of Clinical Oncology, J Clin Oncol, 2013. 31(26): p. 3272-8., https://pubmed.ncbi.nlm.nih.gov/23897955 /

504. Wagner-Johnston, ND, Link, BK, Byrtek, M, Dawson, KL, Hainsworth, J, Flowers, CR, et.al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).Blood, Blood, 2015. 126(7): p. 851-7., https://pubmed.ncbi.nlm.nih.gov/26105149 /

505. Sarkozy, C, Trneny, M, Xerri, L, Wickham, N, Feugier, P, Leppa, S, et.al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial.Journal of Clinical Oncology, J Clin Oncol, 2016. 34(22): p. 2575-82., https://pubmed.ncbi.nlm.nih.gov/27298402 /

506. Federico, M, Caballero Barrigón, MD, Marcheselli, L, Tarantino, V, Manni, M, Sarkozy, C, et.al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.The Lancet, Lancet Haematol, 2018. 5(8): p. e359-67., https://pubmed.ncbi.nlm.nih.gov/30078408 /

507. Montoto, S, Davies, AJ, Matthews, J, Calaminici, M, Norton, AJ, Amess, J, et.al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2007. 25(17): p. 2426-33., https://pubmed.ncbi.nlm.nih.gov/17485708 /

508. Koch, K, Hoster, E, Ziepert, M, Unterhalt, M, Ott, G, Rosenwald, A, et.al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.Annals of Oncology, Ann Oncol, 2016. 27(7): p. 1323-9., https://pubmed.ncbi.nlm.nih.gov/27117536 /

509. Horn, H, Schmelter, C, Leich, E, Salaverria, I, Katzenberger, T, Ott, MM, et.al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles.Haematologica, Haematologica, 2011. 96(9): p. 1327-34., https://pubmed.ncbi.nlm.nih.gov/21659362 /

510. Klapper, W, Hoster, E, Rölver, L, Schrader, C, Janssen, D, Tiemann, M, et.al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.Journal of Clinical Oncology, J Clin Oncol, 2007. 25(22): p. 3330-6., https://pubmed.ncbi.nlm.nih.gov/17664481 /

511. Leich, E, Hoster, E, Wartenberg, M, Unterhalt, M, Siebert, R, Koch, K, et.al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.Leukemia, Leukemia, 2016. 30(4): p. 854-60., https://pubmed.ncbi.nlm.nih.gov/26621338 /

512. Al-Tourah, AJ, Gill, KK, Chhanabhai, M, Hoskins, PJ, Klasa, RJ, Savage, KJ, et.al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2008. 26(32): p. 5165-9., https://pubmed.ncbi.nlm.nih.gov/18838711 /

513. Gleeson, M, Hawkes, EA, Peckitt, C, Wotherspoon, A, Attygalle, A, Sharma, B, et.al. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.Leukemia and Lymphoma, Leuk Lymphoma, 2017. 58(8): p. 1805-13., https://pubmed.ncbi.nlm.nih.gov/27931133 /

514. Lerch, K, Meyer, AH, Stroux, A, Hirt, C, Keller, U, Viardot, A, et.al. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.Annals of Hematology, Ann Hematol, 2015. 94(6): p. 981-8., https://pubmed.ncbi.nlm.nih.gov/25645656 /

515. Mead, GM, Bleehen, NM, Gregor, A, Bullimore, J, Shirley, D, Rampling, RP, et.al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.Cancer, Cancer, 2000. 89(6): p. 1359-70., https://pubmed.ncbi.nlm.nih.gov/11002232 /

516. Ferreri, AJM, Doorduijn, JK, Re, A, Cabras, MG, Smith, J, Ilariucci, F, et.al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.The Lancet, Lancet Haematol, 2021. 8(2): p. e110-21., https://pubmed.ncbi.nlm.nih.gov/33513372 /

517. Ferreri, AJ, Cwynarski, K, Pulczynski, E, Ponzoni, M, Deckert, M, Politi, LS, et.al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.The Lancet, Lancet Haematol, 2016. 3(5): p. e217-27., https://pubmed.ncbi.nlm.nih.gov/27132696 /

518. Korfel, A, Elter, T, Thiel, E, Hänel, M, Möhle, R, Schroers, R, et.al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.Haematologica, Haematologica, 2013. 98(3): p. 364-70., https://pubmed.ncbi.nlm.nih.gov/23242601 /

519. Ferreri, AJM, Cwynarski, K, Pulczynski, E, Fox, CP, Schorb, E, La Rosée, P, et.al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.The Lancet, Lancet Haematol, 2017. 4(11): p. e510-23., https://pubmed.ncbi.nlm.nih.gov/29054815 /

520. Damaj, G, Ivanoff, S, Coso, D, Ysaebert, L, Choquet, S, Houillier, C, et.al. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.Haematologica, Haematologica, 2015. 100(9): p. 1199-206., https://pubmed.ncbi.nlm.nih.gov/26185174 /

521. Qualls, D, Sullivan, A, Li, S, Brunner, AM, Collier, K, Hochberg, E, et.al. High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement.Clinical Lymphoma, Myeloma & Leukemia, Clin Lymphoma Myeloma Leuk, 2017. 17(12): p. 884-8., https://pubmed.ncbi.nlm.nih.gov/28870642 /

522. Perry, C, Ben Barouch, S, Goldschmidt, N, Sarid, N, Herishanu, Y, Shvidel, L, et.al. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.American Journal of Hematology, Am J Hematol, 2019. 94(9): p. 992-1001., https://pubmed.ncbi.nlm.nih.gov/31211434 /

523. Borie, R, Wislez, M, Antoine, M, Cadranel, J, Lymphoproliferative disorders of the lung.Respiration, Respiration, 2017. 94(2): p. 157-175., https://pubmed.ncbi.nlm.nih.gov/28609772 /

524. Guinee, D, Jaffe, E, Kingma, D, Fishback, N, Wallberg, K, Krishnan, J, et.al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis.The American Journal of Surgical Pathology, Am J Surg Pathol, 1994. 18(8): p. 753-64., https://pubmed.ncbi.nlm.nih.gov/8037289 /

525. Jaffe, E, Harris, N, Stein, H, WHO classification of Tumours of Haematopoietic and Lymphoid TissuesInternational Agency for Research on Cancer, 2001. p. 185-7.

526. Travis, WD, Brambilla, E, Burke, AP, Marx, A, Nicholson, AG, Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.Journal of Thoracic Oncology, J Thorac Oncol, 2015. 10(9): p. 1240-2., https://pubmed.ncbi.nlm.nih.gov/26291007 /

527. Katzenstein, AL, Doxtader, E, Narendra, S, Lymphomatoid granulomatosis: insights gained over 4 decades.The American Journal of Surgical Pathology, Am J Surg Pathol, 2010. 34(12): p. e35-48., https://pubmed.ncbi.nlm.nih.gov/21107080 /

528. Roschewski, M, Wilson, WH, Lymphomatoid granulomatosis.Cancer Journal, Cancer J, 2012. 18(5): p. 469-74., https://pubmed.ncbi.nlm.nih.gov/23006954/

529. Song, JY, Pittaluga, S, Dunleavy, K, Grant, N, White, T, Jiang, L, et.al. Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations.The American Journal of Surgical Pathology, Am J Surg Pathol, 2015. 39(2): p. 141-56., https://pubmed.ncbi.nlm.nih.gov/25321327 /

530. Ponzoni, M, Campo, E, Nakamura, S, Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks.Blood, Blood, 2018. 132(15): p. 1561-7., https://pubmed.ncbi.nlm.nih.gov/30111607 /

531. Brunet, V, Marouan, S, Routy, JP, Hashem, MA, Bernier, V, Simard, R, et.al. Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports.Medicine, Medicine (Baltimore), 2017. 96(5): p. e5985., https://pubmed.ncbi.nlm.nih.gov/28151891 /

532. Ferreri, AJ, Campo, E, Seymour, JF, Willemze, R, Ilariucci, F, Ambrosetti, A, et.al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'.British Journal of Haematology, Br J Haematol, 2004. 127(2): p. 173-83., https://pubmed.ncbi.nlm.nih.gov/15461623 /

533. Ferreri, AJ, Dognini, GP, Campo, E, Willemze, R, Seymour, JF, Bairey, O, et.al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.Haematologica, Haematologica, 2007. 92(4): p. 486-92., https://pubmed.ncbi.nlm.nih.gov/17488659 /

534. Boyer, DF, McKelvie, PA, de Leval, L, Edlefsen, KL, Ko, YH, Aberman, ZA, et.al. Fibrin-associated EBV-positive large B-Cell Lymphoma: An indolent neoplasm with features distinct from diffuse large B-cell lymphoma associated with chronic inflammation.The American Journal of Surgical Pathology, Am J Surg Pathol, 2017. 41(3): p. 299-312., https://pubmed.ncbi.nlm.nih.gov/28195879 /

535. King, RL, Goodlad, JR, Calaminici, M, Dotlic, S, Montes-Moreno, S, Oschlies, I, et.al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.Virchows Archiv, Virchows Arch, 2020. 476(5): p. 647-65., https://pubmed.ncbi.nlm.nih.gov/31863183 /

536. Geer, M, Roberts, E, Shango, M, Till, BG, Smith, SD, Abbas, H, et.al. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.British Journal of Haematology, Br J Haematol, 2019. 186(2): p. 255-62., https://pubmed.ncbi.nlm.nih.gov/31044423, /

537. Shimada, K, Murase, T, Matsue, K, Okamoto, M, Ichikawa, N, Tsukamoto, N, et.al. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.Cancer Science, Cancer Sci, 2010. 101(6): p. 1480-6., https://pubmed.ncbi.nlm.nih.gov/20412122 /

538. Shimada, K, Yamaguchi, M, Atsuta, Y, Matsue, K, Sato, K, Kusumoto, S, et.al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.The Lancet, Lancet Oncol, 2020. 21(4): p. 593-602., https://pubmed.ncbi.nlm.nih.gov/32171071/

539. Gisselbrecht, C, Glass, B, Mounier, N, Linch, D, Gill, D, Trneny, M, R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL studyJournal of Clinical Oncology, 2009. 27: p. 15s.

540. van Imhoff, GW, McMillan, A, Matasar, MJ, Radford, J, Ardeshna, KM, Kuliczkowski, K, et.al. Ofatumumab versus Rituximab sallvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(5): p. 544-51., https://pubmed.ncbi.nlm.nih.gov/28029326 /

541. Guglielmi, C, Gomez, F, Philip, T, Hagenbeek, A, Martelli, M, Sebban, C, et.al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.Journal of Clinical Oncology, J Clin Oncol, 1998. 16(10): p. 3264-9., https://pubmed.ncbi.nlm.nih.gov/9779700 /

542. Sorror, ML, Maris, MB, Storb, R, Baron, F, Sandmaier, BM, Maloney, DG, et.al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.Blood, Blood, 2005. 106(8): p. 2912-9., https://pubmed.ncbi.nlm.nih.gov/15994282 /

543. Raimondi, R, Tosetto, A, Oneto, R, Cavazzina, R, Rodeghiero, F, Bacigalupo, A, et.al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.Blood, Blood, 2012. 120(6): p. 1327-33., https://pubmed.ncbi.nlm.nih.gov/22740454 /

544. Farina, L, Bruno, B, Patriarca, F, Spina, F, Sorasio, R, Morelli, M, et.al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.Leukemia, Leukemia, 2009. 23(6): p. 1131-8., https://pubmed.ncbi.nlm.nih.gov/19194465 /

545. Berro, M, Arbelbide, JA, Rivas, MM, Basquiera, AL, Ferini, G, Vitriu, A, et.al. Hematopoietic cell transplantation-specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation.Biology of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 2017. 23(10): p. 1646-50., https://pubmed.ncbi.nlm.nih.gov/28669923 /

546. DGHO, Positronenemissionstomographie (PET) in der Onkologie - Einsatz zur Steuerung von Diagnostik und TherapieDGHO, 2021. online:

547. Sauter, CS, Matasar, MJ, Meikle, J, Schoder, H, Ulaner, GA, Migliacci, JC, et.al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.Blood, Blood, 2015. 125(16): p. 2579-81., https://pubmed.ncbi.nlm.nih.gov/25758829 /

548. Dickinson, M, Hoyt, R, Roberts, AW, Grigg, A, Seymour, JF, Prince, HM, et.al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.British Journal of Haematology, Br J Haematol, 2010. 150(1): p. 39-45., https://pubmed.ncbi.nlm.nih.gov/20507301 /

549. Lambert, JR, Bomanji, JB, Peggs, KS, Thomson, KJ, Chakraverty, RK, Fielding, AK, et.al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.Blood, Blood, 2010. 115(14): p. 2763-8., https://pubmed.ncbi.nlm.nih.gov/20124510 /

550. Mounier, N, El Gnaoui, T, Tilly, H, Canioni, D, Sebban, C, Casasnovas, RO, et.al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.Haematologica, Haematologica, 2013. 98(11): p. 1726-31., https://pubmed.ncbi.nlm.nih.gov/23753028 /

551. Locke, FL, Miklos, DB, Jacobson, CA, Perales, MA, Kersten, MJ, Oluwole, OO, et.al. Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma.The New England Journal of Medicine, N Engl J Med, 2021. Online ahead of print:

552. Kamdar, M, Solomon, SR, Arnason, J, Johnston, PB, Glass, B, Bachanova, V, et.al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialLancet, 2022. 399(10343): p. 2294-308., https://pubmed.ncbi.nlm.nih.gov/35717989/

553. Bishop, MR, Dickinson, M, Purtill, D, Barba, P, Santoro, A, Hamad, N, et.al. Second-line Tisagenlecleucel or standard care in aggressive B-cell lymphoma.The New England Journal of Medicine, N Engl J Med, 2021. Online ahead of print:, https://pubmed.ncbi.nlm.nih.gov/34904798 /

554. Crump, M, Kuruvilla, J, Couban, S, MacDonald, DA, Kukreti, V, Kouroukis, CT, et.al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.Journal of Clinical Oncology, J Clin Oncol, 2014. 32(31): p. 3490-6., https://pubmed.ncbi.nlm.nih.gov/25267740 /

555. Guglielmi, C, Martelli, M, Federico, M, Zinzani, PL, Vitolo, U, Bellesi, G, et.al. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.Haematologica, Haematologica, 2001. 86(9): p. 941-50., https://pubmed.ncbi.nlm.nih.gov/11532622 /

556. Philip, T, Guglielmi, C, Hagenbeek, A, Somers, R, Van der Lelie, H, Bron, D, et.al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.The New England Journal of Medicine, N Engl J Med, 1995. 333(23): p. 1540-5., https://pubmed.ncbi.nlm.nih.gov/7477169 /

557. Vellenga, E, van Putten, WL, van 't Veer, MB, Zijlstra, JM, Fibbe, WE, van Oers, MH, et.al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.Blood, Blood, 2008. 111(2): p. 537-43., https://pubmed.ncbi.nlm.nih.gov/17971487 /

558. Van Den Neste, E, Schmitz, N, Mounier, N, Gill, D, Linch, D, Trneny, M, et.al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.Bone Marrow Transplantation, Bone Marrow Transplant, 2017. 52(2): p. 216-21., https://pubmed.ncbi.nlm.nih.gov/27643872 /

559. Gulati, S, Yahalom, J, Acaba, L, Reich, L, Motzer, R, Crown, J, et.al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.Journal of Clinical Oncology, J Clin Oncol, 1992. 10(6): p. 936-41., https://pubmed.ncbi.nlm.nih.gov/1588372/

560. Kessinger, A, Armitage, JO, Smith, DM, Landmark, JD, Bierman, PJ, Weisenburger, DD, High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.Blood, Blood, 1989. 74(4): p. 1260-5., https://pubmed.ncbi.nlm.nih.gov/2569900/

561. Patti, C, Majolino, I, Scimè, R, Indovina, A, Vasta, S, Liberti, G, et.al. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.European Journal of Haematology, Eur J Haematol, 1993. 51(1): p. 18-24., https://pubmed.ncbi.nlm.nih.gov/8348940/

562. Vose, JM, Peterson, C, Bierman, PJ, Weisenburger, DD, Linder, J, Harrington, D, et.al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas.Blood, Blood, 1990. 76(2): p. 424-31., https://pubmed.ncbi.nlm.nih.gov/1973361/

563. Sellner, L, Boumendil, A, Finel, H, Choquet, S, de Rosa, G, Falzetti, F, et.al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.Bone Marrow Transplantation, Bone Marrow Transplant, 2016. 51(2): p. 212-8., https://pubmed.ncbi.nlm.nih.gov/26569093 /

564. de Magalhaes-Silverman, M, Lister, J, Rybka, W, Wilson, J, Ball, E, Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma.Bone Marrow Transplantation, Bone Marrow Transplant, 1997. 19(8): p. 777-81., https://pubmed.ncbi.nlm.nih.gov/9134168/

565. Kröger, N, Hoffknecht, M, Dreger, P, Krüger, W, Zeller, W, Krüll, A, et.al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy.Bone Marrow Transplantation, Bone Marrow Transplant, 1998. 21(1): p. 55-7., https://pubmed.ncbi.nlm.nih.gov/9486495/

566. Glass, B, Dohm, AJ, Truemper, LH, Pfreundschuh, M, Bleckmann, A, Wulf, GG, et.al. Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial.Annals of Oncology, Ann Oncol, 2017. 28(12): p. 3058-64., https://pubmed.ncbi.nlm.nih.gov/29232438 /

567. Salles, G, Duell, J, González Barca, E, Tournilhac, O, Jurczak, W, Liberati, AM, et.al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.The Lancet, Lancet Oncol, 2020. 21(7): p. 978-88., https://pubmed.ncbi.nlm.nih.gov/32511983 /

568. Duell, J, Maddocks, KJ, González-Barca, E, Jurczak, W, Liberati, AM, De Vos, S, et.al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.Haematologica, Haematologica, 2021. 106(9): p. 2417-26., https://pubmed.ncbi.nlm.nih.gov/34196165/

569. Sehn, LH, Hertzberg, M, Opat, S, Herrera, AF, Assouline, S, Flowers, CR, et.al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataBlood Adv, 2022. 6(2): p. 533-43., https://pubmed.ncbi.nlm.nih.gov/34749395/

570. Sehn, LH, Herrera, AF, Flowers, CR, Kamdar, MK, McMillan, A, Hertzberg, M, et.al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2020. 38(2): p. 155-65., https://pubmed.ncbi.nlm.nih.gov/31693429 /

571. López, A, Gutiérrez, A, Palacios, A, Blancas, I, Navarrete, M, Morey, M, et.al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.European Journal of Haematology, Eur J Haematol, 2008. 80(2): p. 127-32., https://pubmed.ncbi.nlm.nih.gov/18005385 /

572. Vacirca, JL, Acs, PI, Tabbara, IA, Rosen, PJ, Lee, P, Lynam, E, Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.Annals of Hematology, Ann Hematol, 2014. 93(3): p. 403-9., https://pubmed.ncbi.nlm.nih.gov/23955074 /

573. Ohmachi, K, Niitsu, N, Uchida, T, Kim, SJ, Ando, K, Takahashi, N, et.al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2013. 31(17): p. 2103-9., https://pubmed.ncbi.nlm.nih.gov/23650408 /

574. Gaiolla, R, Hartley, S, Beech, A, Knight, H, Smith, D, Bishton, M, et.al. Extended follow-up of CD4Hematological Oncology, Hematol Oncol, 2021. 39(1): p. 137-40., https://pubmed.ncbi.nlm.nih.gov/32860715 /

575. Martínez-Calle, N, Hartley, S, Ahearne, M, Kasenda, B, Beech, A, Knight, H, et.al. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.British Journal of Haematology, Br J Haematol, 2019. 184(6): p. 957-68., https://pubmed.ncbi.nlm.nih.gov/30548597 /

576. McMillan, AK, Matasar, MJ, Sancho, JM, Viardot, A, Hernandez, J, Perretti, T, et.al. POLARGO: A randomized phase III study evaluating Polatuzumab Vedotin plus Rituximab, Gemcitabine, and Oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma who had received one or more previous therapies.Blood, 2019. 134(Suppl. 1): p. 5317.

577. Jurczak, W, Zinzani, PL, Gaidano, G, Goy, A, Provencio, M, Nagy, Z, et.al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.Annals of Oncology, Ann Oncol, 2018. 29(5): p. 1266-72., https://pubmed.ncbi.nlm.nih.gov/29444231 /

578. Winderlich, M, Ness, D, Steidl, S, Endell, J, Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphomaJournal of Clinical Oncology, 30, 2012. p. 6574.

579. Salles, G, Goswami, B, Bagnardi, V, Dey, D, Winderlich, M, Ambarhane, S, et.al. Estimation of long-term survival with Tafasitamab + Lenalidomide in relapsed/refractory diffuse large B-cell lymphomaBlood, 2020. 136(Suppl. 1): p. 9-10.

580. Maddocks, KJ, Duell, J, Gonzales-Barca, E, Jurczak, W, Liberati, AM, de Vos, S, et.al. Long-term subgroup analyses from L-Mind, a phase II study of Tafasitamab (MOR208) combined with Lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaBlood, 2020. 136: p. 19-21.

581. Ng, AK, Yahalom, J, Goda, JS, Constine, LS, Pinnix, CC, Kelsey, CR, et.al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.International Journal of Radiation Oncology, Biology, Physics, Int J Radiat Oncol Biol Phys, 2018. 100(3): p. 652-69., https://pubmed.ncbi.nlm.nih.gov/29413279/

582. Vose, JM, Zhang, MJ, Rowlings, PA, Lazarus, HM, Bolwell, BJ, Freytes, CO, et.al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.Journal of Clinical Oncology, J Clin Oncol, 2001. 19(2): p. 406-13., https://pubmed.ncbi.nlm.nih.gov/11208832/

583. Long, AH, Haso, WM, Shern, JF, Wanhainen, KM, Murgai, M, Ingaramo, M, et.al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nature Medicine, Nat Med, 2015. 21(6): p. 581-90., https://pubmed.ncbi.nlm.nih.gov/25939063 /

584. Majzner, RG, Rietberg, SP, Sotillo, E, Dong, R, Vachharajani, VT, Labanieh, L, et.al. Tuning the antigen density requirement for CAR T-cell activity.Cancer Discovery, Cancer Discov, 2020. 10(5): p. 702-23., https://pubmed.ncbi.nlm.nih.gov/32193224 /

585. Hunter, BD, Rogalski, M, Jacobson, CA, Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.Expert Opinion on Biological Therapy, Expert Opin Biol Ther, 2019. 19(11): p. 1157-64., https://pubmed.ncbi.nlm.nih.gov/31342797 /

586. Nair, R, Neelapu, SS, The promise of CAR T-cell therapy in aggressive B-cell lymphoma.Best Practice and Research, Best Pract Res Clin Haematol, 2018. 31(3): p. 293-8., https://pubmed.ncbi.nlm.nih.gov/30213399 /

587. Schuster, SJ, Bishop, MR, Tam, CS, Waller, EK, Borchmann, P, McGuirk, JP, et.al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.The New England Journal of Medicine, N Engl J Med, 2019. 380(1): p. 45-56., https://pubmed.ncbi.nlm.nih.gov/30501490 /

588. Crump, M, Neelapu, SS, Farooq, U, Van Den Neste, E, Kuruvilla, J, Westin, J, et.al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood, Blood, 2017. 130(16): p. 1800-8., https://pubmed.ncbi.nlm.nih.gov/28774879 /

589. Jaeger, U, Bishop, MR, Salles, G, Schuster, SJ, Maziarz, RT, Han, X, et.al. MYC Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet TrialBlood, Blood, 2020. 136: p. 48-9.

590. Jacobson, C, Locke, F, Ghobadi, A, Miklos, DB, Lekakis, LJ, Oluwole, OO, et.al. Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)Blood, Blood, 2020. 136: p. 40-2.

591. Jaglowski, S, Hu, ZH, Zhang, Y, Kamdar, M, Ghosh, M, Lulla, P, et.al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry.Blood, Blood, 2019. 134(Suppl. 1): p. 766.

592. Glass, B, Hasenkamp, J, Wulf, G, Dreger, P, Pfreundschuh, M, Gramatzki, M, et.al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.The Lancet, Lancet Oncol, 2014. 15(7): p. 757-66., https://pubmed.ncbi.nlm.nih.gov/24827808 /

593. Kyriakou, C, Boumendil, A, Finel, H, Nn Norbert Schmitz, , Andersen, NS, Blaise, D, et.al. The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma: a retrospective study by the European Society For Blood And Marrow Transplantation Lymphoma Working Party.Biology of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 2019. 25(1): p. 86-93., https://pubmed.ncbi.nlm.nih.gov/30219698 /

594. Fenske, TS, Ahn, KW, Graff, TM, DiGilio, A, Bashir, Q, Kamble, RT, et.al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.British Journal of Haematology, Br J Haematol, 2016. 174(2): p. 235-48., https://pubmed.ncbi.nlm.nih.gov/26989808 /

595. van Kampen, RJ, Canals, C, Schouten, HC, Nagler, A, Thomson, KJ, Vernant, JP, et.al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.Journal of Clinical Oncology, J Clin Oncol, 2011. 29(10): p. 1342-8., https://pubmed.ncbi.nlm.nih.gov/21321299 /

596. Robinson, SP, Boumendil, A, Finel, H, Blaise, D, Poiré, X, Nicolas-Virelizier, E, et.al. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.Bone Marrow Transplantation, Bone Marrow Transplant, 2016. 51(3): p. 365-71., https://pubmed.ncbi.nlm.nih.gov/26618550 /

597. Ghosh, N, Ahmed, S, Ahn, KW, Khanal, M, Litovich, C, Aljurf, M, et.al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant.Journal of the American Medical Association, JAMA Oncol, 2020. 6(7): p. 1011-8., https://pubmed.ncbi.nlm.nih.gov/32496525 /

598. Sorror, ML, Logan, BR, Zhu, X, Rizzo, JD, Cooke, KR, McCarthy, PL, et.al. Prospective validation of the predictive power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center For International Blood And Marrow Transplant research study.Biology of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 2015. 21(8): p. 1479-87., https://pubmed.ncbi.nlm.nih.gov/25862591 /

599. Sorror, ML, Sandmaier, BM, Storer, BE, Maris, MB, Baron, F, Maloney, DG, et.al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.Journal of Clinical Oncology, J Clin Oncol, 2007. 25(27): p. 4246-54., https://pubmed.ncbi.nlm.nih.gov/17724349 /

600. Wais, V, Bunjes, D, Kuchenbauer, F, Sorror, ML, Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes.Expert Review of Hematology, Expert Rev Hematol, 2018. 11(10): p. 805-16., https://pubmed.ncbi.nlm.nih.gov/30092693 /

601. Wolff, D, Herzberg, PY, Herrmann, A, Pavletic, SZ, Heussner, P, Mumm, F, et.al. Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health.Bone Marrow Transplantation, Bone Marrow Transplant, 2021. 56(1): p. 243-56., https://pubmed.ncbi.nlm.nih.gov/32737446/

602. Pettengell, R, Długosz-Danecka, M, Andorsky, D, Belada, D, Georgiev, P, Quick, D, et.al. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).British Journal of Haematology, Br J Haematol, 2020. 188(2): p. 240-8., https://pubmed.ncbi.nlm.nih.gov/31879945 /

603. Czuczman, MS, Trněný, M, Davies, A, Rule, S, Linton, KM, Wagner-Johnston, N, et.al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of Lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma.Clinical Cancer Research, Clin Cancer Res, 2017. 23(15): p. 4127-37., https://pubmed.ncbi.nlm.nih.gov/28381416 /

604. Goy, A, Ramchandren, R, Ghosh, N, Munoz, J, Morgan, DS, Dang, NH, et.al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.Blood, Blood, 2019. 134(13): p. 1024-36., https://pubmed.ncbi.nlm.nih.gov/31331917 /

605. Kalakonda, N, Maerevoet, M, Cavallo, F, Follows, G, Goy, A, Vermaat, JSP, et.al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.The Lancet, Lancet Haematol, 2020. 7(7): p. e511-22., https://pubmed.ncbi.nlm.nih.gov/32589977 /

606. de Boer, AG, Taskila, TK, Tamminga, SJ, Feuerstein, M, Frings-Dresen, MH, Verbeek, JH, Interventions to enhance return-to-work for cancer patients.The Cochrane Database of Systematic Reviews, Cochrane Database Syst Rev, 2015. p. CD007569., https://pubmed.ncbi.nlm.nih.gov/26405010 /

607. Arboe, B, Olsen, MH, Goerloev, JS, Duun-Henriksen, AK, Johansen, C, Dalton, SO, et.al. Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.Clinical Epidemiology, Clin Epidemiol, 2017. 9: p. 321-9., https://pubmed.ncbi.nlm.nih.gov/28652814 /

608. Dauelsberg T, Almanasreh N, Mumm A, Rehabilitation bei Patienten nach StammzelltransplantationenInFo Hamatologie + Onkologie, InFo Hämatologie + Onkologie, 2020. 9(23): p. 13-7.

609. Baumann W, Heymanns J, Sozialmedizinische Aufgaben in Hamatologie und OnkologieAngewandte Sozialmedizin, 2019.

610. Seifart, U, Schmielau, J, Return to work of cancer survivors.Oncology Research and Treatment, Oncol Res Treat, 2017. 40(12): p. 760-3., https://pubmed.ncbi.nlm.nih.gov/29183032/

611. Mehnert, Anja, Employment and work-related issues in cancer survivorsCritical Reviews in Oncology/Hematology, 2011. 77(2): p. 109-30., https://linkinghub.elsevier.com/retrieve/pii/S1040842810000053

612. Dührsen, U, Deppermann, KM, Pox, C, Holstege, A, Evidence-based follow-up for adults with cancer.Deutsches Arzteblatt international, Dtsch Arztebl Int, 2019. 116(40): p. 663-9., https://pubmed.ncbi.nlm.nih.gov/31658935 /

613. Maurer, MJ, Ghesquières, H, Jais, JP, Witzig, TE, Haioun, C, Thompson, CA, et.al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.Journal of Clinical Oncology, J Clin Oncol, 2014. 32(10): p. 1066-73., https://pubmed.ncbi.nlm.nih.gov/24550425 /

614. Sussman, J, Varela, NP, Cheung, M, Hicks, L, Kraftcheck, D, Mandel, J, et.al. Follow-up care for survivors of lymphoma who have received curative-intent treatment.Current Oncology, Curr Oncol, 2016. 23(5): p. e499-513., https://pubmed.ncbi.nlm.nih.gov/27803611 /

615. Cheah, CY, Hofman, MS, Dickinson, M, Wirth, A, Westerman, D, Harrison, SJ, et.al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.British Journal of Cancer, Br J Cancer, 2013. 109(2): p. 312-7., https://pubmed.ncbi.nlm.nih.gov/23807169 /

616. El-Galaly, TC, Jakobsen, LH, Hutchings, M, de Nully Brown, P, Nilsson-Ehle, H, Székely, E, et.al. Routine imaging for diffuse large b-Cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study.Journal of Clinical Oncology, J Clin Oncol, 2015. 33(34): p. 3993-8., https://pubmed.ncbi.nlm.nih.gov/26438115 /

617. Goldschmidt, N, Or, O, Klein, M, Savitsky, B, Paltiel, O, The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.Annals of Hematology, Ann Hematol, 2011. 90(2): p. 165-71., https://pubmed.ncbi.nlm.nih.gov/20706721

618. Hong, J, Kim, JH, Lee, KH, Ahn, HK, Park, S, Sym, SJ, et.al. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2014. 55(10): p. 2312-8., https://pubmed.ncbi.nlm.nih.gov/24428199 /

619. Huntington, SF, Svoboda, J, Doshi, JA, Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.Journal of Clinical Oncology, J Clin Oncol, 2015. 33(13): p. 1467-74., https://pubmed.ncbi.nlm.nih.gov/25823735 /

620. Suh, KJ, Kim, KH, Kim, R, Byun, JM, Kim, M, Park, JH, et.al. Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.The Korean Journal of Internal Medicine, Korean J Intern Med, 2019. 34(4): p. 894-901., https://pubmed.ncbi.nlm.nih.gov/29466847 /

621. Chasty, B, Patterson, M, Murray, LJ, Johnson, R, Thomas, E, Gilson, D, et.al. Lack of effectiveness of routine clinic and blood test-based follow-up for diffuse large B cell lymphoma.British Journal of Haematology, Br J Haematol, 2018. 182(1): p. 138-40., https://pubmed.ncbi.nlm.nih.gov/28485468 /

622. Elis, A, Blickstein, D, Klein, O, Eliav-Ronen, R, Manor, Y, Lishner, M, Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies.American Journal of Hematology, Am J Hematol, 2002. 69(1): p. 41-4., https://pubmed.ncbi.nlm.nih.gov/11835330 /

623. Guppy, AE, Tebbutt, NC, Norman, A, Cunningham, D, The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.Leukemia and Lymphoma, Leuk Lymphoma, 2003. 44(1): p. 123-5., https://pubmed.ncbi.nlm.nih.gov/12691151 /

624. Liedtke, M, Hamlin, PA, Moskowitz, CH, Zelenetz, AD, Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.Annals of Oncology, Ann Oncol, 2006. 17(6): p. 909-13., https://pubmed.ncbi.nlm.nih.gov/16672295 /

625. Lin, TL, Kuo, MC, Shih, LY, Dunn, P, Wang, PN, Wu, JH, et.al. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.Annals of Hematology, Ann Hematol, 2012. 91(11): p. 1741-5., https://pubmed.ncbi.nlm.nih.gov/22729139 /

626. Truong, Q, Shah, N, Knestrick, M, Curley, B, Hu, Y, Craig, M, et.al. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.Clinical Lymphoma, Myeloma and Leukemia, Clin Lymphoma Myeloma Leuk, 2014. 14(1): p. 50-5., https://pubmed.ncbi.nlm.nih.gov/24119465 /

627. Weeks, JC, Yeap, BY, Canellos, GP, Shipp, MA, Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission.Journal of Clinical Oncology, J Clin Oncol, 1991. 9(7): p. 1196-203., https://pubmed.ncbi.nlm.nih.gov/1710656 /

628. Thompson, CA, Ghesquieres, H, Maurer, MJ, Cerhan, JR, Biron, P, Ansell, SM, et.al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2014. 32(31): p. 3506-12., https://pubmed.ncbi.nlm.nih.gov/25267745 /

629. Morbelli, S, Capitanio, S, De Carli, F, Bongioanni, F, De Astis, E, Miglino, M, et.al. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2016. 43(2): p. 232-9., https://pubmed.ncbi.nlm.nih.gov/26283504 /

630. Zinzani, PL, Stefoni, V, Tani, M, Fanti, S, Musuraca, G, Castellucci, P, et.al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2009. 27(11): p. 1781-7., https://pubmed.ncbi.nlm.nih.gov/19273712/

631. Thompson, CA, Charlson, ME, Schenkein, E, Wells, MT, Furman, RR, Elstrom, R, et.al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors.Annals of Oncology, Ann Oncol, 2010. 21(11): p. 2262-6., https://pubmed.ncbi.nlm.nih.gov/20423914 /

632. Smith-Bindman, R, Lipson, J, Marcus, R, Kim, KP, Mahesh, M, Gould, R, et.al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer.Archives of Internal Medicine, Arch Intern Med, 2009. 169(22): p. 2078-86., https://pubmed.ncbi.nlm.nih.gov/20008690 /

633. Berrington de González, A, Mahesh, M, Kim, KP, Bhargavan, M, Lewis, R, Mettler, F, et.al. Projected cancer risks from computed tomographic scans performed in the United States in 2007.Archives of Internal Medicine, Arch Intern Med, 2009. 169(22): p. 2071-7., https://pubmed.ncbi.nlm.nih.gov/20008689 /

634. Semelka, RC, Armao, DM, Elias, J, Huda, W, Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI.Journal of Magnetic Resonance Imaging, J Magn Reson Imaging, 2007. 25(5): p. 900-9., https://pubmed.ncbi.nlm.nih.gov/17457809 /

635. Chien, SH, Liu, CJ, Hu, YW, Hong, YC, Teng, CJ, Yeh, CM, et.al. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study.International Journal of Cancer, Int J Cancer, 2015. 137(3): p. 658-65., https://pubmed.ncbi.nlm.nih.gov/25630766 /

636. Fabritius, G, Brix, G, Nekolla, E, Klein, S, Popp, HD, Meyer, M, et.al. Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma.Scientific Reports, Sci Rep, 2016. 6: p. 35181., https://pubmed.ncbi.nlm.nih.gov/27748377/

637. Bundesamt für Strahlenschutz, Röntgen - Nutzen und Risiken mit integriertem Röntgenpass, 2020., https://www.bfs.de/SharedDocs/Downloads/BfS/DE/broschueren/ion/stko-roentgen.pdf?__blob=publicationFile&v=4

638. Spector, DJ, Noonan, D, Mayer, DK, Benecha, H, Zimmerman, S, Smith, SK, Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma?Cancer, Cancer, 2015. 121(18): p. 3343-51., https://pubmed.ncbi.nlm.nih.gov/26036473 /

639. Damlaj, M, El Fakih, R, Hashmi, SK, Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care.Blood Reviews, Blood Rev, 2019. 33: p. 63-73., https://pubmed.ncbi.nlm.nih.gov/30093158 /

640. Ng, AK, LaCasce, A, Travis, LB, Long-term complications of lymphoma and its treatment.Journal of Clinical Oncology, J Clin Oncol, 2011. 29(14): p. 1885-92., https://pubmed.ncbi.nlm.nih.gov/21483015 /

641. Howlader, N, Mariotto, AB, Besson, C, Suneja, G, Robien, K, Younes, N, et.al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.Cancer, Cancer, 2017. 123(17): p. 3326-34., https://pubmed.ncbi.nlm.nih.gov/28464214 /

642. Pryzant, RM, Meistrich, ML, Wilson, G, Brown, B, McLaughlin, P, Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas.Journal of Clinical Oncology, J Clin Oncol, 1993. 11(2): p. 239-47., https://pubmed.ncbi.nlm.nih.gov/8426200 /

643. Eschenhagen, T, Force, T, Ewer, MS, de Keulenaer, GW, Suter, TM, Anker, SD, et.al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.European Journal of Heart Failure, Eur J Heart Fail, 2011. 13(1): p. 1-10., https://pubmed.ncbi.nlm.nih.gov/21169385 /

644. Moser, EC, Noordijk, EM, van Leeuwen, FE, le Cessie, S, Baars, JW, Thomas, J, et.al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.Blood, Blood, 2006. 107(7): p. 2912-9., https://pubmed.ncbi.nlm.nih.gov/16339404 /

645. Hershman, DL, McBride, RB, Eisenberger, A, Tsai, WY, Grann, VR, Jacobson, JS, Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2008. 26(19): p. 3159-65., https://pubmed.ncbi.nlm.nih.gov/18591554 /

646. Salz, T, Zabor, EC, de Nully Brown, P, Dalton, SO, Raghunathan, NJ, Matasar, MJ, et.al. Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(34): p. 3837-43., https://pubmed.ncbi.nlm.nih.gov/28922087 /

647. Limat, S, Demesmay, K, Voillat, L, Bernard, Y, Deconinck, E, Brion, A, et.al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.Annals of Oncology, Ann Oncol, 2003. 14(2): p. 277-81., https://pubmed.ncbi.nlm.nih.gov/12562656 /

648. Hequet, O, Le, QH, Moullet, I, Pauli, E, Salles, G, Espinouse, D, et.al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.Journal of Clinical Oncology, J Clin Oncol, 2004. 22(10): p. 1864-71., https://pubmed.ncbi.nlm.nih.gov/15143078 /

649. Armenian, SH, Mertens, L, Slorach, C, Venkataraman, K, Mascarenhas, K, Nathwani, N, et.al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma.Cancer, Cancer, 2018. 124(4): p. 850-7., https://pubmed.ncbi.nlm.nih.gov/29112235 /

650. Shree, T, Li, Q, Glaser, SL, Brunson, A, Maecker, HT, Haile, RW, et.al. Impaired immune health in survivors of diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2020. 38(15): p. 1664-75., https://pubmed.ncbi.nlm.nih.gov/32083991 /

651. Casulo, C, Maragulia, J, Zelenetz, AD, Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.Clinical Lymphoma, Myeloma and Leukemia, Clin Lymphoma Myeloma Leuk, 2013. 13(2): p. 106-11., https://pubmed.ncbi.nlm.nih.gov/23276889 /

652. Hancock, SL, Cox, RS, McDougall, IR, Thyroid diseases after treatment of Hodgkin's disease.The New England Journal of Medicine, N Engl J Med, 1991. 325(9): p. 599-605., https://pubmed.ncbi.nlm.nih.gov/1861693 /

653. Pirani, M, Marcheselli, R, Marcheselli, L, Bari, A, Federico, M, Sacchi, S, Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.Annals of Oncology, Ann Oncol, 2011. 22(8): p. 1845-58., https://pubmed.ncbi.nlm.nih.gov/21310758 /

654. Armitage, JO, Carbone, PP, Connors, JM, Levine, A, Bennett, JM, Kroll, S, Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.Journal of Clinical Oncology, J Clin Oncol, 2003. 2(5): p. 897-906., https://pubmed.ncbi.nlm.nih.gov/12610191 /

655. Fleury, I, Chevret, S, Pfreundschuh, M, Salles, G, Coiffier, B, van Oers, MH, et.al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.Annals of Oncology, Ann Oncol, 2016. 27(3): p. 390-7., https://pubmed.ncbi.nlm.nih.gov/26681685

656. Tward, JD, Wendland, MM, Shrieve, DC, Szabo, A, Gaffney, DK, The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.Cancer, Cancer, 2006. 107(1): p. 108-15., https://pubmed.ncbi.nlm.nih.gov/16708354 /

657. Hemminki, K, Jiang, Y, Steineck, G, Skin cancer and non-Hodgkin's lymphoma as second malignancies. markers of impaired immune function?European Journal of Cancer, Eur J Cancer, 2003. 39(2): p. 223-9., https://pubmed.ncbi.nlm.nih.gov/12509955 /

658. Herr, MM, Schonfeld, SJ, Dores, GM, Withrow, DR, Tucker, MA, Curtis, RE, et.al. Mutual risks of cutaneous melanoma and specific lymphoid neoplasms: Second cancer occurrence and survival.Journal of the National Cancer Institute, J Natl Cancer Inst, 2018. 110(11): p. 1248-58., https://pubmed.ncbi.nlm.nih.gov/29659938 /

659. Parnes, R, Safai, B, Myskowski, PL, Basal cell carcinomas and lymphoma: biologic behavior and associated factors in sixty-three patients.Journal of the American Academy of Dermatology, J Am Acad Dermatol, 1988. 19(6): p. 1017-23., https://pubmed.ncbi.nlm.nih.gov/3204176 /

660. Dührsen, U, Therapy-induced leukemia - an underestimated complication of antineoplastic chemotherapy?.Zentralblatt fur Gynäkologie, Zentralbl Gynakol, 2005. 127(4): p. 235-41., https://pubmed.ncbi.nlm.nih.gov/16037905 /

661. Travis, LB, Curtis, RE, Glimelius, B, Holowaty, EJ, Van Leeuwen, FE, Lynch, CF, et.al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.Journal of the National Cancer Institute, J Natl Cancer Inst, 1995. 87(7): p. 524-30., https://pubmed.ncbi.nlm.nih.gov/7707439 /

662. Mudie, NY, Swerdlow, AJ, Higgins, CD, Smith, P, Qiao, Z, Hancock, BW, et.al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study.Journal of Clinical Oncology, J Clin Oncol, 2006. 24(10): p. 1568-74., https://pubmed.ncbi.nlm.nih.gov/16520465 /

663. McDonald, AM, Chen, Y, Wu, J, Hageman, L, Francisco, L, Kung, M, et.al. Total body irradiation and risk of breast cancer after blood or marrow transplantation: A blood or marrow transplantation survivor study report.Journal of Clinical Oncology, J Clin Oncol, 2020. 38(25): p. 2872-82., https://pubmed.ncbi.nlm.nih.gov/32673169/

664. Moser, EC, Noordijk, EM, van Leeuwen, FE, Baars, JW, Thomas, J, Carde, P, et.al. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.Haematologica, Haematologica, 2006. 91(11): p. 1481-8., https://pubmed.ncbi.nlm.nih.gov/17043014 /

665. Mulder, RL, Hudson, MM, Bhatia, S, Landier, W, Levitt, G, Constine, LS, et.al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the International Guideline Harmonization Group.Journal of Clinical Oncology, J Clin Oncol, 2020. 38(35): p. 4194-207., https://pubmed.ncbi.nlm.nih.gov/33078972 /

666. Arzneimittelkommission der deutschen Ärzteschaft, Aus der UAW-Datenbank - Schwere immundefekte nach Behandlung mit Rituximab, Dtsch Arztebl, 2018. 115(49): p. A-2313 / B-1895 / C-1869.

667. Carter, SJ, Bernstein, SH, Friedberg, JW, Barr, PM, Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.Leukemia Research, Leuk Res, 2011. 35(11): p. e223-4., https://pubmed.ncbi.nlm.nih.gov/21824654 /

668. Klippstein, A, Schneider, CP, Sayer, HG, Höffken, K, Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer.Journal of Cancer Research and Clinical Oncology, J Cancer Res Clin Oncol, 2003. 129(5): p. 316-9., https://pubmed.ncbi.nlm.nih.gov/12756557 /

669. Rieger, CT, Liss, B, Mellinghoff, S, Buchheidt, D, Cornely, OA, Egerer, G, et.al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).Annals of Oncology, Ann Oncol, 2018. 29(6): p. 1354-65., https://pubmed.ncbi.nlm.nih.gov/29688266 /

670. Christopeit, M, Rieger, C, Vakzinierung gegen die saisonale Influenza unter oder nach der Therapie mit Anti-CD20-Antikorpern - Stellungname vom 2.11.2020.AGIHO, 2020. Online:, https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/grippeschutzimpfung_anti-cd20-antikoerper/agiho_vakzinierung_saisonale_influenza_anti_b_zell_20201031.pdf

671. Sandherr, M, Hentrich, M, von Lilienfeld-Toal, M, Massenkeil, G, Neumann, S, Penack, O, et.al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).Annals of Hematology, Ann Hematol, 2015. 94(9): p. 1441-50., https://pubmed.ncbi.nlm.nih.gov/26193852 /

672. Heinz, WJ, Buchheidt, D, Christopeit, M, von Lilienfeld-Toal, M, Cornely, OA, Einsele, H, et.al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of Hematology, Ann Hematol, 2017. 96(11): p. 1775-92., https://pubmed.ncbi.nlm.nih.gov/28856437 /

673. Park, SB, Goldstein, D, Krishnan, AV, Lin, CS, Friedlander, ML, Cassidy, J, et.al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis.CA - A Cancer Journal for Clinicians, CA Cancer J Clin, 2013. 63(6): p. 419-37., https://pubmed.ncbi.nlm.nih.gov/24590861 /

674. Oerlemans, S, Mols, F, Issa, DE, Pruijt, JH, Peters, WG, Lybeert, M, et.al. A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands.Haematologica, Haematologica, 2013. 98(3): p. 479-86., https://pubmed.ncbi.nlm.nih.gov/22929981 /

675. Oerlemans, S, Issa, DE, van den Broek, EC, Nijziel, MR, Coebergh, JW, Huijgens, PC, et.al. Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.Annals of Hematology, Ann Hematol, 2014. 93(10): p. 1705-15., https://pubmed.ncbi.nlm.nih.gov/24807105 /

676. Kangas, M, Bovbjerg, DH, Montgomery, GH, Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients.Psychological Bulletin, Psychol Bull, 2008. 134(5): p. 700-41., https://pubmed.ncbi.nlm.nih.gov/18729569 /

677. Mustian, KM, Alfano, CM, Heckler, C, Kleckner, AS, Kleckner, IR, Leach, CR, et.al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: A meta-analysis.JAMA Oncology, JAMA Oncol, 2017. 3(7): p. 961-8., https://pubmed.ncbi.nlm.nih.gov/28253393 /

678. Knips, L, Bergenthal, N, Streckmann, F, Monsef, I, Elter, T, Skoetz, N, Aerobic physical exercise for adult patients with haematological malignancies.The Cochrane Database of Systematic Reviews, Cochrane Database Syst Rev, 2019. 1: p. CD009075., https://pubmed.ncbi.nlm.nih.gov/30702150 /

679. Adler, NE, Page, AEK, Cancer care for the whole patient: Meeting psychosocial health needs.National Academies Press (US), 2008., https://pubmed.ncbi.nlm.nih.gov/20669419 /

680. Kusch, M, Labouvie, H, Hein-Nau, B, Schwarzkamp, U, Wolf, J, Hallek, M, Integrated psychooncology: implementation of psychooncological health care at the Center for Integrated Oncology Cologne - Bonn.Deutsche medizinische Wochenschrift, Dtsch Med Wochenschr, 2014. 139(46): p. 2357-60., https://pubmed.ncbi.nlm.nih.gov/25369048 /

681. Kusch, M, Labouvie, H, Hein-Nau, B, Klinische PsychoonkologieSpringer, 2013.

682. Donovan, KA, Grassi, L, McGinty, HL, Jacobsen, PB, Validation of the distress thermometer worldwide: state of the science.Psycho-Oncology, Psychooncology, 2014. 23(3): p. 241-50., https://pubmed.ncbi.nlm.nih.gov/25160838 /

683. Pirl, WF, Fann, JR, Greer, JA, Braun, I, Deshields, T, Fulcher, C, et.al. Recommendations for the implementation of distress screening programs in cancer centers: report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force.Cancer, Cancer, 2014. 120(19): p. 2946-54., https://pubmed.ncbi.nlm.nih.gov/24798107 /

684. Andersen, BL, DeRubeis, RJ, Berman, BS, Gruman, J, Champion, VL, Massie, MJ, et.al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation.Journal of Clinical Oncology, J Clin Oncol, 2014. 32(15): p. 1605-19., https://pubmed.ncbi.nlm.nih.gov/24733793 /

685. Herrmann, C, HADS-D: Hospital Anxiety and Depression Scale - Deutsche Version - Testdokumentation und HandanweisungHuber, 1993.

686. Holland, J, Psycho-OncologyOxford University Press, 2010. 2nd edition:

687. Brintzenhofe-Szoc, KM, Levin, TT, Li, Y, Kissane, DW, Zabora, JR, Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type.Psychosomatics, Psychosomatics, 2009. 50(4): p. 383-91., https://pubmed.ncbi.nlm.nih.gov/19687179 /

688. Mitchell, AJ, Chan, M, Bhatti, H, Halton, M, Grassi, L, Johansen, C, et.al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.The Lancet, Lancet Oncol, 2011. 12(2): p. 160-74., https://pubmed.ncbi.nlm.nih.gov/21251875 /

689. Wise, T, Biondi, M, Constantini, A, Psycho-OncologyAmerican Psychiatric Publishing, 2013. 1st edition:

690. Gascón, P, Arranz, R, Bargay, J, Ramos, F, Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma.Supportive Care in Cancer, Support Care Cancer, 2018. 26(4): p. 1253-64., https://pubmed.ncbi.nlm.nih.gov/29116407 /

691. Oerlemans, S, Mols, F, Nijziel, MR, Zijlstra, WP, Coebergh, JW, van de Poll-Franse, LV, The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry.Journal of Cancer Survivorship, J Cancer Surviv, 2014. 8(4): p. 555-64., https://pubmed.ncbi.nlm.nih.gov/24820429 /

692. Radbruch, L, Payne, S, White Paper on standards and norms for hospice and palliative care in Europe: part 1European Journal of Palliative Care, European Journal of Palliative Care, 2009. 16(6): p. 278-89.

693. World Health Organization, World Health Organization definition: Palliative careWorld Health Organization, 2019., https://www.who.int/cancer/palliative/definition/en/

694. Oechsle, K, Palliative Care in patients with hematological malignancies.Oncology Research and Treatment, Oncol Res Treat, 2019. 42(1-2): p. 25-30., https://pubmed.ncbi.nlm.nih.gov/30537761/

695. Held, G, Glaß, B, Diffuses grosszelliges B-Zell Lymphom: Primar- und RezidivtherapieDer Onkologe, 2019. p. 880-91.

696. Tilly, H, Gomes da Silva, M, Vitolo, U, Jack, A, Meignan, M, Lopez-Guillermo, A, et.al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of Oncology, Ann Oncol, 2015. 26(Suppl 5): p. v116-25., https://pubmed.ncbi.nlm.nih.gov/26314773/

697. Alt-Epping, B, Nauck, F, Schneider, N, Leben bis zuletzt. Hausarztliche und Spezialisierte Palliativversorgung bei schwerstkranken Patienten.Der Hausarzt, 2012. 11: p. 43-6.

698. Adler, K, Schlieper, D, Kindgen-Milles, D, Meier, S, Schwartz, J, van Caster, P, et.al. Integration of palliative care into intensive care: Systematic review.Der Anaesthesist, Anaesthesist, 2017. 66(9): p. 660-6., https://pubmed.ncbi.nlm.nih.gov/28589374/

699. Dalgaard, KM, Bergenholtz, H, Nielsen, ME, Timm, H, Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome.Palliative and Supportive Care, Palliat Support Care, 2014. 12(6): p. 495-513., https://pubmed.ncbi.nlm.nih.gov/24621947/

700. Davis, MP, Temel, JS, Balboni, T, Glare, P, A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses.Annals of Palliative Medicine, Ann Palliat Med, 2015. 4(3): p. 99-121., https://pubmed.ncbi.nlm.nih.gov/26231807/

701. Gaertner, J, Siemens, W, Meerpohl, JJ, Antes, G, Meffert, C, Xander, C, et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis.The BMJ, BMJ, 2017. 357: p. j2925., https://pubmed.ncbi.nlm.nih.gov/28676557/

702. Haun, MW, Estel, S, Rücker, G, Friederich, HC, Villalobos, M, Thomas, M, et.al. Early palliative care for adults with advanced cancer.The Cochrane Database of Systematic Reviews, Cochrane Database Syst Rev, 2017. 6: p. CD011129., https://pubmed.ncbi.nlm.nih.gov/28603881/

703. Hui, D, Kim, YJ, Park, JC, Zhang, Y, Strasser, F, Cherny, N, et.al. Integration of oncology and palliative care: a systematic review.The Oncologist, Oncologist, 2015. 20(1): p. 77-83., https://pubmed.ncbi.nlm.nih.gov/25480826/

704. Hui, D, Meng, YC, Bruera, S, Geng, Y, Hutchins, R, Mori, M, et.al. Referral criteria for outpatient palliative cancer care: A systematic review.The Oncologist, Oncologist, 2016. 21(7): p. 895-901., https://pubmed.ncbi.nlm.nih.gov/27185614/

705. Tassinari, D, Drudi, F, Monterubbianesi, MC, Stocchi, L, Ferioli, I, Marzaloni, A, et.al. Early palliative care in advanced oncologic and non-oncologic chronic diseases: A systematic review of literature.Reviews on Recent Clinical Trials, Rev Recent Clin Trials, 2016. 11(1): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/26464077/

706. El-Jawahri, A, Nelson, AM, Gray, TF, Lee, SJ, LeBlanc, TW, Palliative and end-of-life care for patients with hematologic malignancies.Journal of Clinical Oncology, J Clin Oncol, 2020. 38(9): p. 944-53., https://pubmed.ncbi.nlm.nih.gov/32023164/

707. Moss, AH, Lunney, JR, Culp, S, Auber, M, Kurian, S, Rogers, J, et.al. Prognostic significance of the "surprise" question in cancer patients.Journal of Palliative Medicine, J Palliat Med, 2010. 13(7): p. 837-40., https://pubmed.ncbi.nlm.nih.gov/20636154/

708. Ferrell, BR, Temel, JS, Temin, S, Alesi, ER, Balboni, TA, Basch, EM, et.al. Integration of palliative care into standard oncology care: American society of clinical oncology clinical practice guideline update.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(1): p. 96-112., https://pubmed.ncbi.nlm.nih.gov/28034065/

709. Institute for Clinical Systems Improvement, Health care guidelines: Palliative careInstitute for Clinical Systems Improvement, 2009. 3rd edition:

710. Odejide, OO, Cronin, AM, Condron, NB, Fletcher, SA, Earle, CC, Tulsky, JA, et.al. Barriers to quality end-of-life care for patients with blood cancers.Journal of Clinical Oncology, J Clin Oncol, 2016. 34(26): p. 3126-32., https://pubmed.ncbi.nlm.nih.gov/27400944/

711. Gerlach, C, Alt-Epping, B, Oechsle, K, Specific challenges in end-of-life care for patients with hematological malignancies.Current Opinion in Supportive and Palliative Care, Curr Opin Support Palliat Care, 2019. 13(4): p. 369-79., https://pubmed.ncbi.nlm.nih.gov/31644451/

712. Hudson, KE, Wolf, SP, Samsa, GP, Kamal, AH, Abernethy, AP, LeBlanc, TW, The surprise question and identification of palliative care needs among hospitalized patients with advanced hematologic or solid malignancies.Journal of Palliative Medicine, J Palliat Med, 2018. 21(6): p. 789-95., https://pubmed.ncbi.nlm.nih.gov/29420142/

713. El-Jawahri, A, Traeger, L, Greer, JA, VanDusen, H, Fishman, SR, LeBlanc, TW, et.al. Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: Results of a randomized clinical trial.Journal of Clinical Oncology, J Clin Oncol, 2017. 35(32): p. 3714-21., https://pubmed.ncbi.nlm.nih.gov/28926288/

714. Oerlemans, S, Nijziel, MR, van de Poll-Franse, LV, Age-related differences in quality of life among patients with diffuse large B-cell lymphoma.Cancer, Cancer, 2015. 121(16): p. 2857-8., https://pubmed.ncbi.nlm.nih.gov/25926003/

715. Philip, J, Collins, A, Ritchie, D, Le, B, Millar, J, McLachlan, SA, et.al. Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape.Leukemia and Lymphoma, Leuk Lymphoma, 2019. 60(8): p. 1908-16., https://pubmed.ncbi.nlm.nih.gov/30732498/

716. Kelly, JL, Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis.Blood, Blood, 2012. 120(21): p. 4287.

717. van de Poll-Franse, L, Oerlemans, S, Bredart, A, Kyriakou, C, Sztankay, M, Pallua, S, et.al. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.Quality of Life Research, Qual Life Res, 2018. 27(2): p. 333-45., https://pubmed.ncbi.nlm.nih.gov/29127596/

718. El-Jawahri, A, LeBlanc, T, VanDusen, H, Traeger, L, Greer, JA, Pirl, WF, et.al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: A randomized clinical trial.Journal of the American Medical Association, JAMA, 2016. 316(20): p. 2094-103., https://pubmed.ncbi.nlm.nih.gov/27893130/

719. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF), Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, 2020, AWMF-Registernummer: 128/001OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/

720. McCaughan, D, Roman, E, Smith, AG, Garry, AC, Johnson, MJ, Patmore, RD, et.al. Haematology nurses' perspectives of their patients' places of care and death: A UK qualitative interview study.European Journal of Oncology Nursing, Eur J Oncol Nurs, 2019. 39: p. 70-80., https://pubmed.ncbi.nlm.nih.gov/30850141/

721. McCaughan, D, Roman, E, Smith, AG, Garry, AC, Johnson, MJ, Patmore, RD, et.al. Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study.Palliative Medicine, Palliat Med, 2019. 33(5): p. 518-30., https://pubmed.ncbi.nlm.nih.gov/30696347/

722. Preston, NJ, Hurlow, A, Brine, J, Bennett, MI, Blood transfusions for anaemia in patients with advanced cancer.The Cochrane Database of Systematic Reviews, Cochrane Database Syst Rev, 2012. p. CD009007., https://pubmed.ncbi.nlm.nih.gov/22336857 /

723. Chin-Yee, N, Taylor, J, Rourke, K, Faig, D, Davis, A, Fergusson, D, et.al. Red blood cell transfusion in adult palliative care: a systematic review.Transfusion, Transfusion, 2018. 58(1): p. 233-41., https://pubmed.ncbi.nlm.nih.gov/29194669/

724. To, TH, To, LB, Currow, DC, Can we detect transfusion benefits in palliative care patients?Journal of Palliative Medicine, J Palliat Med, 2016. 19(10): p. 1110-3., https://pubmed.ncbi.nlm.nih.gov/27355984/

725. Goksu, SS, Gunduz, S, Unal, D, Uysal, M, Arslan, D, Tatli, AM, et.al. Use of blood transfusion at the end of life: does it have any effects on survival of cancer patients?Asian Pacific Journal of Cancer Prevention, Asian Pac J Cancer Prev, 2014. 15(10): p. 4251-4., https://pubmed.ncbi.nlm.nih.gov/24935379/

726. Howell, DA, Roman, E, Cox, H, Smith, AG, Patmore, R, Garry, AC, et.al. Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy.The BMC, BMC Palliat Care, 2010. 9: p. 9., https://pubmed.ncbi.nlm.nih.gov/20515452/

727. Howell, DA, Wang, HI, Roman, E, Smith, AG, Patmore, R, Johnson, MJ, et.al. Preferred and actual place of death in haematological malignancy.BMJ Supportive and Palliative Care, BMJ Support Palliat Care, 2017. 7(2): p. 150-7., https://pubmed.ncbi.nlm.nih.gov/26156005/

728. Howell, DA, Wang, HI, Roman, E, Smith, AG, Patmore, R, Johnson, MJ, et.al. Variations in specialist palliative care referrals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myeloma.BMJ Supportive and Palliative Care, BMJ Support Palliat Care, 2015. 5(5): p. 496-502., https://pubmed.ncbi.nlm.nih.gov/24644210 /

729. Gomes, B, Calanzani, N, Curiale, V, McCrone, P, Higginson, IJ, Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers.The Cochrane Database of Systematic Reviews, Cochrane Database Syst Rev, 2013. p. CD007760., https://pubmed.ncbi.nlm.nih.gov/23744578/

730. Eichenauer, DA, Golla, H, Thielen, I, Hallek, M, Voltz, R, Perrar, KM, Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital.Annals of Hematology, Ann Hematol, 2019. 98(11): p. 2605-7., https://pubmed.ncbi.nlm.nih.gov/31253997/

731. Russell, NC, Hoelscher, DM, Lowenstein, N, Patients previously treated for lymphoma consume inadequate or excessive amounts of five key nutrients.Journal of the Society for Integrative Oncology, J Soc Integr Oncol, 2007. 5(3): p. 118-24., https://pubmed.ncbi.nlm.nih.gov/17761131 /

732. Arends, J, Klinische Ernahrung in der OnkologieAktuelle Ernahrungsmedizin, 2015. 40(5): p. e1-74., doi.org/10.1055/s-0035-1552741

733. Paul, C, Ernahrung und Krebs - Was kann die Diatberatung leisten?Aktuelle Ernahrungsmedizin, Aktuelle Ernahrungsmedizin, 2001. 26(4): p. 153-9., doi.org/10.1055/s-2001-16658

734. Schmitz, KH, Campbell, AM, Stuiver, MM, Pinto, BM, Schwartz, AL, Morris, GS, et.al. Exercise is medicine in oncology: Engaging clinicians to help patients move through cancer.CA - A Cancer Journal for Clinicians, CA Cancer J Clin, 2019. 69(6): p. 468-84., https://pubmed.ncbi.nlm.nih.gov/31617590 /

735. Güthlin, C, Bartsch, HH, Joos, S, Längler, A, Lampert, C, Ritter, C, et.al. KOKON: A Germany-wide collaborative research project to identify needs, provide information, foster communication and support decision-making about complementary and alternative medicine in oncology.Complementary Medicine Research, Complement Med Res, 2020. 27(2): p. 105-11., https://pubmed.ncbi.nlm.nih.gov/31722354 /

736. Deng, GE, Frenkel, M, Cohen, L, Cassileth, BR, Abrams, DI, Capodice, JL, et.al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals.Journal of the Society for Integrative Oncology, J Soc Integr Oncol, 2009. 7(3): p. 85-120., https://pubmed.ncbi.nlm.nih.gov/19706235 /

737. Jütte, R, Geschichte der alternativen Medizin - Von der Volksmedizin zu den unkonventionellen Therapien von heuteBeck, 1996. 1. Auflage:

738. Blödt, S, Mittring, N, Schützler, L, Fischer, F, Holmberg, C, Horneber, M, et.al. A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study.BMC Cancer, BMC Cancer, 2016. 16(1): p. 843., https://pubmed.ncbi.nlm.nih.gov/27809814 /

739. Frenkel, M, Cohen, L, Effective communication about the use of complementary and integrative medicine in cancer care.Journal of Alternative and Complementary Medicine, J Altern Complement Med, 2014. 20(1): p. 12-8., https://pubmed.ncbi.nlm.nih.gov/23863085 /

740. Horneber, M, van Ackeren, G, Fischer, F, Kappauf, H, Birkmann, J, Addressing Unmet Information Needs: Results of a Clinician-Led Consultation Service About Complementary and Alternative Medicine for Cancer Patients and Their Relatives.Integrative Cancer Therapies, Integr Cancer Ther, 2018. 17(4): p. 1172-82., https://pubmed.ncbi.nlm.nih.gov/30352519 /

741. Witt, CM, Helmer, SM, Schofield, P, Wastell, M, Canella, C, Thomae, AV, et.al. Training oncology physicians to advise their patients on complementary and integrative medicine: An implementation study for a manual-guided consultation.Cancer, Cancer, 2020. 126(13): p. 3031-41., https://pubmed.ncbi.nlm.nih.gov/32286693/

742. Ben-Arye, E, Schiff, E, Golan, O, Ethical issues in integrative oncology.Hematology/Oncology Clinics of North America, Hematol Oncol Clin North Am, 2008. 22(4): p. 737-53., https://pubmed.ncbi.nlm.nih.gov/18638699 /

743. Weiger, WA, Smith, M, Boon, H, Richardson, MA, Kaptchuk, TJ, Eisenberg, DM, Advising patients who seek complementary and alternative medical therapies for cancer.Annals of Internal Medicine, Ann Intern Med, 2002. 137(11): p. 889-903., https://pubmed.ncbi.nlm.nih.gov/12458989 /

744. Cassileth, BR, Berlyne, D, Counseling the cancer patient who wants to try unorthodox or questionable therapies.Oncology, Oncology, 1989. 3(4): p. 29-33; discussion 34, 40-1., https://pubmed.ncbi.nlm.nih.gov/2701416 /

745. Davis, EL, Oh, B, Butow, PN, Mullan, BA, Clarke, S, Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review.The Oncologist, Oncologist, 2012. 17(11): p. 1475-81., https://pubmed.ncbi.nlm.nih.gov/22933591 /

746. Montbriand, MJ, Abandoning biomedicine for alternate therapies: oncology patients' stories.Cancer Nursing, Cancer Nurs, 1998. 21(1): p. 36-45., https://pubmed.ncbi.nlm.nih.gov/9494229 /

747. Schofield, P, Diggens, J, Charleson, C, Marigliani, R, Jefford, M, Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians.Patient Education and Counseling, Patient Educ Couns, 2010. 79(2): p. 143-51., https://pubmed.ncbi.nlm.nih.gov/19783116 /

748. Tasaki, K, Maskarinec, G, Shumay, DM, Tatsumura, Y, Kakai, H, Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives.Psycho-oncology, Psychooncology, 2002. 11(3): p. 212-20., https://pubmed.ncbi.nlm.nih.gov/12112481 /

749. Habermann, TM, Thompson, CA, LaPlant, BR, Bauer, BA, Janney, CA, Clark, MM, et.al. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study.American Journal of Hematology, Am J Hematol, 2009. 84(12): p. 795-8., https://pubmed.ncbi.nlm.nih.gov/19894247 /

750. Hamilton, AS, Miller, MF, Arora, NK, Bellizzi, KM, Rowland, JH, Predictors of use of complementary and alternative medicine by non-hodgkin lymphoma survivors and relationship to quality of life.Integrative Cancer Therapies, Integr Cancer Ther, 2013. 12(3): p. 225-35., https://pubmed.ncbi.nlm.nih.gov/22791309 /

751. Rausch Osian, S, Leal, AD, Allmer, C, Maurer, MJ, Nowakowski, G, Inwards, DJ, et.al. Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors.Leukemia and Lymphoma, Leuk Lymphoma, 2015. 56(2): p. 434-9., https://pubmed.ncbi.nlm.nih.gov/24745936 /

752. Ben-Arye, E, Attias, S, Tadmor, T, Schiff, E, Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions.Leukemia and Lymphoma, Leuk Lymphoma, 2010. 51(8): p. 1414-23., https://pubmed.ncbi.nlm.nih.gov/20528250 /

753. Gorter, RW, Joller, P, Stoss, M, Cytokine release of a keratinocyte model after incubation with two different Viscum album L extracts.American Journal of Therapeutics, Am J Ther, 2003. 10(1): p. 40-7., https://pubmed.ncbi.nlm.nih.gov/12522519 /

754. Hallek, M, Interleukin-6-mediated cell growth in multiple myeloma--a role for Viscum album extracts?Onkologie, Onkologie, 2005. 28(8-9): p. 387., https://pubmed.ncbi.nlm.nih.gov/16160399 /

755. Hugo, F, Dittmar, T, Treutler, EK, Zänker, KS, Kuehn, JJ, The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines.Onkologie, Onkologie, 2005. 28(8-9): p. 415-20., https://pubmed.ncbi.nlm.nih.gov/16160404 /

756. Kovacs, E, Kuehn, JJ, Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters?Biomedicine and Pharmacotherapy, Biomed Pharmacother, 2002. 56(3): p. 152-8., https://pubmed.ncbi.nlm.nih.gov/12046687 /

757. Mishra, R, Sharma, S, Sharma, RS, Singh, S, Sardesai, MM, Sharma, S, et.al. Viscum articulatum Burm. f. aqueous extract exerts antiproliferative effect and induces cell cycle arrest and apoptosis in leukemia cells.Journal of Ethnopharmacology, J Ethnopharmacol, 2018. 219: p. 91-102., https://pubmed.ncbi.nlm.nih.gov/29555410 /

758. Pryme, IF, Bardocz, S, Pusztai, A, Ewen, SW, Pfüller, U, A mistletoe lectin (ML-1)-containing diet reduces the viability of a murine non-Hodgkin lymphoma tumor.Cancer Detection and Prevention, Cancer Detect Prev, 2004. 28(1): p. 52-6., https://pubmed.ncbi.nlm.nih.gov/15041078 /

759. Hagenah, W, Dörges, I, Gafumbegete, E, Wagner, T, Subcutaneous manifestations of a centrocytic non-Hodgkin lymphoma at the injection site of a mistletoe preparation.Deutsche medizinische Wochenschrift, Dtsch Med Wochenschr, 1998. 123(34-35): p. 1001-4., https://pubmed.ncbi.nlm.nih.gov/9739765 /

760. Kameda, G, Kempf, W, Oschlies, I, Michael, K, Seifert, G, Längler, A, Nodal anaplastic large-cell lymphoma ALK-1- with CD30+ cutaneous lymphoproliferation treated with mistletoe: spontaneous remission or treatment response?Klinische Padiatrie, Klin Padiatr, 2011. 223(6): p. 364-7., https://pubmed.ncbi.nlm.nih.gov/22052633 /

761. Orange, M, Lace, A, Fonseca, MP, von Laue, BH, Geider, S, Kienle, GS, Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: Two case reports.Global Advances in Health and Medicine, Glob Adv Health Med, 2012. 1(1): p. 18-25., https://pubmed.ncbi.nlm.nih.gov/24278797 /

762. Pierach, CA, Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non hodgkin lymphoma.Deutsche medizinische Wochenschrift, Dtsch Med Wochenschr, 2000. 125(31-32): p. 958-60., https://pubmed.ncbi.nlm.nih.gov/10967963 /

763. Stumpf, C, Rosenberger, A, Rieger, S, Tröger, W, Schietzel, M, Mistletoe extracts in the therapy of malignant, hematological and lymphatic diseases--a monocentric, retrospective analysis over 16 years.Forschende Komplementarmedizin und klassische Naturheilkunde, Forsch Komplementarmed Klass Naturheilkd, 2000. 7(3): p. 139-46., https://pubmed.ncbi.nlm.nih.gov/10899748 /

764. Meirow, D, Hardan, I, Dor, J, Fridman, E, Elizur, S, Ra'anani, H, et.al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.Human Reproduction, Hum Reprod, 2008. 23(5): p. 1007-13., https://pubmed.ncbi.nlm.nih.gov/18344563 /

765. Bataillard, EJ, Cheah, CY, Maurer, MJ, Khurana, A, Eyre, TA, El-Galaly, TC, Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review.Blood Advances, Blood Adv, 2021. 5(9): p. 2426-37., https://pubmed.ncbi.nlm.nih.gov/33961018/

766. Williams, JN, Rai, A, Lipscomb, J, Koff, JL, Nastoupil, LJ, Flowers, CR, Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.Cancer, Cancer, 2015. 121(11): p. 1800-8., https://pubmed.ncbi.nlm.nih.gov/25675909 /

767. Isaksen, KT, Mastroianni, MA, Rinde, M, Rusten, LS, Barzenje, DA, Ramslien, LF, et.al. A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.Blood Advances, Blood Adv, 2021. 5(22): p. 4771-82., https://pubmed.ncbi.nlm.nih.gov/34543384 /

768. Mohile, SG, Mohamed, MR, Xu, H, Culakova, E, Loh, KP, Magnuson, A, et.al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.The Lancet, Lancet, 2021. 398(10314): p. 1894-904., https://pubmed.ncbi.nlm.nih.gov/34741815 /

769. Orlhac, F, Eertink, JJ, Cottereau, AS, Zijlstra, JM, Thieblemont, C, Meignan, M, et.al. A guide to ComBat harmonization of imaging biomarkers in multicenter studies.Journal of Nuclear Medicine, J Nucl Med, 2022. 63(2): p. 172-9., https://pubmed.ncbi.nlm.nih.gov/34531263/

770. Burggraaff, CN, de Jong, A, Hoekstra, OS, Hoetjes, NJ, Nievelstein, RAJ, Jansma, EP, et.al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.European Journal of Nuclear Medicine and Molecular Imaging, Eur J Nucl Med Mol Imaging, 2019. 46(1): p. 65-79., https://pubmed.ncbi.nlm.nih.gov/30141066/

771. Bologna, S, Vander Borght, T, Briere, J, Ribrag, V, , Damaj, GL, Thieblemont, C, Early positron emission tomography response‐adapted treatment in localized diffuse large B-cell lymphoma (aaIPI=0): Results of the phase 3 LYSA LNH 09‐1B trialHematological Oncology, Hematol Oncol, 2021. 39(S2):, https://onlinelibrary.wiley.com/doi/full/10.1002/hon.5_2879

772. Moskowitz, CH, Schöder, H, Teruya-Feldstein, J, Sima, C, Iasonos, A, Portlock, CS, et.al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2010. 28(11): p. 1896-903., https://pubmed.ncbi.nlm.nih.gov/20212248/

773. Tokola, S, Kuitunen, H, Turpeenniemi-Hujanen, T, Kuittinen, O, Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions.Cancer Medicine, Cancer Med, 2021. 10(9): p. 3035-44., https://pubmed.ncbi.nlm.nih.gov/33792190/

774. Scherer, F, Kurtz, DM, Newman, AM, Stehr, H, Craig, AF, Esfahani, MS, et.al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Science Translational Medicine, Sci Transl Med, 2016. 8(364): p. 364ra155., https://pubmed.ncbi.nlm.nih.gov/27831904/

775. Kurtz, DM, Scherer, F, Jin, MC, Soo, J, Craig, AFM, Esfahani, MS, et.al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma.Journal of Clinical Oncology, J Clin Oncol, 2018. 36(28): p. 2845-53., https://pubmed.ncbi.nlm.nih.gov/30125215/

776. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Manual Qualitätsindikatoren. Manual für Autoren., 2009. äzq Schriftenreihe: 36:, https://www.researchgate.net/publication/306104963_Qualitatsindikatoren_-_Manual_fur_Autoren

777. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 3.0, 2021., https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik